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SUMMARY
This thesis reviews the literature relating vascular 
disease to fibrinolysis and describes a number of clinical 
studies which have attempted to evaluate the components of 
the fibrinolytic enzyme system in a variety of different 
medical disorders and in healthy subjects. In these 
clinical settings a comparison has been made between the 
plasma fibrinolytic activity (fibrin plate: ex vivo
fibrinolysis) and BBeta 15-42 fragment (in vivo 
plasmin-mediated fibrinolysis) as indicators of 
fibrinolysis, and the relative importance of fibrinolysis 
and coagulation has been estimated by measuring both 
plasmin (BBeta 15-42) and thrombin generation 
(fibrinopeptide A). The effect on fibrinolysis of a 
number of clinical and laboratory measures have been made 
with fibrinolysis studied in the basal state and following 
pharmacological intervention and exercise.
In a double-blind, placebo-controlled study, exercise 
in young healthy male subjects was shown to be associated 
with enhanced plasma fibrinolytic activity without a 
concomitant activation of coagulation. The rise in plasma 
fibrinolytic activity was not influenced by prior 
administration of beta-blocker drugs and therefore 
adrenergic mechanisms made no contribution to the exercise 
enhanced plasma fibrinolytic activity. Exercise in 
middle-aged men was related, in part, to the workload and 
was associated with both thrombin and plasmin generation 
suggesting that the enhanced fibrinolysis may have been 
secondary to activation of coagulation. In men of the
21
same age group with coronary artery disease no alterations 
of haemostasis were detected. Whether such defective in 
vivo fibrinolysis was related to coronary artery disease 
per se, to the lack of changes in coagulation or to the 
workload intensity requires further study.
Defective fibrinolysis has been noted in coronary 
artery disease and in 100 men with angiographically 
defined coronary artery disease we have examined the 
inter-relationships between fibrinolysis, lipids and 
hormones and the relationships between these 3 factors and 
the severity of coronary artery disease. We found that 
patients with a previous myocardial infarction had raised 
oestradiol levels but that these were not related to the 
tests of fibrinolysis. While higher alpha2-antiplasmin 
levels were found in hypertriglyceridaemia,. lipid levels 
were not associated with altered fibrinolysis. We have 
provided evidence that BBeta 15-42 is a reliable indicator 
of in vivo fibrinolysis by showing significant 
correlations with plasminogen (negative) and FDP's 
(positive). This is consistent with activation of 
fibrinolysis (increased BBeta levels) being associated 
with decreased plasminogen and raised FDP's. Apart from 
fibrinogen levels, none of the laboratory measures were 
related to the severity of coronary artery disease which 
fails to provide support for defective basal fibrinolysis 
being associated with coronary artery disease.
The anabolic steroid, stanozolol is felt to be the 
most promising oral agent to induce long-term enhancement 
of fibrinolysis. We have performed a number of studies 
with this drug and have found that, given via the
22
intramuscular route, stanozolol did not decrease 
fibrinogen and alpha2-macroglobulin levels (unlike the 
orally administered drug ) and while it led to rapid and 
sustained changes in plasma fibrinolytic activity and 
plasminogen in young healthy males, it failed to effect 
such changes on fibrinolysis in elderly patients with 
medical illness. In studies using oral stanozolol we have 
shown that it caused plasmin-mediated fibrinolysis in 
normal subjects but not in type II (non-insulin dependent) 
diabetic patients. We have also noted favourable effects 
on carbohydrate metabolism in diabetics given stanozolol, 
but adverse hormonal and lipid effects in other studies. 
The weight of evidence suggests that stanozolol is not a 
useful anti-thrombotic agent.
Vascular disease is the major complication affecting 
diabetic patients and conflicting reports abound on the 
function of the fibrinolytic enzyme system in diabetes 
mellitus. We have performed large and detailed controlled 
studies in diabetes and have found that poor glycaemic 
control was associated with reduced plasmin and enhanced 
thrombin generation, and that sex status, type of diabetes 
and diabetic therapy have an important influence on basal 
fibrinolysis. Failure to take these factors into account 
may have led to some of the confused literature on this 
subject. In diabetes, females had reduced plasma 
fibrinolytic activity compared to males while the opposite 
was seen in control subjects. In addition, diabetic 
females had raised alpha2-antiplasmin levels and augmented 
thrombin generation. Whether such adverse haemostatic 
changes could be relevant to the increased risk of
23
cardiovascular disease in diabetic females remains 
speculative. Alpha2-antiplasmin levels were both
positively correlated with triglyceride levels and raised 
in type II diabetics and this explains why defective 
fibrinolysis has been found in such patients when whole 
blood clot lysis time assays have been employed. Basal 
fibrinolysis was not related to micro or macrovascular 
disease. Our results suggest that patients taking 
sulphonylurea drugs have an alteration of haemostatic 
balance favouring a thrombotic tendency, and that insulin 
therapy reversed such abnormalities. In diabetes, the 
trend was towards enhanced plasmin generation which may, 
in part, be secondary to the significantly greater 
thrombin generation found • in all diabetic groups. The 
design and analysis of further studies on fibrinolysis in 
diabetes must allow for these differences in fibrinolysis 
related to sex status and type of diabetes.
Throughout these studies we have analysed the effect 
of beta-blockade, body weight and lipid levels on 
fibrinolysis and have been unable to provide any clear 
evidence to show that these factors have a major influence 
on fibrinolysis.
Plasma fibrinolytic activity, assayed on fibrin 
plates, has been widely used as a global measure of 
fibrinolysis, the assumption being that in vivo 
fibrinolysis is a simple function of the absolute level of 
circulating plasminogen activators. There are however a 
number of problems associated with this assay. The 
activity determined is much smaller than the total 
activator potential of the plasma, and the variation among
individuals contributes to a wide normal range which means 
in effect that, unless extreme and prolonged differences 
exist between patients and controls, a single estimation 
could fail to detect significant differences between such 
groups. In addition to these problems we have 
consistently been unable to show any correlation between 
plasma fibrinolytic activity and the BBeta 15-42 fragment 
which places further doubt as to the value of the fibrin 
plate assay giving a reliable indication of in vivo 
fibrinolysis. We have failed to find differences in BBeta 
15-42 in situations when both the basal plasma 
fibrinolytic activity (subgroups of patients with diabetes 
and coronary artery disease) and exercise stimulated 
plasma fibrinolytic activity were increased (men with 
coronary artery disease). We have also found increased 
BBeta 15-42 concentrations without alterations in plasma 
fibrinolytic activity in healthy males given oral 
stanozolol. These results suggest therefore that the 
BBeta 15-42 fragment may be a more useful assay of 
fibrinolysis in the future investigation of patients with 
vascular disease.
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CHAPTER 1
THE FIBRINOLYTIC ENZYME SYSTEM; 
HISTORICAL BACKGROUND AND MECHANISMS OF ACTION
26
I.I INTRODUCTION
Fibrinolysis is the proteolytic digestion of solid 
fibrin polymer into smaller soluble fragments. It 
functions therefore as the physiological process capable 
of removing fibrin that is deposited in the vascular 
system or in other compartments of the body. While a 
variety of proteolytic mechanisms may be involved in 
fibrin digestion I will concentrate only on plasmin - 
mediated fibrinolysis and its role in the removal of 
fibrin from the vascular bed. Fibrinolysis may also 
function in several other biological phenomena such as 
tissue repair, neoplasia, macrophage activity, 
neovascularisation, ovulation and embryo implantation 
(Collen, 1985; Erickson et al., 1985) but this thesis is 
primarily concerned with its effects as part of the 
haemostatic system and these other sites of action will 
not be further discussed.
1.2 HISTORICAL BACKGROUND
Although Hippocrates, in the first century BC, noted 
that the blood of deer and of roe never clotted (Smith and 
Ross, 1912) it was John Hunter (1794) who made the first 
scientific observations on fibrinolysis. He noted that 
fluidity of post mortem blood was more likely to occur in 
individuals who died as a result of "fits, anger, 
electricity, or lightning", and later found that the blood 
of 2 deer that he had "run, till they dropped down and
27
died", failed to clot. The word fibrinolysis was first 
coined by Dastre (189 3) who noted that fibrin lysed when 
left in contact with blood from dogs who had been 
repeatedly venesected. This proteolytic property was 
localised by Hedin (1904) to the globulin fraction of ox 
blood. In addition to this spontaneous fibrin lysis it 
was noted that pharmacological potentiation of fibrin 
lysis could be induced by chloroform (Denys and de 
Marbaix, 1889) probably by removing the fibrinolytic 
inhibitors (Delezenne and Pozerski, 1903) - the first
demonstration of inhibitors of fibrinolysis. At that 
time, Nolf (1908) described experiments in which he 
induced fibrinolytic activity in vivo in dogs by means of 
intravenous injections of peptones (polyelectrolytes 
similar to dextran sulphate which is used in the modified 
fibrin plate technique due to its ability to activate 
factor XII and increase the precipitation of proactivators 
of fibrinolysis). He considered that the lysis of blood
clots was the normal end result of the coagulation process 
and, like coagulation, fibrinolysis was due to proteolytic 
enzymes. He further suggested that the linings of blood
vessels contribute components of the fibrinolytic system
and that disturbances of fibrinolysis could result in 
deposition of fibrin on the vessel wall. This concept of 
the dynamic equilibrium between coagulation and 
fibrinolysis was restated by Astrup (1958) and still 
remains one of the most popular theories on haemostasis. 
Thus at the beginning of the century the process of 
fibrinolysis was well established although the exact
28
identity of some of the components remained unknown.
Interest in fibrinolysis was again stimulated by 
Tillett and Garner (1933) who found that bacteria-free 
filtrates of beta-haemolytic streptococci contained a 
substance that rapidly dissolved clotted plasma or fibrin; 
this agent was called streptococcal fibrinolysin. 
Milstone (1941) later demonstrated that the streptococcal 
fibrinolysin activity depended on the presence of a 
substance in the euglobulin fraction of plasma which was 
then identified to be plasminogen by Kaplan (1944). A 
year later this streptococcal fibrinolysin was renamed 
streptokinase (Christensen and MacLeod, 1945) in the 
mistaken belief that it was a kinase-like enzyme. It is 
now known that streptokinase reacts with plasminogen in a 
nonenzymatic fashion.
Although the spontaneous fibrinolytic activity of 
plasma was known from the beginning of the century and 
reported to be increased in liver cirrhosis (Goodpasture, 
1914) the mechanism for this process was unknown. Sherry, 
Fletcher, and Alkjaersig (1959) reported that the 
spontaneous fibrinolytic activity was due to the presence 
of a plasminogen activator in plasma; Kwaan (1957) 
suggested that this activator might be derived from the 
venous endothelium, as had Nolf (1908), and the 
histological identification of the plasminogen activator 
was confirmed by Todd (1959).
Other important events included the demonstration of 
enhanced fibrinolysis by intravenous adrenaline and 
exercise (Biggs et al., 1947), the discovery of urokinase
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(Williams, 1951) and the findings relating the fluidity of 
menstrual fluid with large amounts of fibrinolytic 
activity produced by the endometrium (Albrechtsen, 1956). 
This fluidity of menstrual flow is probably the most 
common clinical manifestation of fibrinolysis which Hunter 
(1794) had noted as an example of blood liquidity.
At no time in the past has there been such a rapid 
accumulation of knowledge in the field of fibrinolysis as 
during the last 10 years. Large prospective 
epidemiological studies and clinical studies on patients 
with vascular disease have started to provide evidence as 
to the role of fibrinolysis in thrombosis, while the 
molecular mechanisms of fibrinolysis have been greatly 
advanced. Alpha2-antiplasmin, tissue-type plasminogen 
activator, tissue-type plasminogen activator inhibitor, 
histidine-rich glycoprotein, protein C, intrinsic pathway 
fibrinolysis have all been discovered or their mechanisms 
of action defined in the last few years, and these 
advances will be more closely evaluated throughout this 
thesis.
1^ .2 MECHANISMS OF FIBRINOLYSIS
The current fibrinolysis cascade is illustrated in 
figures 1.1 and 1.2. Briefly, activation of plasminogen 
may occur via an intrinsic or extrinsic pathway. The 
intrinsic pathway includes (a) a factor Xll-dependent 
mechanism that is initiated by negatively charged surfaces 
and involves factor XII, prekallikrein, and high-molecular
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Figure 1.3
Illustrates the pathway of fibrin (ogen) degradation by 
thrombin or plasmin and the mechanism of production 
of the Bp peptides and fibrinopeptide A (FPA).
weight kininogen and possibly other, as yet unknown 
proactivators and (b) a factor Xll-independent mechanism 
that involves a urokinase-like activity. The extrinsic 
pathway involves a tissue-type plasminogen activator that 
circulates in plasma after its release from the 
endothelium in the vessel wall or from other tissues. 
This tissue-plasminogen activator acts directly on 
plasminogen to yield plasmin.
Inhibitors regulate the process of fibrinolysis. 
Alpha2- antiplasmin is the major inhibitor of plasmin, 
whereas alpha2-macroglobulin only comes into play when 
plasmin is formed in excess of the inhibitory capacity of 
alpha2-antiplasmin. The main inhibitor of the intrinsic 
pathway is Cl-inactivator, but alpha2-macroglobulin, 
antithrombin III and alphal-antitrypsin may also play a 
role in the regulation of this pathway. The most recent 
discovery is that of a fast-acting inhibitor to 
tissue-plasminogen activator which is also produced by the 
vascular endothelium. Protein C, activated by thrombin 
(Protein Ca), is known to stimulate fibrinolysis and 
recent evidence suggests that its mode of action could be 
related to a reduction of tissue-plasminogen activator 
inhibitor. ■ That hereditary protein C deficiency is 
associated with recurrent venous thrombosis (Broekmans, 
1985) suggests that protein. C may have a clinically 
relevant effect on fibrinolysis.
Activation of fibrin (ogen) by plasmin releases small 
peptide fragments from the carboxy terminals of the BBeta 
chain which are cleaved before the X, Y, D and E fragments
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are formed (figure 1.2). Measurement of BBeta 15-42 
therefore allows an accurate assessment of minor changes 
in endogenous fibrinolysis, while changes in 
fibrinogen/fibrin degradation products (FDP's) only takes 
place when major activation of fibrinogen occurs - ie, 
when systematic fibrinolysis is induced.
Having given a brief synopsis of the components of 
the fibrinolytic enzyme system I would now like to 
describe these individual components in more detail. Table
1.1 lists some of the characteristiscs of these 
components.
1-i PLASMINOGEN 
Plasminogen, the inactive precursor of plasmin, 
circulates in the blood, and although in low
concentrations, is present in practically all body
fluids. (Hedner and Nilsson, 1981). Human plasminogen 
(see table 1.1) is a single chain glycoprotein consisting 
of 7 90 aminoacids which is manufactured primarily in the 
liver (Marsh, 1981). Native plasminogen has an amino 
terminal glutamic acid (glu-plasminogen) but is easily 
converted by plasmic digestion to amino terminal lysine, 
valine or methionine - called lys-plasminogen. Both glu- 
and lys- plasminogen exist in multiple iso-electric
forms. This plasminogen is converted to plasmin by
cleavage of a single peptide bond, which is brought about 
by urokinase or the other plasminogen activators.
Activation of glu-plasminogen to plasmin by urokinase is
TABLE 1.1
COMPONENTS OF THE FIBRINOLYTIC SYSTEM
COMPONENT
^  MOLECULAR 
WEIGHT
PLASMA
CONCENTRATIONS
Fibrinogen 340,000 10 jamol/1
c>C 2-Macroglobulin 725,000 3.5 pmol/1
Plasminogen 90,000 2.4 pmol/1
C< 2-Antiplasmin 67,000 1,0 pmol/1
t-PA 72,000 7 0 pmol/1
t-PA Inhibitor 50,000 2 0-100 pmol/1
BBeta 15-42 3040 50 0 pmol/1
Legend
Approximate ( ^ )  molecular weight (daltons) and plasma 
concentrations of the main components of fibrinolysis.
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much slower in purified systems than that of 
lys-plasminogen and this is reflected in the plasma 
half-lives (t-1/2) of the 2 forms; glu-plasminogen with a 
mean t-1/2 of 2.24 days, lys-plasminogen with a t-1/2 of 
0.8 days (Marsh, 1981). In vivo it is unclear in which 
sequence the hydrolysis occurs. The plasminogen molecule 
contains lysine-binding sites through which it binds to 
fibrin. Lys-plasminogen has a higher affinity for fibrin 
than glu-plasminogen. These lysine-binding sites also 
bind 6-aminohexanoic acid which can abolish the absorption 
of plasminogen to fibrin (Collen, 1985) and these binding 
sites also mediate its interaction with
alpha2-antiplasmin. More recently it has been
demonstrated that histidine-rich glycoprotein has 
fibrinolysis-regulating properties. This protein also 
interacts with the lysine- binding sites of plasminogen to 
form a reversible complex and thereby inhibits binding of 
plasmin (ogen) to fibrin (Lijnen, De Cock and Collen, 
1981). Changes in concentration of plasma plasminogen or 
histidine-rich glycoprotein may alter the concentrations 
of "free" (ie, available) plasminogen.
1.5 PLASMIN
Plasmin is a 2 chain molecule composed of a heavy 
chain or A chain, originating from the amino terminal end 
of plasminogen and a light chain or B chain constituting 
the carboxy terminal part. Plasmin is a trysin - like 
serine protease whose action is much more specific for 
fibrin (ogen) than trypsin, but plasmin can split peptide
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bonds in practically all protein substrates and a wide 
variety of esters of arginine and lysine. It is not 
normally detected in human plasma as it is rapidly 
neutralised by inhibitors.
1-6 PLASMINOGEN ACTIVATORS 
A number of substances can convert plasminogen to 
plasmin, and a brief classification is given in table 
1*2. I will concentrate only on the physiological 
activators. Plasminogen activation may occur by an 
intrinsic or humoral pathway in which all the components 
involved are present in the blood, or by an extrinsic 
pathway in which the activators originate from the vessel 
wall. Alternatively, plasminogen may be activated by an 
exogenous pathway by administration of streptokinase or 
urokinase. All plasminogen activators act through 
hydrolysis of the arginine 560 - valine 561 bond in
plasminogen (Erickson et al., 1985), although the mode of 
action of urokinase differs from streptokinase.
]^ .^ ._1 Intrinsic Pathway Activation
The existence of an intrinsic pathway of activation 
of plasminogen was first suggested over 25 years ago 
(Niewiarowski and Prou-Wartelle, 1959; latridis and
Ferguson, 1962) since when most work has concentrated on 
the factor Xll-dependent pathway. The factor XII (Hageman 
factor)-dependent pathway involves prekallikrien (Fletcher 
factor), high-molecular weight kininogen (Fitzgerald
TABLE 1 . 2
CLASSIFICATION OF PLASMINOGEN ACTIVATORS
Physiological
Extrinsic plasma activators 
tissue activator* 
vascular endothelial activator*
Intrinsic plasma activators 
factor XII - dependent 
- factor XII - independent 
Urinary activator (urokinase)
Non-physiological 
Bacterial
streptokinase
staphylokinase
Chemical
chloroform
glycerol
(Taken from Marsh, 1981)
Legend
Division of plasminogen activators by physiological
function.
*tissue and vascular endothelial activator are 
identical and are now called tissue-plasminogen 
activator (International Committee on Thrombosis 
and Haemostasis recommendation).
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factor) or other components not yet identified, yet 
patients with these factor deficiencies do not have 
clinically relevant abnormalities of haemostatic function 
(Bennett and Ogston, 1981). The factor Xll-independent 
pathway has received much less attention and overall the 
pathophysiological role of intrinsic pathway activation is 
largely unknown (Hedner and Nilsson, 1981; Marsh, 1981; 
Collen, 1985).
Extrinsic Pathway Activation 
Plasminogen activators are present in most tissues 
while the plasminogen activator derived from the vessel 
wall, designated as extrinsic (Kluft, 1978) has received 
the most attention. Kluft (1978) demonstrated that the 
Cl-inactivator-resistant activity on fibrin plates 
reflected extrinsic plasminogen activator and he later 
demonstrated that the short-term fluctuations in plasma 
fibrinolytic activity were due to variations in secretion 
from the vessel wall (Kluft, 1981). These fluctuations, 
such as the diurnal rhythm of fibrinolytic activity, the 
increase in fibrinolytic activity induced by exercise, 
stress, venous occlusion, or by pharmacological means (ie, 
DDAVP, adrenaline, nicotinic acid), had in the past been 
inferred from changes detected in euglobulin fibrinolytic 
activity. It is probable that the activator found in 
blood represents release of vascular plasminogen activator 
(Rijken et al., 1980) and a number of studies have 
demonstrated that vascular plasminogen activators are
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similar or identical to the tissue plasminogen activator 
(Collen, 1985). These plasminogen activators will be 
referred to as tissue-type plasminogen activator (t-PA), 
as suggested by the International Committee on Thrombosis 
and Haemostasis in 1982. Refinements in the assays for 
t-PA have included specific quenching antibodies to t-PA 
on fibrin plates (Kluft, Jie and Allen, 1983) and since 
1982 reports have appeared using an immunoradiometric 
assay. These reports have confirmed the rise in t-PA with 
exercise, venous occlusion and DDAVP (Rijken, Hoylaerts 
and Collen, 1982; Kluft et al., 1983). While basal levels 
of t-PA tend to be constant for a period of weeks, a large 
inter-individual variation was noted, and dramatic 
temporary fluctuations (by a factor of 50) occurs 
following such stimuli (Kluft et al., 1983).
Human t-PA is a single chain plasma protein 
consisting of 527 amino acids (see table 1.1) which 
requires a co-factor to express its activity, the most 
efficient being fibrin itself (Collen, 1985; Erickson et 
al., 1985). This supports the hypothesis that 
fibrinolysis is both triggered by and directed towards 
fibrin (Collen, 1985). The commercial assay for t-PA has 
only become available in our laboratory from 1986 and will 
not be evaluated in this thesis.
1-Z BBETA 15-42 FRAGMENT
To explain the mechanism whereby the BBeta 15-42 
fragment is generated, and the value of the BBeta 15-42 
assay, it is first necessary to briefly describe the
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degradation of fibrin (ogen) (see figure 1.2). The 
digestive action of plasmin results in the early cleavage 
of two-thirds of the carboxy terminal of the AAlpha chain 
- peptide A, and cleavage of peptides BBeta 1-42 from the 
amino terminal of the BBeta chain. On the other hand 
thrombin cleaves fibrinopeptide A from the amino terminal 
of the AAlpha chain producing fibrin I and thereafter 
thrombin and plasmin may compete for the amino terminal 
end of the BBeta chain. If thrombin cleaves the BBeta 
14-15 bond, fibrinopeptide B is released and fibrin II is 
formed, whereas if plasmin now acts on the BBeta 42-43 
bond, the products are BBeta 1-4 2 and fragment X. Thus 
measurement of the BBeta peptides can indicate in vivo 
fibrino(geno)lysis (Nossel, 1981; Kudryk et al., 1982). 
If both fibrinopeptide A and BBeta peptides are 
simultaneously measured a differential diagnosis of 
thrombosis or fibrinolysis can be made. Primary 
fibrinolysis occurs when levels of BBeta peptides alone 
are elevated, while secondary fibrinolysis occurs if there 
is a simultaneous elevation of both fibrinopeptide A and 
BBeta peptides indicating both thrombin and plasmin 
generation.
1^ .^  INHIBITORS OF FIBRINOLYSIS
Since chloroform was shown to stimulate fibrinolysis 
by destruction of fibrinolytic inhibitors (Delezenne and 
Pozerski, ,1903) several inhibitors of fibrinolysis have
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been discovered including most recently alpha2-antiplasmin 
and t-PA inhibitor.
l_.^ .l^  Intrinsic Pathway Inhibitors
Cl-inactivator is known to inhibit factor 
Xlla-induced fibrinolysis, and alpha2-macroglobulin and 
antithrombin III also inhibit this pathway (Collen, 
1981). Since the role of the intrinsic fibrinolytic 
pathway is not established, the physiolgic role of these 
inhibitors remain speculative.
Alpha2-Antiplasmin 
It is now known that there are at least six plasma 
protein inhibitors of plasmin, alpha2-antiplasmin, 
alpha2-macroglobulin, alphal-antitrypsin,
inter-alpha-trypsin inhibitor, antithrombin III and
complement 1-inhibitor (Marsh, 1981) although it seems
likely that only the first 2 have any physiological 
importance. Alpha2-antiplasmin is a single chain 
glycoprotein which is the major plasmin inhibitor (see
table 1.1). Alpha2-antiplasmin forms a stable 1:1 
stoichiometric relationship with plasmin and is one of the 
fastest protein-protein interactions found. In addition 
to its major role in inhibiting plasmin, 
alpha2-antiplasmin inhibits plasminogen activator, 
inhibits the absorption of plasminogen to fibrin, and 
cross-links to fibrin rendering it less susceptible to
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plasmin (Collen, 1980; Aoki et al., 1981). 
Alpha2-antiplasmin has a mean t-1/2 of 2.6 days which 
shortens to 0.5 days during thrombolytic therapy (Collen, 
1981). There are 4 families in whom congenital 
alpha2-antiplasmin deficiency has been noted, and the 
bleeding tendancies in homozygous patients confirms the 
physiological importance of this inhibitor (Aoki, 1984). 
Alpha2-antiplasmin is also a weak acute phase reactant 
(Matsuda et al., 1980).
1^. 8 ._3 Alpha2-Macroqlobulin
Alpha2-macroglobulin is a large glycoprotein (see 
table 1.1). which represents the slower reacting plasmin 
inhibitor, and its role seems to be inactivate plasmin 
formed in excess of the inhibitory capacity of 
alpha2-antiplasmin (Collen, 1976).
t-PA Inhibitor 
Although it was noted that cultured endothelial cells
have an anti-fibrinolytic activity (Loskutoff and
Edgington, 1977) it has only been in the last 2-3 years 
that a fast-acting inhibitor to t-PA has been 
characterised (see table 1.1). The purified inhibitor is
a single-chain glycoprotein which forms a 1:1 
stoichometric complex with t-PA and thereby modifies its 
action. It is an example therefore of an antiactivator as 
opposed to an antiplasmin. This inhibitor is a major
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secretory product of the endothelial cell accounting for 
between 2.5% to 12% of all the proteins released by the 
cell, and an immunological1y related t-PA inhibitor is 
found in platelets (Erickson, Ginsberg and Loskutoff,
1984). Although the exact mechanism for clearing the 
fast-acting t-PA inhibitor is not established, its t-1/2 
(in rabbits) has been reported to be about 7 minutes 
(Colucci, Paramo and Collen, 1985). Recent studies have 
shown that elevated levels of t-PA inhibitor have been 
found in patients with hyperlipidaemia (Brommer et al., 
1984a), coronary artery disease (Paramo et al., 1985; 
Estelles et al., 1985), venous thrombosis (Nilsson, 
Ljungner and Tengborn, 1985), septicaemia (Colucci et al.,
1985) and in patients who show a poor fibrinolytic 
response to bicycle exercise or DDAVP (Brommer et al., 
1^84a). The raised t-PA inhibitor levels may be relevant 
to the defective fibrinolysis associated with these 
varying conditions. In addition, improved fibrinoytic 
activity has been observed in association with a reduced 
t-PA inhibitor level induced by stanozolol (Verheijen et 
al., 1984) and activated protein C (Van Hinsbergh et al., 
1985). This accumulating evidence points to t-PA 
inhibitor being an important physiological regulator of 
t-PA activity in vivo.
i-Z F D P 'S
A brief summary of fibrinogen/fibrin degradation is 
illustrated in figure 1.2. FDP's have a marked influence 
on coagulation by prolongation of the thrombin clotting
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time and by inhibiting platelet function (Marsh, 1981). 
Fragment X is still susceptible to thrombin action but 
fragments Y, D and E form soluble complexes and are non 
clottable (Lowe and Prentice, 1980). '
1.1_0 REGULATION OF FIBRINOLYSIS
While the interaction between the various components 
of the fibrinolytic enzyme system have been clearly 
illustrated (figure 1.1) the trigger factors controlling 
the release of t-PA are unknown. Observations that 
pitressin (Schneck and von Kaulla, 1961) and later 
vasopression (Gader, Da Costa and Cash, 1973) or 
hypothalamic stimulation could enhance plasma fibrinolytic 
activity led to the suggestion that the
hypothalamic-hypophyseal region could be a central 
regulator of plasminogen activator release (Cash, 1975). 
Recent studies however have failed both to show any 
abnormalities of fibrinolysis in panhypopituitary patients 
(Juhan-Vague et al., 1984) and to isolate a plasminogen 
activator releasing hormone (PARK) from the 
neurohypophysis (Colucci et al., 1984). The fact that 
intra-arterial adrenaline but not DDAVP stimulated the 
release of plasminogen activator from the infused local 
vascular bed, indicates that the catecholamine-responding 
and vasopression-responding receptors • are both molecule 
specific and different in anatomical site (Cash et al., 
1978). The central control or mediator system of 
plasminogen activator release is still therefore largely
4 l
unknown (Kluft, 1981).
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CHAPTER 2
REVIEW OF THE CHARACTERISTICS AFFECTING FIBRINOLYSIS
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2.1 INTRODUCTION
In this chapter I will attempt to review the previous 
studies on fibrinolysis which are relevant to this thesis, 
and to evaluate the evidence linking defective
fibrinolysis to thrombosis. The effects of acute injury 
on fibrinolysis will not be reviewed since, in the main, 
the work presented in this thesis relates to fibrinolysis 
studied in the non-acute phase, i e , the basal state. This 
review covers work published up to March of 1986 and 
concentrates on the more recent studies. For detailed 
reviews, prior to 1981, of the clinical relevance of 
fibrinolysis to thrombosis the reader is referred to the 
following articles: Davidson and Walker, 1979a; Davies,
Crandon and McNicol, 1981; Davidson and Walker, 1981;
Hedner and Nilsson, 1981.
2'Z Venous Thrombosis
Deep vein thrombosis (DVT) and fibrinolysis has not 
been formally evaluated in this thesis and I will 
therefore only give a brief summary on the large volume of 
evidence on this topic. The link between recurrent DVT, 
thrombophlebitis and defective blood and vein wall 
fibrinolytic activity was first reported in 1972 (Isacson 
and Nilsson, 1972) and this has been confirmed in other 
large studies (Browse et al., 1977a; Stormorken, Lund, and 
Holmsen, 1983). It has also been shown that the 
recurrence rate for patients with DVT or pulmonary 
embolism is less in patients with better fibrinolytic
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capacity (Korninger et al., 1984). Recent studies have 
shown that defective fibrinolysis is due to either 
defective release of t-PA or an increase in t-PA inhibitor 
(Bergsdorf, Nilsson and Wallen, 1983; Nilsson, Ljungner 
and Tengborn, 1985). Post-operative DVT has also been 
associated with diminished fibrinolytic activity 
(Mansfield, 1972; Gordon-Smith, Hickman and le Quesne, 
1984; Clayton, Anderson and McNicol, 1976) and 
pre-operatively the euglobulin clot lysis time has been 
used as a part of a predictive index for venous thrombosis 
(Clayton et al., 1976; Crandon et al., 1980). There 
appears to be little doubt that fibrinolysis plays a role 
in DVT. For a more detailed account of the accumulated 
evidence, the reader is referred to previous reviews on 
this subject (Davidson and Walker, 1979a; Vermylen and 
Chamone, 197 9; Hedner and Nilsson, 1981).
^.3_ EXERCISE AND FIBRINOLYSIS
2yZ-l Mechanisms of the Increased Fibrinolytic Activity
In his treatise on blood, John Hunter (179 4) was 
probably the first to record the effects of exercise on 
haemostasis, observing the phenomenon of incoagulable 
blood in deer run to death. The association between 
exercise and fibrinolysis was first reported however in 
1947 when an increase in plasma fibrinolytic activity was 
detected in subjects immediately after running up and down 
stairs (Biggs, MacFarlane and Pilling, 1947). This 
finding has since received widespread confirmation. The
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rise in fibrinolytic activity is due to increased plasma 
levels of plasminogen activator (Sawyer et al., 1960) and 
the magnitude of this rise has been related to the 
duration of exercise (Bennett, Ogston, and Ogston, 1968), 
the intensity of exercise (Davis et al., 1976) and the 
time of the day that exercise is performed (Rosing et al., 
1970). Although there is a significant difference in 
response between individuals, the fibrinolytic response to 
exercise is reproducible in any one individual (Cash, 
1966). The increase in plasma fibrinolytic activity in 
these studies, as assessed by euglobulin lysis times, 
could be due to increases in either the intrinsic or 
extrinsic plasminogen activator systems. Marsh and 
Gaffney (1980), in a small study of 4 subjects, found no 
increase in the intrinsic plasminogen activators with 
exercise while a more detailed study (Huisveld et al.,
1984) has shown that the increases in fibrinolytic 
activity are due to increased levels of both intrinsic and 
extrinsic plasminogen activators. Kluft and colleagues 
(1983) demonstrated that extrinsic (tissue-type) 
plasminogen activator activity (measured on fibrin plates 
with added Cl-inactivator) post exercise could be totally 
suppressed by the addition of specific antibodies to t-PA 
thus suggesting the rise in fibrinolytic activity with 
exercise was due to a rise in extrinsic plasminogen 
activators alone. Using specific assays for t-PA activity 
and antigen it has been noted that both increase markedly 
after strenuous bicycle exercise (Bergsdorf et al., 1983; 
Wiman, Mellbring and Ranby, 1983). The different
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half-lives (t-1/2) of t-PA antigen (t-1/2 = 10 minutes) 
and t-PA activity (t-1/2 = 5 minutes) was taken as
evidence for the existence of an inhibitor to t-PA 
activity which acts rapidly to inactivate about half of 
the exercise-related t-PA activity generated (Bergsdorf et 
al., 1983). Kluft and co-workers (1983) had previously 
noted that the rise in t-PA following exercise was 
short-lived (t-1/2 = 5.5 minutes) and suggested that the
short half-life was due to rapid clearance by the liver. 
Previous studies have shown that some patients have a 
consistently poor response to exercise and that such 
patients continue to show impaired responses despite 
prolonged and exhaustive exercise (Cash, 1966; Cash and 
Woodfield, 1967). Recent work suggests that these 
patients have high t-PA inhibitor levels (Brommer et al., 
1984a). The rise in plasma plasminogen activator is not 
associated with a reduction in plasminogen concentration 
(Bennett et al., 1968; Marsh and Gaffney, 1980; Huisveld 
et al., 1984) but plasminogen turnover is slightly 
increased by repeated strenuous exercise (Collen et al., 
1977). The exact mechanism responsible for this 
exercise-stimulated fibrinolytic activity is still an 
enigma although it is thought that the increased perfusion 
of muscle capillaries and veins, in association with 
physical activity, leads to an increased release of t-PA 
from the endothelial cells in the vessel wall (Nilsson, 
Hedner and Pandolfi, 1980; Rijken, Wijngaards and 
Welbergen, 1980). Exercise also increases factor VIII 
concentrations and it is possible that a higher level of
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plasminogen activator is important for maintaining a 
satisfactory haemostatic balance. The possible role of 
adrenergic mechanisms in the enhanced fibrinolytic 
activity after exercise will be discussed in Chapter 4.
2_.3.2_ Does Exercise Activate Fibrinolysis ?
Despite the elevation of plasma fibrinolytic activity 
the evidence that actual fibrinolysis occurs, as evidenced 
by a rise in fibrin (ogen) degradation products (FDP's), 
is equivocal. A rise in FDP's has been described by some 
workers (Ferguson et al., 1979; Hyers et al., 1980; 
Mandalaki et al., 1980; Dufaux, Order and Hollman, 1984) 
but not others (Collen et al., 1977; Vogt, Hoffman and 
Straud, 1979; Marsh and Gaffney, 1982). Factors which may 
explain such discrepancies include the intensity and 
duration of exercise in combination with the different FDP 
assays used in these studies. Degradation of the AAlpha 
chain of fibrinogen has been shown to increase (Collen et 
al., 1977; Marsh and Gaffney, 1980) or to remain unchanged 
following exercise (Ferguson, Barr and Bernier, 1979). 
The AAlpha chain is of particular interest because it is 
the chain of fibrinogen most susceptible to degradation by 
plasmin (Ferguson, Fretto and McKee, 1975). In addition, 
Collen and co-workers (1977) demonstrated a small increase 
in the level of plasmin-antiplasmin complexes following 
exercise, but it seems likely that any small amount of 
plasmin generated by exercise would be rapidly inactivated 
by alpha2-antiplasmin. Overall it is felt that despite
the rise in plasma fibrinolytic activity with exercise.
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plasma proteolytic activity does not occur - ie, the 
actual fibrinolytic effect is non-existent (Marsh and 
Gaffney, 1982; Ogston, 1983).
^._3.^ Physical Fitness and Fibrinolysis
There appears to be no differences in the resting 
level of fibrinolytic activity between inactive men and 
men who perform regular exercise (Moxley, Brakman and 
Astrup, 1970; Korsan-Bengtsen, Wilhelmsen and
Tibblin,1973) while fibrinolytic activity at rest is 
decreased by a period of physical training (Keber et al., 
1979; Williams et al., 1980). Physical training does not 
augment the fibrinolytic response to exercise (Keber et 
al., 1979; Dufaux et al., 1984), but it does clearly 
increase the fibrinolytic response to venous occlusion 
which may be relevant to the beneficial effects of 
exercise with regard to the risk of cardiovascular disease 
(Williams et al., 1980). This latter study (Williams et 
al., 1980) involving a large group of subjects, provided 
the best evidence to date of a positive effect of exercise 
training on the fibrinolytic enzyme system.
2.4 EFFECTS OF SMOKING 
While smoking is associated with higher fibrinogen 
concentrations (Korsan-Bengtsen, Wilhelmsen and Tibblin, 
1972; Meade et al., 1979; Scarabin et al., 1982) the 
effects on plasma fibrinolytic activity are more 
controversial. Thus Korsan-Bengtsen and co-workers (197 2) 
found no difference in plasma fibrinolytic activity
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in smokers in a population study of middle-aged men, while 
Janzon and Nilsson (1975) found no differences in plasma 
or vein wall fibrinolytic activity in healthy smokers 
compared to non-smokers. The largest population study to 
date did detect a small decrease in fibrinolytic activity 
in smokers compared to non-smokers (Meade et al., 1979). 
More detailed studies on the effect of smoking on the 
components of fibrinolysis have shown that smoking is 
associated with diminished plasma fibrinolytic activity 
(measured on both dilute blood clot lysis times and 
euglobulin activity) due to diminished extrinsic 
plasminogen activator levels (Allen, Kluft and Brommer, 
1983). This latter study also showed a significantly 
smaller rise in extrinsic plasminogen activator following 
DDAVP infusion. It appears therefore that smoking is 
associated with reduced fibrinolytic activity due to the 
extrinsic system of fibrinolysis and that smoking may 
alter the dynamic responses of fibrinolytic activity.
2.^ EFFECTS OF LIPIDS 
There is growing evidence that hypertriglyceridaemia 
is associated with depressed resting plasma fibrinolytic 
activity (Korsan-Bengtsen et al., 1972; Simpson et al., 
1983), reduced diurnal fluctuations in plasma fibrinolytic 
activity (Rosing et al., 1973) and reduced fibrinolytic 
responses to venous occlusion (Marsh and Shaper, 1977; 
Andersen, Arnessen and Hjermann, 1981) exercise (Epstein 
et al., 1970) and DDAVP (Brommer et al., 1982). 
Triglyceride levels have also been negatively associated
50
with in vivo fibrinolysis (BBeta 15-42 antigen) in an 
epidemiological study (Lowe et al., 1985). Plasma 
fibrinolytic capacity (to venous occlusion) does not 
improve with average reduction in hyperlipidaemia by 
dietary measures (Andersen et al., 1981) but successful 
reduction in lipid profiles, after 6 years of diet
intervention, has been shown to improve fibrinolytic
capacity when compared to hyperlipidaemic controls 
(Andersen, Arnesen and Hjermann, 1983a). Improvements in 
hypertriglyceridaemia, by diet and drugs, over periods of 
between 3-6 months have also resulted in improvements in 
resting fibrinolytic activity (Elkeles et al., 1980;
Simpson et al., 1983). Lowe and co-workers (1982) have 
shown that alpha2-antiplasmin levels are raised in type II 
hyperlipoproteinaemia while a positive association of
alpha2-antiplasmin with triglyceride concentrations has 
been noted in a recent epidemiological study (Lowe et al.,
1985). A previous epidemiological study failed to find 
this association (Scarbin, Bara and Jacqueson, 1983). 
Furthermore, increased triglyceride levels have also been 
associated with increased t-PA inhibitor levels (Brommer 
et al., 1984a) and the evidence to date is in favour of an 
impairment of fibrinolytic activity by
hypertriglyceridaemia due possibly to raised levels of 
fibrinolytic inhibitors acting at distinct sites - ie, 
against plasmin and t-PA.
Cholesterol concentrations, which do not show a clear 
relationship with plasma fibrinolytic activity 
(Korsan-Bengtsen et al., 1972) are positively related to
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fibrinogen (Korsan-Bengtsen, 1972; Baker et al., 1982) and 
alpha2-antiplasmin concentrations (Scarabin et al., 1983; 
Lowe et al., 1985).
2.6 EFFECT OF BODY WEIGHT 
Many authors have examined fibrinolytic activity in 
obesity and found it to be reduced (Fearnley, Chakrabarti 
and Avis, 196 3; Bennett et al., 1966). In the large 
prospective population studies in middle-aged men a 
negative correlation of both weight and fibrinolytic 
activity (Korsan-Bengtsen et al., 1972) and subscapular 
skin fold thickness and fibrinolytic activity have been 
noted (Korsan-Bengtsen et al., 1972; Meade et al., 1979). 
The reduction in plasma fibrinolytic activity in obesity 
is not associated with alterations in the inhibitors of 
fibrinolysis suggesting a decreased production of 
plasminogen activator (Bennett et al., 1966) and indeed a 
decrease in the activity of vessel wall plasminogen 
activator has been noted in obese subjects (Aimer, 
1975a). Obese subjects have also been reported as having 
a poor fibrinolytic response to exercise (Ogston and 
McAndrew, 1964), and venous occlusion (Aimer, 1975a). 
Obese subjects tend to have raised triglyceride 
concentrations and which of these 2 factors are more 
closely related to defective fibrinolysis is difficult to 
estimate. Using multiple regression statistics 
Korsan-Bengtsen and colleagues (1972) found obesity to be 
the more important variable.
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1-Z f i b r i n o l y s i s  a n d  i s c h a e m i c  h e a r t  d i s e a s e
The effects of acute myocardial infarction on 
fibrinolysis have been well documented and it appears that 
significant changes occur in most of the components of the 
fibrinolytic system as part of an acute phase response 
rather than a cause of, or response to, thrombosis per se 
(Hume, 1958; Bennett, Ogston and Ogston, 1967; Knudsen et 
al., 1979; Haines et al., 1983; Juhan-Vague et al.,
1983). The following review therefore concerns studies 
involving patients outwith the period of their acute 
myocardial infarct.
The effect of ischaemic heart disease on fibrinolysis 
(or vice versa) was first investigated in the early 1960 "s 
when the plasma fibrinolytic activity (clot lysis times) 
of men with ischaemic heart disease (known angina pectoris 
or a previous myocardial infarction) did not differ from 
that of matched control groups (Merskey et al., 1960; 
Ogston, 1962; Katz et al., 1963). Other control studies 
failed to confirm these findings reporting a greater 
incidence of low fibrinolytic activity among patients with 
ischaemic heart disease (Gajewski, 1961; Chakrabarti et 
al., 1966). Chakrabarti et al., (1968), in a large study 
of male survivors of a myocardial infarction and 
age-matched controls, confirmed that a greater percentage 
of their patients had persistently defective fibrinolytic 
activity which was more marked in patients under 50 years 
of age. Similar results were reported by Lipinska and 
co-workers (1979) who in addition noted reduced 
fibrinolytic activity in healthy subjects with a family
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history of coronary disease. These previous studies 
assessed the resting level of plasma fibrinolytic activity 
in men with ischaemic heart disease, but normal
physiological variations, such as the diurnal rhythm of 
fibrinolytic activity, and dynamic tests have also been 
employed. Patients with coronary artery disease were 
noted to have reduced diurnal variations in plasma
fibrinolytic activity (Rosing et al., 1973), and reduced
fibrinolytic potential was 'more commonly' found using
venous occlusion (Walker et al., 1977; O'Connor et al., 
1984a) or exercise (Khanna et al., 1975) when compared to 
controls. O'Connor and co-workers also noted higher basal 
protein C values in these same patients with impaired 
fibrinolytic capacity when compared to controls, which 
remains unexplained, since protein C is thought to 
stimulate fibrinolysis (O'Connor, Broekmans and Bertina, 
1984b). Fibrinolysis has also been found to be defective 
in coronary artery disease when bicycle exercise was used 
as the dynamic stimulus to fibrinolysis (Khanna et al., 
1975; Estelles et al., 1985). The alteration of diurnal 
rhythm and fibrinolytic potential are compatible with the 
hypothesis that an impairment in the responsiveness of the 
fibrinolytic system may be related to the development of 
coronary artery disease.
Two large epidemiological, prospective studies in 
middle-aged men have failed to show a significant 
difference in fibrinolytic activity in men who died of 
cardiovascular disease as compared to survivors (Meade et 
al., 1980) and in men who sustained a myocardial
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infarction compared to men who remain healthy (Wilhelmsen 
et al., 1984). Fibrinolytic activity was however slightly 
lower in men who died of cardiovascular diseases compared 
to survivors (Meade et al., 1980).
The above studies have utilised the clot lysis time 
or euglobulin fibrinolytic activity as a global assessment 
of fibrinolysis. In a large controlled study involving 
patients with angiographically proven coronary artery 
disease, euglobulin fibrinolytic activity was not 
significantly different from controls, while patients had 
significantly elevated concentrations of plasminogen 
activator inhibitor activity and t-PA antigen (Paramo et 
al.,1985). These authors stress the possible importance 
of the elevated concentrations of plasminogen activator 
inhibitor and questioned the value of euglobulin
fibrinolytic activity as a test of in vivo fibrinolysis, 
but ignored the findings of elevated t-PA levels which 
would be expected to enhance fibrinolysis. Patients with 
coronary artery disease performing bicycle exercise show 
an impaired response of t-PA compared to controls, without 
significant differences in t-PA inhibitor or euglobulin 
fibrinolytic activity (Estelles et al., 1985).
In summary there appears to be little evidence that 
euglobulin fibrinolytic activity, in patients with 
ischaemic heart disease, is different from healthy
controls, while dynamic tests of fibrinolysis may show 
defective euglobulin fibrinolytic activity in such
patients. More detailed assays have not clarified the 
situation by showing elevated t-PA antigen and protein C
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(17-beta-hydroxy-17-alpha-methandrostano (3.2,-c)
pyrazole) has proved the most promising drug available at 
present and has therefore been intensively studied in a 
variety of disorders. At the 7th International Congress 
on Fibrinolysis held in Venice in 1984, stanozolol
remained the most widely studied oral agent to cause 
pharmacological potentiation of fibrinolysis.
Interest in drug stimulated fibrinolysis stemmed from 
the observations of poor blood fibrinolytic activity in 
survivors of myocardial infarction (Chapter 2.7) and it 
was suggested that survivors of myocardial infarction 
might benefit from long-term fibrinolytic therapy 
(Anonymous, 1968). The initial studies revealed that 
drugs given orally (such as biguanides or the anabolic 
steroid ethyloestrenol) could enhance fibrinolysis for up 
to 3 months but when given in combination could act for up 
to 3 years (Fearnley, Chakrabarti and Evans, 1969; 
Chakrabarti, Evans and Fearnley, 1970). In open studies 
on fibrinolytic enhancement using phenfcrmin and 
ethyloestrenol in patients with Raynaud's disease, 
ischaemic heart disease, and occlusive vascular disease it 
was found that replacing ethyloestrenol by stanozolol, in 
combination with phenformin, produced similar effects on 
fibrinolysis (Chakrabarti et al., 1970; Menon et al., 
1970). Fibrinolytic enhancement also occurred when 
stanozolol was combined with either of the biguanide 
drugs, phenformin or metformin, in patients with DVT or 
ischaemic heart disease (Menon, 1971). The combination of 
stanozolol plus phenformin has also been shown to enhance
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fibrinolysis in patients with occlusive vascular disease 
and Behcet's syndrome (Asbeck, Meyer-Boernecke and van de 
Loo, 1978; Bielawiec, Mysliwiec and Perzanowski, 1978). 
In a double-blind randomised study involving 34 men with 
ischaemic heart disease it was shown that stanozolol by 
itself (10 mg/day for one year) was capable of stimulating 
fibrinolytic activity to a similar extent as the 
stanozolol plus phenformin combination, and that 
stanozolol therapy was associated with a rise in
plasminogen and fall in fibrinogen (Davidson et al., 
1972). The same workers later showed that anabolic 
steroids could lead both to a fall in alpha2-macroglobulin 
concentrations and to a sustained increase in fibrinolytic 
activity in men with ischaemic heart disease over a 5 year 
period (Walker et al., 1975; Walker et al., 1978). There 
followed a series of clinical trials which indicated that 
fibrinolytic enhancement by stanozolol may have 
therapeutic potential in a variety of situations. A 
double-blind, placebo-controlled study involving 25 
patients with cutaneous vasculitis indicated the 
therapeutic benefit of phenformin plus stanozolol (Dodman 
et al., 1973; Cunliffe et al., 1975). Open studies by the 
same workers, using stanozolol as sole therapy, showed 
that 13 of 16 patients with idiopathic recurrent
superficial thrombophlebitis had their attacks of 
thrombophlebitis stopped completely, and fibrinolysis 
enhanced, during 6 months taking stanozolol (Jarrett,
Morland and Browse, 1977); that an improvement in all 14 
patients with longstanding lipodermatosclerosis was noted
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while patients received stanozolol (Browse et al., 1977b); 
and that all 20 patients with advanced Raynaud's 
phenomenon showed an increase in hand blood flow and a 
reduction in symptoms while receiving stanozolol (Jarrett, 
Morland and Browse, 1978). In a double-blind, cross-over 
trial involving 23 patients with venous
lipodermatosclerosis it was found that stanozolol plus 
elastic stcckings reduced the extravascular fibrin 
detected in skin biopsy specimens and doubled the rate of 
skin healing compared to the group taking placebo plus 
elastic stockings (Burnand et al., 1980). The same 
authors later produced evidence to show that pericapillary 
fibrin is the likely cause of lipodermatosclerosis and 
venous ulceration (Burnand et al., 1982). The therapeutic 
effect of stanozolol in this condition is thought to be 
related to improved fibrinolysis with reduced fibrin 
deposition in the ulcer bearing area of the leg (Burnand 
et al., 1982).
Interest in stanozolol was again generated by the 
study of Preston et al., (1981) showing that oral 
stanozolol could enhance plasma fibrinolytic activity, 
lower fibrinogen, alpha2-macroglobulin and increase 
plasminogen levels in normal subjects. In addition they 
showed that these alterations were all detected within one 
week of starting stanozolol. It was felt that if 
stanozolol could enhance fibrinolysis in normal subjects 
then in patients with depressed fibrinolysis a more 
pronounced effect was likely (Preston et al., 1981). It 
was at this time that our laboratory became involved with
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a number of clinical studies using stanozolol, some of 
which are presented in this thesis. The encouraging 
results of fibrinolytic enhancement following a single 
intramuscular injection of stanozolol (Small et al., 
1982b) has led others to study the effects of 
intramuscular stanozolol in patients undergoing major 
surgery. Although stanozolol prevented the fibrinolytic 
shutdown associated with surgery (Bla.mey et al., 1983 ) it 
failed to prevent DVT (McArdle et al., 1983; Blamey et 
al., 1984) or post-operative pulmonary dysfunction 
(Cuschieri et al., 1985) in a double-blind controlled 
trial.
The mechanism whereby stanozolol exerts its effects 
has also received closer study. Protein C, which may 
stimulate fibrinolysis in addition to its potent 
anti-coagulant action (Comp and Esmon, 1981) has been 
shown to increase following stanozolol administration to 
healthy volunteers, surgical patients and elderly medical 
patients (Kluft et al., 1984a; Small et al., 1984c). 
However in a controlled study in patients undergoing major 
abdominal surgery given oral or intramuscular stanozolol 
protein C levels were not significantly different in 
patients with and without DVT (Blamey et al., 1985). 
Stanozolol has also been shown to stimulate in vivo 
fibrinolysis, as measured by increased BBeta 15-42 
concentrations, in healthy male subjects (Small et al., 
1983b), findings which have been confirmed in surgical 
patients (Douglas et al., 1985). Detailed studies by 
Kluft and co-workers (1984b) have shown that the increased
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fibrinolytic activity following stanozolol administration 
is due to increased t-PA activity which in turn is due to 
a marked fall in the recently discovered inhibitor of t-PA 
activity (Verheijen et al., 1984; Sue-Ling et al., 1985). 
Plasminogen circulates as a reversible complex with its 
carrier protein histidine-rich glycoprotein (Lijnen, 
Hoylaerts and Collen, 1980) and stanozolol has been shown 
to ■ decrease histidine-rich glycoprotein, increase 
plasminogen and therefore increase the concentration of 
"free" (ie, biologically active) plasminogen which 
theoretically should also contribute to the improved
fibrinolysis (Kluft et al., 1984b). The effects of 
stanozolol on the components of fibrinolysis are
illustrated in figure 2.1.
Stanozolol has also been used in hereditary 
coagulation disorders in an attempt to increase the
coagulation factor concentration and correct the 
disorder. Stanozolol has been shown to increase protein C 
and antithrombin III in patients with these deficiencies 
but to have no effects on factor VIII or IX concentrations 
(Mannucci et al., 1984; Winter et al., 1984; Greer et al., 
1985). While stanozolol increased fibrinolysis in all 3 
disorders a therapeutic effect on preventing 
thromboembolic problems in patients with protein C and 
antithrombin III deficiency remains unproven.
In summary, although stanozolol has been shown to
stimulate fibrinolysis in a variety of conditions, and the 
mechanism for its effect has been clearly delineated, the 
uncontrolled clinical trials allow no clear conclusion to
be reached as to its therapeutic benefit. The controlled 
trials indicate that stanozolol does not prevent DVT but 
does improve lipodermatosclerosis and cutaneous 
vasculitis.
2.9^ FIBRINOLYSIS AND DIABETES MELLITUS 
Z-Z-i Fibrinolytic Activity in Diabetes
Fibrinolysis in diabetes mellitus was first reported 
in 1961 when the plasma fibrinolytic activity in a small 
group of diabetics in England was found not to be 
significantly different from a matched control group 
(James et al., 1961). This was later confirmed from 
studies in Australia (Denborough and Paterson, 1962), 
North America (Sandberg et al., 1963; Moser and Hajjar , 
1966) and Scotland (McKay and Hume, 1964). However the 
largest study of that time compared 100 diabetics with 100 
controls and demonstrated a significantly low fibrinolytic 
activity in diabetic patients (Fearnley, Chakrabarti and 
Avis, 1963). Later controlled studies examined the 
dynamic response of plasma fibrinolytic activity ' to 
subcutaneous adrenaline (Tanser, 1967) and treadmill 
exercise (Cash and McGill, 1969) and produced further 
conflicting results. These studies employed a variety.of 
modified clot lysis times, tested diabetics at different 
times of day (never fasting), and usually failed to 
differentiate patients into type I (insulin-dependent) and
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type II (non-insulin dependent) diabetes. It is perhaps 
not surprising therefore that discrepant findings were 
produced. There followed a number of smaller studies but 
the next important evidence was reported by Aimer and 
co-workers (1975b). They compared plasma fibrinolytic 
activity (on fibrin plates pre and post venous occlusion) 
and plasminogen activator activity of the vein vessel wall 
in 221 diabetics with 221 control subjects and found that 
spontaneous plasma fibrinolytic activity and plasminogen 
activator content were significantly reduced in diabetic 
patients, and that the responses to venous occlusion were 
also impaired. The same workers also noted a close 
correlation between the plasminogen activator activity of 
veins and arteries in diabetes, indicating a widespread 
endothelial defect of the defence system against 
deposition of fibrin (Aimer, Pandolfi and Aberg, 1975c). 
In addition, the defective fibrinolytic activity could be 
related to the degree of obesity (Aimer, 1975a) and 
elevated triglyceride levels (Aimer, 1975a; Aimer et al, 
1975b). The largest study to date was reported by Fuller 
and co-workers (1979) who examined the plasma fibrinolytic 
activity in 154 diabetics compared to 1079 controls and 
found decreased fibrinolytic activity in the diabetics. 
When the type of diabetes was evaluated it was found that 
type I diabetic females had a small, but significantly 
reduced fibrinolytic activity, but that marked reductions 
in fibrinolytic activity were noted in both male and 
female type II diabetic subjects, which was only partially 
attributable to the greater obesity in the type II
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patients. In South Africa a comparison of fibrinolytic 
activity in Zulu diabetics (mainly type I) with Indian 
diabetics (mainly type II) revealed a greater depression 
of fibrinolysis in the Indian diabetics (Hathorn, Gillman 
and Campbell, 1961). The results of these studies 
indicated that diabetic patients, especially type II 
diabetics, have a depressed plasma fibrinolytic activity. 
More recent control studies, involving smaller number of 
patients, have given further conflicting results (Elder et 
al., 1980; Bern et al., 1981; Grignani et al., 1981; 
Sharma, 1981; Juhan-Vague et al., 1984; Haitas et al., 
1984; Knaap et al., 1985), although depressed fibrinolytic 
activity has been confirmed in other studies (Gurewich et 
al., 1981; Christe et al., 1984). Using more specific 
assays, both the total and fibrin binding extrinsic 
plasminogen activator related antigen were found not to be 
significantly different in diabetic patients compared to 
controls (Juhan-Vague et al., 1983; Juhan-Vague et al.,
1984).
To evaluate the effect of diabetic drug therapy on 
fibrinolysis, cross-sectional studies have been performed 
and show that patients taking sulphonylurea drugs have a 
marked depression of plasma fibrinolytic activity (Farid 
et al., 1974; Aimer and Nilsson, 1974) and more recently a 
small study has shown a defective plasminogen activator 
content of the vessel wall to occur commonly in patients 
on long-term, first generation sulphonylurea therapy 
(Aimer, 1984). Fibrinolytic activity and the treatment of 
diabetes will be discussed more fully in Chapter 10.
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Fibrinolytic Activity in Relation to the 
Microvascular Complications of Diabetes
Four main studies have assessed the effects of 
microvascular disease on fibrinolytic activity. The first 
and largest study of 221 diabetes and 153 controls found 
no difference in the spontaneous fibrinolytic activity in 
patients with and without diabetic retinopathy, but that 
patients with diabetes of greater than 10 years duration 
with retinopathy had significantly reduced fibrinolytic 
responses to venous occlusion which was even more marked 
in patients with nephropathy when compared to patients 
free of microvascular disease (Aimer et al., 1975a; Aimer 
and Pandolfi, 1976). In addition these authors also found 
no correlation of vessel wall plasminogen activator 
activity with the release of fibrinolytic activity on 
venous occlusion and postulated a faulty plasminogen 
activator release mechanism associated with microvascular 
disease. Haitas and colleagues (1984) compared the 
fibrinolytic activity pre and post venous occlusion in 13 
control subjects to 10 type I diabetics without, and 11 
type I diabetics with proliferative diabetic retinopathy. 
An impaired response to venous occlusion was noted in the 
proliferative group compared to both patients with no 
retinopathy and control subjects, while no differences 
between uncomplicated diabetics and control subjects were 
found. Christe and co-workers (1984) comparing 36 
diabetics with and 44 diabetics without complications
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found no differences in fibrinolytic activity either
before or after venous occlusion and Lowe and colleagues 
(1986) found no difference in unstimulated fibrinolytic 
activity in 18 patients with proliferative retinopathy 
compared to patients with no or minimal diabetic
retinopathy. These studies therefore have produced 
conflicting results but it appears that patients with 
microvascular disease have normal unstimulated 
fibrinolytic activity compared to diabetics without
complications, but that differences can perhaps be
demonstrated using a dynamic stimulus such as venous
occlusion, and that the most marked changes are found in 
patients with severe microvascular disease (proliferative 
diabetic retinopathy or nephropathy). It is possible
therefore that slow deposition of fibrin may occur in both 
the intra- and extravascular compartments in diabetic 
microangiopathy and that such fibrin deposition may be 
caused by a defective plasminogen activator release from 
the vascular endothelium. The demonstration of fibrin 
(ogen) within the glomerular capillary basement membrane 
in percutaneous renal biopsy samples taken at post mortem, 
add support to this theory (Davis, Woolf and Carstairs, 
1966; Farquhar, MacDonald and Ireland, 1972). While these 
findings suggest an important association between 
defective fibrinolysis and microangiopathy, large 
prospective studies are needed to clarify whether this 
association is a causal one. Microvascular disease will 
occur in approximately 70-80% of diabetics after 10-15 
years of type I diabetes and therefore it is likely that
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any prospective study would require a long period of 
follow-up. There are no such studies on-going at 
present.
In a comparison of diabetic patients with and without 
autonomic neuropathy patients with autonomic neuropathy 
have been reported to have better fibrinolytic responses 
to venous occlusion . (Aimer, Sundkvist and Lilja, 1982; 
Aimer, Sunkvist and Lilja, 1983) but others have found no 
correlation between fibrinolytic activity and autonomic 
neuropathy function tests (Haitas et al., 1984). Since 
autonomic neuropathy is thought to be a microvascular 
complication associated with both a long duration of 
diabetes and other microvascular complications, the 
improved fibrinolytic response to venous occlusion is 
unexpected, and the effect of autonomic neuropathy on 
fibrinolysis requires clarification.
"2 Fibrinolysis and Glycaemic Control
Lack of accurate techniques to assess long-term 
glycaemic control in diabetic patients made it difficult, 
in the past, to evaluate the effect of glycaemic control 
on fibrinolysis. With the realisation that practically 
all proteins become glycosylated, an accurate measure of 
long-term glycaemic control has become available. In 
non-enzymatic glycosylation, glucose becomes bound to free 
amino-groups of plasma, membrane and cellular proteins, 
depending on glucose concentration, incubation time and 
temperature (McVerry et al., 1981). Because of this 
glycosylation, the tertiary or quaternary structure.
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function and/or degradation of the protein molecule may be 
altered, as has been demonstrated for a number of proteins 
(Wieland, 1983). Glycosylation of haemoglobin moietes, 
ie, HbAl or HbAlc allows an overall assessment of 
glycaemic control over a period of 6-8 weeks prior to the 
test being taken. Clinical studies have utilised HbAl 
measurements from about 1978-79 and a number of studies 
reported on the relationship of glycaemic control in 
fibrinolysis. While Gunnarsson and colleagues (1980), in 
a cross-sectional study, found a significant inverse 
association of HbAl with fibrinolytic activity other 
workers have failed to confirm this association (Grignani 
et al., 1981; Dornan et al., 1983; Christe et al., 1984; 
Haitas et al., 1984). Longitudinal studies have shown 
that improvement of glycaemic control with significant 
lowering of HbAl concentrations have not been associated 
with any alterations in fibrinolytic activity (Paton et 
al., 1981; Knaap et al., 1985) although one study in type 
I diabetics treated with continuous subcutaneous insulin 
infusion showed a significant increase in fibrinolytic 
activity after 16 weeks of improved glycaemic control, 
while no changes in the respcnse to venous occlusion were 
noted (Greaves et al., 1983). Euglycaemia over a 24 hour 
period using the artificial pancreas has been shown to 
improve fibrinolytic activity and t-PA antigen levels 
(Juhan-Vague et al., 1984) but this type of insulin 
regimen is of little clinical relevance to the management 
of diabetic patients.
In vitro studies have demonstrated non-enzymatic
68
glycosylation of fibrinogen, plasminogen and vascular 
plasminogen activator (McVerry et al., 1981; Geiger, 
Beckmann and Binder, 1983); that glycosylation reduces the 
susceptibility of fibrin to plasmin degradation (Brownlee, 
Vlassara and Cerami, 1983); and that fibrin enhanced 
plasmin formation by diabetic vascular plasminogen 
activator is significantly impaired, and can be normalised 
by improved glycaemic control (Geiger and Binder, 1984; 
Geiger and Binder, 1985). An in vivo study has 
demonstrated that in type I diabetics there is increased 
glycosylation of fibrinogen as compared to controls 
(Lutjens et al., 1985). It has also been shown that 
fibrinogen survival is reduced in diabetes (Ferguson et 
al., 1975b; Jones and Paterson, 1979); that such changes 
are more marked in patients with diabetic retinopathy 
(Cederholm-Williams, Dornan and Turner, 1981); and that 
correction of hyperglycaemia improves fibrinogen survival 
(Jones and Paterson, 1979). Improved glycaemic control 
has been shown to lower (Greaves et al., 1983) or to have 
no effect on fibrinogen concentrations (Paton et al., 
1981; Knaap et al., 1985).
Hyperlipidaemia is common in diabetes mellitus and is 
closely linked to poor glycaemic control. The effect of 
elevated blood lipids in non-diabetics has already been 
discussed (Chapter 2.5) and in diabetes, hyperlipidaemia 
has also been associated with diminished fibrinolytic 
activity (Aimer et al., 1975b) and, more specifically, 
hypertriglyceridaemia has been shown to depress 
fibrinolytic activity in uncomplicated type II diabetes
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(Grignani et al., 1981). Whether the poor fibrinolytic 
activity in diabetes is more closely linked to poor 
glycaemic control or the resultant hyperlipidaemia has not 
been evaluated.
While there seems little doubt that glycosylation of 
proteins involved in the fibrinolytic enzyme system 
occurs, the lack of correlation of HbAl with the 
fibrinolytic activity in clinical studies casts some doubt 
on the effects of glycaemic control on fibrinolysis.
2.10 COMPONENTS OF FIBRINOLYSIS IN DIABETES 
2.10.1 Plasminogen
No differences in plasminogen concentration are found 
in either type I or type II diabetes when compared to 
control subjects ( Cederholm.-Wi 1 liams, et al, 1981; Hughes 
et al., 1983) and plasminogen levels are not related to 
diabetic retinopathy (Aimer et al., 1975b). Although 
plasminogen may be glycosylated in vitro (Geiger et al.,
1983) plasminogen turnover is normal in diabetes 
(Cederholm- Williams et al., 1981).
2.10_.2 Alpha 2-antiplasmin
Alpha 2-antiplasmin concentrations do not differ in 
type II diabetes when compared to controls (Grignani et 
al., 1981; Hughes et al., 1983), while in type I diabetes
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alpha2 antiplasmin levels have been reported to be either 
increased (Ambrus et al., 1979) cr not different from 
controls (Coccheri et al., 1983; Dornan et al., 1983).
Dornan and colleagues (1983) found that alpha2-antiplasmin 
concentrations were not related to the severity of 
diabetic retinopathy while Christe and colleagues (1984) 
found raised alpha 2- antiplasmin concentrations only in 
patients with microvascular disease compared to controls. 
This requires clarification.
2-12.*A Alpha 2-macroglobulin
The alterations of alpha 2-macroglobulin in diabetes 
resembles those changes seen in fibrinogen levels, ie,
alpha 2-macroglobulin has been noted to be higher in
diabetics compared to controls (James et al., 1980; 
Christe et al., 1984) and still higher levels are found in 
advancing microvascular disease (Aimer et al., 1975b; 
James et al., 1980; Dornan et al., 1983; Christe et al.,
1984).
2-12-2 Fibrinogen
It is clear that fibrinogen concentrations are higher 
in type I and type II diabetes as compared to matched 
controls (Badawi et al., 1970; Aimer et al., 1975a; Fuller 
et al., 1979; De Silva et al., 1979; Brooks et al., 1983; 
Borsey et al., 1984), and that the changes in fibrinogen 
are more marked in patients with increasing severity of
71
microvascular disease (Aimer et al., 1975b; Fuller et al., 
1979 ; Borsey et al., 1984 ; Christe et al., 1984; Lowe et 
al., 1986). In a prospective controlled trial 
sulphonylurea therapy was shown to increase fibrinogen 
concentrations (De Silva et al., 1979) but this has not 
received confirmation. The effect of improved glycaemia 
on fibrinogen concentrations is controversial (Paton et 
al., 1981; Simpson et al., 1982; Greaves et al., 1983).
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CHAPTER 3
METHODOLOGY
73
3 . 1  INTRODUCTION
In this section, a description of the haemostatic 
tests used in our laboratory, and analysed in this thesis, 
will be presented. The assay methods, used in the various 
studies to be discussed in the thesis, have not changed 
(except for plasminogen) and, in the main, have been 
performed by the same expert laboratory staff over the 5 
years during which this work was carried out. Special 
emphasis will be placed on the fibrin plate method of 
estimation of plasma fibrinolytic activity since 
laboratory techniques vary for this assay, especially in 
relation to the type of fibrinogen used.
3_.2 Blood Sampling
Whole blood is obtained by clean venepuncture through 
a 19G needle into a plastic syringe, and mixed 9:1 parts 
with 3.8% trisodium citrate in a plastic collection tube. 
The sample is then placed on ice and is spun at 4^C for 20 
minutes at 3000G, within 30 minutes of collection. The 
plasma is then aliquoted into separate containers and 
stored at -70° C until ready for assay. Plasma for 
fibrinogen and serum for FDP's is kept at -20°C. Small but 
significant decreases in the concentrations of plasma 
fibrinolytic activity, plasminogen, alpha2-antiplasmin, 
alpha2-macroglobulin, FDP's and fibrinogen occurred after 
one month of storage at these temperatures (McArdle, 1983)
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and therefore all samples were assayed as soon as 
possible, and usually within 3 weeks of sample 
collection. The anti-coagulants and storage of both BBeta 
15-42 and fibrinopeptide A are different from the above 
components and will be discussed separately. With the 
restrictions on storage mentioned above comparison samples 
for an individual were performed, where possible, in the 
same assay and the intra-assay coefficient of variance for 
the assays used in our laboratory are listed in Table 
3.1.
Plasma Fibrinolytic Activity : Fibrin Plate Method
_ 3 1. Introduction
Plasminogen activators can be assayed by measuring 
the mean diameter of the area of lysis around a small 
volume of plasma euglobulin fraction placed on a plate of 
fibrin. The fibrin contains plasminogen as a contaminant, 
and so activator present in samples placed on the fibrin 
surface will bring about plasminogen to plasmin 
conversion. The advantages of the fibrin plate method 
include the fact that plasminogen and fibrinogen 
substrates are controlled and plasma can be stored at -70° 
C and assayed in batches whereas euglobulin clot lysis 
assays for example have to be performed immediately.
The fibrin plate method used in our laboratory is a 
modification of that described by Astrup and Mullertz 
(1952), Kluft et al., (1976) using Owren's buffer and Kabi 
fibrinogen. This area of lysis gives a measure of
TABLE 3.1
THE LABORATORY INTRA-ASSAY COEFFICIENT OF VARIANCE
Intra-Assay C.V. 
(%)
Fibrinolytic
Activity
5.0
BBeta 15-4 2 antigen 9.7
Plasminogen Activity 
(caseinolytic)
3.8
Plasminogen Activity 
(chromogenic)
5.2
o^2-Antiplasmin
Activity
4.2
oC2-Macroglobulin 
Antigen
1.1
F.D.P. "s 0
Fibrinogen Activity 3.0
Fibrinopeptide A 4.4
Antigen
Legend
The intra-assay coefficient of variance (C.V.) values 
for the tests of fibrinolysis used in our laboratory.
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plasminogen activator activity although it may also detect 
plasmin activity.
3.3.2 METHOD
Twenty mis of fibrinogen (Human Grade L; Kabivitrium 
Ltd, Flow Laboratories, Irvine) is made up to 200 mls with 
Tris HCL buffer. Twenty mis of this mixture is placed on 
a level Petri dish which allows 10 fibrin plates to be 
made. Fibrinogen is clotted by adding 0.5 mis of thrombin 
solution (bovine origin, 5000 NIH units dissolved in 100 
mis of Tris HCL buffer; Parke-Davies) and contents 
thoroughly mixed. The plates are kept on a flat surface. 
The 4 quadrants of the plate are marked off and 20 jul of
the plasma euglobulin precipitate to be tested are
accurately pipetted in triplicate. One quadrant is used
for a streptokinase control (Varidase, Lederele, 
Hampshire, Great Britain) - 0.5 ml aliquot made from 2000 
units dissolved in 50 mls of Tris HCL buffer added to 1.0 
ml of Tris HCL buffer. The plates are then incubated at 
37°C for 18 hours in a vibration free oven with flat
shelves. The zone of lysis is then measured by taking the 
mean of the 2 perpendicular diameters. The area of lysis 
is then calculated by taking the average diameter of the 3 
lysis zones, correcting it against the control values 
obtained using streptokinase, and using the equation-(1/2 
d^) X %  giving a value in m m 2 .
3.3.^ Euglobulin Preparation
This depends on the isoelectric precipitation of
76
euglobulin from diluted plasma leaving inhibitors in the 
supernatent (Nilsson and Olow., 1962). Add 1ml of 
citrated plasma to 9mls of 0.025% acetic acid and check pH 
is 5.9-6.0. Invert the tube and allow to stand at 4°C for 
10 minutes to precipitate the euglobulins. Centrifuge at 
2000G for 5 minutes at 4° C, discard supernatent and 
resuspend euglobulin precipitates in 1ml of Owren's 
buffer.
What Does The Fibrin Plate Measure?
The fibrin plate method is widely used as an overall 
assessment of fibrinolysis but detailed work has been 
carried out to determine the contributions that the 
intrinsic and extrinsic system of fibrinolysis make to the 
overall lysis zOne. The regular euglobulin fraction (used 
in our laboratory) contains about 25% of the plasma level 
of Cl-inhibitor (Kluft, 1976) and the addition of 
flufenamic acid nullifies the affect of Cl-inactivator 
(Kluft, 1979) and therefore allows an assessment of the 
Cl-inactivator fraction (Factor XII - dependent intrinsic 
pathway), the Cl-inactivator resistant fibrinolytic 
activity (extrinsic and urokinase-like fibrinolysis). 
Kluft (1979) also found that the intrinsic system was only 
partially recovered during the preparation of the regular 
euglobulin fraction and that the addition of dextran 
sulphate could precipitate activators of fibrinolysis in 
addition to its ability to activate factor XII (a 
proactivator). Kluft (1979) estimated that using these 2 
manoeuvres (ie, adding flufenamic acid and dextran
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sulphate), the activity recovered from the modified plate 
was at least a two-fold increase. Further work has 
demonstrated that the morning level of fibrinolytic 
activity on the regular fibrin plate contains only 1-2% of 
extrinsic activator (which is completely recovered), the 
remainder belonging to the intrinsic system (which is 
incompletely recovered). The increase in fibrinolytic 
activity on the regular fibrin plate due to diurnal 
rhythm, exercise, DDAVP etc., is however due to an 
increase in the extrinsic pathway of fibrinolysis (Kluft, 
1981; Kluft and Allen, 1983; Kluft et al., 1984).
_3 BBeta 1 3 - ^  Fragment
The measurement of BBeta peptides allows a sensitive 
indicator of endogenous fibrinolysis (Nossel, 1981; Prowse 
et al., 1982). The assay for BBeta peptides (BBeta 1-42, 
BBeta 15-42) is not specific for the BBeta 15-42 since the 
aminoacid sequence is found in all fragments (Walenga et 
al., 1984). The assay however is said to quantitate the 
BBeta 15-42 fragment. The BBeta peptides have a short 
half-life, and in man BBeta 1-42 demonstrates a biphasic 
clearance with a t-1/2 of 10 and 100 minutes (Prowse et 
al., 1982).
Using a new syringe 9mls of blood was removed into 
1ml of anticoagulant containing 1000 lU heparin; 1000 KIU 
Trasylol (Trasylol, Bayer Pharmaceuticals Ltd, Haywards 
Heath, Sussex, England) in sodium chloride, 0.15M. After 
gentle inversion three times the sample was placed on ice 
or centrifuged immediately at 2000g for 20 minutes at 4
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C. Plasma was assayed immediately or snap frozen and 
stored at -70" C until assayed. BBeta 15-42 was measured 
by radioimmunoassay with a commercial kit provided by IMCO 
Corporation Ltd (Stockholm, Sweden). Due to the 
cross-reaction of plasma fibrinogen with the BBeta 15-42 
antisera, the protocol involves an ethanol extraction step 
to remove fibrinogen. The results are expressed in 
pmol/ml. In our laboratory the mean inter-assay 
coefficient of variance of BBeta 15-42 is 10.2% and BBeta 
15-4 2 levels remain stable for at least 5 months when 
stored at -70*C.
2.5 Plasminogen 
Plasminogen activity is measured in our laboratory by 
a caseinolytic assay which involves the initial 
acidification of the plasma sample to remove the effects 
of antiplasmin activity, and streptokinase activation of 
plasminogen. (Remmert and Cohen, 1949; Alkaersig et al., 
1959). This assay has been employed in all the studies in 
this thesis except for the diabetic studies (excluding 
Chapter 13).
From 1985 however we have replaced the caseinolytic 
assay with a chromogenic substrate assay using substrate 
S-2251, (H-D-VAL-LEU-LYS-pNA; Kabi Diagnostica, Stockholm,
Sweden). The principal of this assay is as follows: when
an excess of streptokinase is added to plasma containing 
plasminogen a complex with enzymatic activity is formed 
which catalyses the splitting of p-nitroanaline (pNA) from
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the substrate. As the streptokinase is added in excess, 
no free plasminogen, is left to be activated to plasmin 
and under these conditions the enzymatic activity is not 
inhibited by plasma inhibitors. The rate at which pNA is 
released is measured photometrically at 405 nm and the 
concentration of plasminogen is calculated by using 
standards prepared from normal pool plasma.
2•2 Alpha2-Antiplasmin
2*2*i Introduction
Aoki and von Kaulla (1971), identified a fibrinolytic 
inhibitor in human serum which Morrow and Aoki (1976), 
then named alpha2-plasmin inhibitor having demonstrated 
its site of action at the level of formed plasmin. Collen 
and co-workers (1976) identified this plasma protein as a 
fast-acting inhibitor which they renamed
alpha2-antiplasmin. Alpha2-antiplasmin can be accurately 
determined in plasma either with enzymatic assays based on 
the very fast inhibition of plasmin, or with 
immunochemical assays using specific antisera. Both of 
these are employed in our laboratory.
2*2-2 Alpha2-Antiplasmin Activity : Chromogenic Substrate 
Plasmin catalyses the amidolytic cleavage of 
p-nitroanaline from the specific plasmin substrate, 
TOSYL-GLY-PRO- lys-pNA (Chromozym PI, Boehringer Mannheim, 
Germany). The activity of a given quantity of plasmin, as 
well as the residual plasmin activity after incubation
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with an excess of plasmin are determined. The difference 
between these 2 measurements corresponds to the 
antiplasmin activity of the plasma sample. Since the 
substrate also reacts slightly with thrombin, hirudin is 
therefore added to the test solution in order to inhibit 
enzymatic thrombin activity which may be present in the 
plasma.
2'2"2 Alpha2-Antiplasmin Antigen : Electroimmunoassay
Alpha2-antiplasmin can be quantitated in human plasma 
with the use of monospecific antisera, and in our 
laboratory an electroimmunoassay is in use (Laurell, 
1966). This assay is based on the fact that during 
electrophoresis of an antigen in an antibody containing 
medium, antigen-antibody complexes will precipitate in a 
"rocket" shaped precipitin zone. The height of the rocket 
is proportional to the amount of antigen present. The 
monospecific antisera was obtained from Nordic 
Immunological Laboratories, Netherlands.
2.2 Alpha2-Macroglobulin Antigen 
Norman and Hill (1958), detected a plasmin inhibitor 
in the alpha2-region on electrophoresis which Schwick and 
co-workers (1966), later identified as
alpha2-macroglobulin. Alpha2-macroglobulin can be 
accurately quantitated by radial immunodiffusion (Mancini, 
1965) using commercially available antisera (Behringwerke 
Laboratories) .
8 l
2.8 FDP's
Degradation products of fibrinogen and fibrin can be 
measured by assay of their biological activation 
(prolongation of thrombin time, staphylococcal clumping 
tests) but our laboratory utilises the tanned red cell 
haemaglutination inhibition immunoassay described by 
Merskey et al., (1969). This is an automated method with 
commerical kits (Wellcome FDP kit) available from Wellcome 
Reagents, Beckenham, UK. A suspension of formalin treated 
sheep red cells is a very sensitive indicator of the 
presence of antibodies to fibrinogen. Aliquots of a 
specific anti-fibrinogen serum, diluted to a concentration 
just high enough to agglutinate the sensitised cells, are 
added to serial dilutions of the sample to be assayed. If 
sufficient fibrinogen is present in the sample it will 
combine with the anti- fibrinogen serum and sensitised red 
cells, added subsequently, will fail to agglutinate. The 
last completely unagglutinated well is taken as the "end 
point" and the amount of FDP in the sample can be assayed 
by comparison with a known standard.
2.2 Fibrinogen
Fibrinogen is a large glycoprotein (see Table 1.1) 
synthesized in the liver and to a lesser extent by 
platelets (Marsh, 1981). The fibrinogen molecule is a 
dimer, each half of the dimer consisting of 3 polypeptide 
chains, the AAlpha, BBeta and gamma chains - joined by 
disulphide bonds (see figure 1.2). Fibrinogen is an acute 
phase reactant, and release into blood occurs during a
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variety of stimuli in addition to normal haemostatic 
requirements. The mean plasma t-1/2 is approximately 4 
days. Fibrinogen is involved with the central event of 
coagulation, ie, the thrombin-catalysed conversion of 
fibrinogen to fibrin, and while the natural substrate for 
plasmin in vivo is fibrin, plasmin-mediated 
fibrinogenolysis may occur in conditions of systemic 
hyperplasminaemia. Fibrinogen is measured in our 
laboratory by the thrombin clotting time method (Clauss, 
1957) where the thrombin clotting time is inversely 
proportional to the fibrinogen concentration present in 
the plasma sample. Automatic recording of the thrombin 
time is performed in duplicate using the Dade fibrometer.
2-22 Fibrinopeptide A
Fibrinopeptide A is a 16 aminoacid long peptide chain 
with a molecular weight of 1536 daltons. It is released 
by the action of thrombin on the amino terminal of the 
AAlpha chain of fibrinogen, leaving intermediate fibrin 
monomer (fibrinopeptide B is then cleaved from the BBeta 
chain leaving fibrin monomer). The measurement of 
fibrinopeptide A therefore is a sensitive index of 
thrombin generation in vivo (see figure 1.2). 
Fibrinopeptide A has a mean t-1/2 of 4 minutes and appears 
to be a sensitive marker of prethrombotic states (Nossel, 
1981; Amiral et al., 1984; Walenga et al., 1984).
It is especially important to take blood via a clean 
flawless venepuncture without trauma to avoid local 
thrombin generation. The patient plasma is prepared as
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described in the BBeta 15-42 assay, plasmin being assayed 
immediately or snap frozen and stored at -70° C until 
assayed. Fibrinopeptide A was measured by
radioimmunoassay using the commercial kit supplied by IMCO 
Corporation Ltd (Stockholm, Sweden). As in the BBeta 
15-42 assay, ethanol extraction of fibrinogen was
performed. The results are expressed in pmol/ml while 1 
pmol is equivalent to 1.535 ng/ml. In our laboratory the 
mean inter-assay coefficient of variance of fibrinopeptide 
A is 3.2% and levels remain stable for at least 5 'months 
when stored at -70°C.
1-il b o d y  m a s s  i n d e x
In the various groups of patients studied in this
thesis the effect of weight on the components of
fibrinolysis will be assayed using the body mass index or 
Quetelet's index. This is defined as:- weight (kg)/height 
(m)2, and is a convenient and popular index of relative 
weight, which is almost independent of height (Truswell, 
1985). Acceptable weights range from 20-25, while obesity 
is taken to start at values above 30 and gross obesity at 
values above 40.
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CHAPTER 4
THE EFFECTS OF EXERCISE AND BETA-ADRENOCEPTOR BLOCKADE 
ON THE FIBRINOLYTIC ENZYME SYSTEM IN NORMAL VOLUNTEERS
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l-l INTRODUCTION
The effects of exercise on fibrinolysis have been 
reviewed in Chapter 2.3. While it is well recognised that 
plasminogen activator is stored in the endothelial cell 
lining veins and the vasa vasorum of arteries the exact 
mechanism by which activator is released from these 
storage sites remains an enigma. Since epinephrine 
infusion was shown to stimulate fibrinolysis (Biggs et 
al., 1947) the role of adrenoceptor stimulation and 
blockade on the pathways of plasminogen activator release 
has received much attention. The plasminogen activator 
response to catecholamines was thought to be beta2 
receptor related, due to a direct effect on the 
endothelial cell, and could be partially blocked by 
propranolol (Cash, Woodfield and Allan, 1970; Cash 1975). 
Other studies have shown however that the increase in 
fibrinolytic activitiy with bicycle or treadmill exercise 
was not reduced by prior beta-blockade (Cohen et al.,
1968; Korsan-Bengtsen and Conradson, 1974; Britton et al., 
1976) and that the rise in fibrinolytic activity did not 
parallel the change in catecholamine levels (Hawkey et 
al., 1975). More recently, experiments on the
fibrinolytic response to vasoactive drugs suggests that
the major fibrinolytic response proceeded along 
non-adrenergic pathways (Rosing et al., 1978). Studies to 
date therefore tend to indicate that exercise induced 
fibrinolytic enhancement is not mediated by beta-receptor 
stimulation and therefore not attenuated by beta-blocking
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drugs.
The resting level of plasma fibrinolytic activity has 
been reported to be increased (Ponari, Civardi and Poti, 
1972) unchanged (Davidson et al., 1979b) or decreased 
(Nielson, Jessen-Jurgensen and Gormsen, 1981), by
beta-blockers. At the time this study was performed the 
effect of exercise on alpha2-antiplasmin was unknown, 
although antiplasmin levels were reported not to change 
with exercise (Marsh and Gaffney, 1980). No previous
studies on exercise and beta-blockade have included a
double-blind placebo controlled design in their protocol. 
The aims of our study therefore were to assess whether 
beta-blockade had any effect on either resting or exercise 
stimulated plasma fibrinolytic activity or some other 
tests of the fibrinolytic enzyme system.
_4 .2 METHODS
_4 ._2 "1. Patients
Local Ethical Committee permission was obtained and 9 
healthy male volunteers took part in the study. The 
subjects were young (age range 23-32, mean 27.6 years) and 
of normal body mass index (range 19.0-23.6, mean 21.5).
2.2_*2. Study Design
The subjects performed maximal bicycle exercise tests 
on 3 occasions, with or without prior oral administration 
of a single dose of 2 different beta-blockers. The study
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was double-blind, placebo-controlled and crossover in 
design and conducted in 3 stages, each subject receiving 
either 80 mg of the non-selective beta-blocker
propranolol, 10 mg of carteolol (Berk Pharmaceuticals, 
non-selective, partial agonist activity) or placebo. 
Randomisation of treatments were made using a Latin square 
design. The interval between each stage was at least one
month to reduce any "training effect" of repeated exercise
tests. The subjects, who were on no other drug therapy,
were fasted overnight and after 10 minutes at rest, blood 
was withdrawn for estimation of baseline haemostatic 
tests. The drug was administered and subjects were kept 
fasting for a further 2 hours to ensure maximal drug
absorption. Approximately 4 hours after tablet ingestion 
a pre-exercise blood sample was taken. This time interval 
was chosen as a compromise to coincide with peak plasma 
levels of carteolol (Small et al., 1982a) and 
propranolol. Peak concentrations of propranolol are well 
recognised to vary markedly in normal subjects. Exercise 
testing was performed using an upright bicycle ergometer,
peddling at a constant speed, using a graded exercise
protocol with an initial workload of 300 kilopond
meters/minute (300 kpm = 50 watts), increasing by 300 kpm 
at 3 minute intervals. Exercise was maximal. The 
electrocardiogram was monitored using a single lead system 
(modified V5 electrode) and blood pressure from the cuff 
sphygmomanometer. During the last 3 0 seconds of peak 
exercise a final blood sample was taken from a separate
venepuncture. The double product (heart rate x systolic
-3
blood pressure X 10) was calculated as an indicator of 
myocardial oxygen consumption and beta-blocker effect. An 
indirect estimate of maximal oxygen consumption (V02 max) 
at peak exercise was obtained from the equation below 
(Blomqvist, 1973), where the workload is the kpm at the 
end of exercise, corrected from the duration of exercise.
-i- — i.
(Workload x 2) + 300ml. kg. min.
V02 max =
BODY WEIGHT (kg)
■4.2*2 Blood Tests
Plasma fibrinolytic activity and alpha2-antiplasmin 
were measured on 3 occasions while fibrinogen and 
fibrinopeptide A were measured only pre and post 
exercise.
Statistics
Statistical comparisons were performed using the 
unpaired Wilcoxon rank sum test, and correlations were 
determined by the Spearman rank order correlation 
coefficient.
4.3 RESULTS
j4*2*2 Haemodynamic Data
The haemodynamic results are shown in table 4.1. No
TABLE A.I 
HAEMODYNAMIC RESPONSE TO EXERCISE
Placebo Carteolol Propranolol
Heart Rate Pre 82 71 67
(beats/min) ± 15 ± 9 ± 9
Ex 172 128** 131**
± 24 ± 12 ± 12
Systolic BP Pre 110 102 106
(mmHg) ± 12 ± 15 ± 9
Ex 177 146* 151**
± 12 ± 24 ± 21
Double Pre 9 8 7
Product ± 2 ± 1 ± 1
Ex 31 19** 20**
± 5 ± 4 ± 5
V02 max Ex 36 37 36
± 9 ± 5 ± 6
Legend
Pre and exercise (Ex) values in the placebo and beta-blocker 
groups of the heart rate, systolic BP, double product 
(heart rate X systolic BP X 10"^ ) and calculated maximal 02 
consumption (V02 max). Values are mean ± SD.
*p < 0.05
**p < 0.01, beta-blocker versus placebo
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differences in the calculated V02 max during the 3 study 
days were found. Reductions in exercise induced 
tachycardia, systolic BP and double product were noted in 
each beta-blocker group. No differences between the 
active drug groups were found. The mean exercise time was 
10.9 minutes.
2*2*2 Haemostatic Tests
The haemostatic test results and the percentage 
change in fibrinolytic activity are listed in table 4.2, 
figure 4.1. In the 4-5 hour interval between 9am and 
pre-exercise, the fibrinolytic activity increased an 
average of 55% on the placebo leg and no differences were 
noted between the placebo and beta-blocker groups. 
Fibrinolytic activity increased significantly by 53% after 
exercise (placebo leg). The fibrinolytic activity also 
increased significantly in both active drug groups and no 
differences in the magnitude of response were noted 
between the 3 groups. No diurnal rhythm was noted in 
alpha2-antiplasmin levels and no effects of exercise on 
alpha2-antiplasmin, fibrinogen and fibrinopeptide A levels 
were noted. No significant correlations were found 
between the incremental change in fibrinolytic activity 
(on the placebo leg) and the body mass index (r = -0.16), 
peak heart rate (r = 0.38) or V02 max (r = 0.30). The
haematocrit increased by 6%, pre to post-exercise and was 
not affected by beta-blockade.
TABLE 4 .2
EXERCISE, BETA-BLOCKADE AND FIBRINOLYSIS
FA
(mm2 )
oC. 2-AP 
(u/ml)
Fibrinogen
(9/1)
F.P.A.
(ng/ml)
Placebo
9 am 84 2.4
± 34 + 0.6
Pre 131 + 2.3 2.1 0.66
± 46 + 0.7 + 0.3 + 0.12
Post 201* 2.4 2.3 0.71
± 107 ± 0.7 ± 0 . 4 ± 0.27
Carteolol
9 am 89 1.9 — —
± 35 + 1.1
Pre 120+ 2.0 2.1 0.78
± 37 ± 1. P ± 0 . 2 + 0.48
Post 155* 1.9 2.1 0.66
± 41 + 0.8 ± 0.4 ± 0.12
Propranolol
9 am 73 2.1 - -
± 16 + 0.7
Pre 112 + 2.1 2.1 0.62
± 47 ± 0 . 9 ± 0.2 + 0.06
Post 189* 2.0 2.2 1.17
± 103 + 1.0 ± 0.4 ± 1.55
Legend
Effect of exercise and beta-blockade on fibrinolytic activity 
(FA), oC 2-antiplasmin (oC2AP), fibrinogen and fibrinopeptide A 
(FPA) concentrations. Values are mean ± SD.
+ p < 0.01, basal versus pre-exercise
*p < 0.01, pre versus post-exercise.
FA(%change) 
60
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20-
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Pre
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Propranoioi —
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40
30 4
20 4
104
0-^
**
f:ft
P*
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p<0.05
Figure 4.1
Illustrates the percentage rise in plasma fibrinolytic 
activity (FA) from 9am to 2pm and post exercise on the 
3 study days. No differences between the 3 groups 
were detected. Changes are within group comparisons.
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i-i DISCUSSION
In normal subjects plasma fibrinolytic activity is 
lowest at 8am and peaks between 5-8pm (Rosing et al., 
1970). We have noted a marked rise in fibrinolytic 
activity in the 4 hour interval between 9am to 1pm which 
emphasises the importance of the exact timing of samples 
when comparisons are made between fibrinolytic activity in 
different patient groups.
The lack of difference between V02 max. on each drug
indicates that maximum exercise was obtained on each
occasion. The attenuation of exercise tachycardia, 
systolic BP and the double product by both beta-blockers, 
and the lack of difference between the drugs indicate that 
adequate, and equipotent, beta-blockade was achieved on 
each occasion. Beta-blockade therefore failed to make any 
significant modification to the rise . of plasma 
fibrinolytic activity induced by exercise as has been 
noted before in open studies with smaller numbers of 
volunteer subjects. (Cohen et al., 1968; Korsan-Bengtsen 
and Conradson, 1974; Britton et al., 1976). Beta-blockers 
with partial agonist activity have been reported to 
enhance plasma fibrinolytic activity (Ponari et al.,
1972), but carteolol, which has a weak partial agonist 
activity did not alter the resting level of fibrinolytic 
activity. Our findings are in agreement with those of
Davidson and co-workers (1979b) that beta-blockers do not 
alter resting plasma fibrinolytic activity. Since
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publication of this study, Brommer and colleagues (1984b) 
have shown that propranolol has no effect on either the 
resting fibrinolytic activity or the response to DDAVP.
We-have demonstrated that exhaustive, maximal bicycle 
exercise of approximately 11 minutes duration causes a 54% 
rise in plasma fibrinolytic activity. Fibrinopeptide A 
concentrations did not change after exercise, and 
therefore thrombin generation, with significant activation 
of coagulation did not occur. Exercise in our healthy
subjects therefore is an example of primary fibrinolysis 
(ie, not secondary to the activation of coagulation).
We have found that alpha2-antiplasmin levels do not
significantly change with exercise even when a correction
factor is applied for haemoconcentration (haematocrit rise 
of 6% after exercise). This finding has recently been
confirmed (Huisveld et al., 1984). Theoretically any 
plasmin generated by exercise should be rapidly 
inactivated by alpha2-antiplasmin, whose concentration
would then be expected to fall. The lack of change in 
alpha2-antiplasmin is thought to indicate that exercise 
fails to generate significant quantities of plasmin.
The findings from this placebo-controlled, double­
blind study suggests that adrenergic mechanisms make no
contributions to the rise in fibrinolytic activity with 
exercise and that beta-blocking drugs do not affect the 
resting level of fibrinolytic activity (Small et al., 
1984a). While marked changes in plasma fibrinolytic
activity occur with exercise, significant plasmin
generation appears unlikely.
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CHAPTER 5
THE EFFECTS OF EXERCISE ON THE FIBRINOLYTIC ENZYME 
SYSTEM IN MIDDLE-AGED MEN
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5.1^ INTRODUCTION
Dynamic tests of fibrinolysis using venous occlusion 
have shown defective responses in plasma fibrinolytic 
activity occur more commonly in men with coronary artery 
disease (Walker et al., 1977; O'Connor et al., 1984a) and 
that plasma fibrinolytic activity following bicycle 
exercise is significantly impaired in patients with 
coronary artery disease (Khanna et al., 1975). The change 
in plasma fibrinolytic activity in normal volunteers has 
been related to the intensity of exercise, as indicated by 
the maximal oxygen consumption (V02 max), and peak heart 
rates (Davis et al., 1976; Marsh and Gaffney, 1982). The 
effect of exercise on the BBeta 15-42 fragment, and the 
relationship between the intensity of exercise and 
fibrinolysis in middle-aged men have not been reported. 
The main aims of our study were therefore to assess 
whether differences in fibrinolysis occured either at rest 
or following standardised exercise, in men with and 
without coronary artery disease, and to relate the changes 
in fibrinolysis to the intensity of exercise.
5.2 METHODS
Patients
Thirty-four males of mean age 51 years (range 40-66) 
gave their informed consent and took part in the study. 
Patients being routinely evaluated for chest pain with
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exercise electrocardiography were selected provided they 
did not have valvular heart disease or were taking 
anti-coagulants as these are known to affect some tests of 
haemostasis. Ten patients in total had sustained a 
previous well documented myocardial infarction. Fifteen 
patients were being treated with the following groups of 
anti-anginal medication:- beta-adrenoceptor blockers (beta 
1 selective, n = 8; non-selective, n = 5), calcium
antagonists (n = 12), long-acting nitrates (n = 8).
Fourteen patients were non-smokers and 2 0 patients were 
current cigarette smokers. The body mass index was used 
as an indicator of over or underweight.
Study Design
The patients performed erect bicycle exercise using 
the same graded exercise protocol as used in the normal 
volunteer study (Chapter 4), except that exercise was 
terminated if symptoms developed. A positive exercise 
test was defined as one producing ST depression of > 2mm 
persisting 0.08 seconds after the J point in 3 consecutive 
cardiac cycles and/or the development of typical cardiac 
chest pain on exertion. All exercise tests were performed 
between 10-11 am and venous blood was taken from a 
separate venepuncture site prior to exercise, with 
patients seated at rest, and within one minute after peak 
exercise.
_5 .2'_3 Blood Tests
Plasma fibrinolytic activity, BBeta 15-42 antigen.
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fibrinogen, FDP s, alpha2-antiplasmin activity and 
fibrinopeptide A were assayed pre and post exercise.
_5 .2'A Statistics
Statistical comparisons were performed using the 
unpaired Wilcoxon rank sum test, and correlations were 
determined by the Spearman rank order correlation 
co-efficient.
i-1 RESULTS
_5 .2'A Assessment of patient groups
Eleven patients fulfilled the criteria for a positive 
exercise test. In addition to these patients, 9 patients 
had coronary artery disease as evidenced by coronary 
angiography (> 50% occlusion of a major coronary vessel), 
or a definite previous myocardial infarction. Coronary 
angiography was performed in 13 patients (10 with 
positive, and 3 with negative exercise tests) and all 
patients had significant coronary artery disease. No 
significant differences in the ages or body mass index of 
patients with or without coronary artery disease were 
noted.
2 - 2 -A BBeta 15-42 fragment
Figure 5.1 illustrates the changes in the BBeta 15-42 
fragment with exercise in patients with and without
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coronary artery disease. A significant increase in the 
BBeta 15-42 fragment occurred only in patients with no 
coronary artery disease. These patients exercised for a 
significantly longer time but no significant difference in 
the VO2 max was noted between the two groups (table 5.1). 
Neither smoking nor beta-blockade had any effects on the 
resting or stimulated concentrations of the BBeta 15-42 
fragment.
2-2-A. Plasma fibrinolytic activity
Table 5.1 lists the effects of exercise on plasma 
fibrinolytic activity in the various sub- groups. 
Patients with or without coronary artery disease, showed 
similar, significant increases in plasma fibrinolytic 
activity after exercise and neither smoking nor 
beta-blockade influenced the rise in fibrinolytic 
activity. The 10 patients with a previous myocardial 
infarction had elevated resting plasma fibrinolytic 
concentrations compared to those patients without a prior 
myocardial infarction (76 ± 15 versus 58 ± 19 mm2, p <
0.02). The patients with a prior myocardial infarction 
showed no differences in their response to exercise.
2-2-A Other results
Exercise had no effects on the concentration of 
alpha2-antiplasmin, fibrinogen or FDP s (table 5.2). 
Significant increases in fibrinopeptide A were noted in 
men with no coronary artery disease (table 5.2). No 
correlations between plasma fibrinolytic activity and
BBeta 1 5 - 4 2  
(pmol/ml)
1-9
1-7
15
1*3
11
r
CAD No CAD
Pre Post Pre
EXERCISE TEST
Post
Figure 5.1
Illustrates the concentrations (mean ISD) of BBeta 15-42 
antigen, pre and post exercise in patients with and without 
coronary artery disease (CAD).
*p ^  0 .05, pre versus post exercise
TABLE 5 .1
EXERCISE AND PLASMA FIBRINOLYTIC ACTIVITY
No
Exercise 
Time 
(mins)
V02 max
Fibrinolytic 
Activity 
Pre Post
Coronary Disease
Yes : 20 5.2 18 66 81**
+ 2.1 ± 5 + 17 + 22
No : 14 6.9* 23 57 78**
+ 1.4 ± 5 + 25 + 27
Beta-Blockade:
Yes : 13 5.8 19 70 90**
+ 2.5 ± : 5 + 22 + 26
No : 21 6.0 22 60 74**
+ 1.7 ± 6 + 18 + 21
Smoking :
Yes : 20 5.4 18 64 80**
± 2.0 ± 4 + 22 + 21
No : 14 6.6 20 61 80**
± 1.9 ± 6 + 24 + 29
Legend
Effect of coronary artery disease, beta-blockade and smoking 
on plasma fibrinolytic activity. Values are mean ± SD.
*p < 0.05
* * p  < 0 . 005
TABLE 5 .2
HAEMOSTATIC TESTS AND EXERCISE
PRE
CORONARY . 
YES
POST
ARTERY DISEASE
NO
PRE POST
2-Antiplasmin 97 104 97 103
(%) + 15 ± 15 + 21 + 19
F.D.P.s 3.06 3.12 2.75 2.89
(ug/ml) + 1.41 ± 1.47 + 0.90 + 1.10
Fibrinogen 2.88 3.16 2.80 2.95
(9/1) + 0.43 ± 0.53 di 0.55 + 0.76
Fibrinopeptide A 2.7 3.4 2.5 3.9
(pmol/ml) + 1.8 ± 1.7 + 2.2 + 2.3*
Legend
Haemostatic tests pre and post exercise in patients with and 
without coronary artery disease. Values are mean ± SD.
< 0.005, pre versus post exercise
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BBeta 15 4 2 fragment or between the body mass index and 
all the tests of fibrinolysis were noted.
5.3.5 Exercise intensity and fibrinolysis
The correlations between exercise time, V02 max, peak 
heart rate and the incremental change in BBeta 15-42 and 
plasma fibrinolytic activity are shown in table 5.3. The 
alterations in BBeta 15-42 fragment, unlike plasma
fibrinolytic activity, were related to both the exercise 
time and V02 max. The fibrinolytic activity at peak 
exercise also failed to correlate significantly with the 
V02 max (r = 0.33). The percentage rise of plasma
fibrinolytic activity (peak - basal / basal x 100) in
patients with and without coronary artery disease and in 
the normal volunteer study is shown in table 5.4. The 
rise in plasma fibrinolytic activity parallels the V02 
max, despite any significant correlation between the rise 
in fibrinolytic activity with V02 max.
2-i DISCUSSION
The effect of exercise on BBeta 15-42 in patients 
with coronary artery disease has not been studied before, 
and we have demonstrated that plasmin-mediated 
fibrinolysis does not occur in patients with coronary 
artery disease while fibrinolysis is stimulated in 
patients without coronary artery disease. It is possible 
that the defective increase in fibrinolysis in men with
TABLE 5.3
CORRELATION OF HAEMODYNAMIC DATA AND FIBRINOLYSIS
Fibrinolytic
Activity
(mm^)
BBeta 15-42 
Fragment 
(pmol/ml)
Exercise Time 
(mins)
0.03 0.45*
V02 max 0.13 0.56**
Peak heart rate 
(beats/min)
-0.03 0.16
Legend
Spearman correlation (r) values of ex vivo (fibrin plate) 
and in vivo (BBeta 15-42 fragment) fibrinolysis with 
haemodynamic values.
*p < 0.01
**p < 0.005
TABLE 5 .4
FIBRINOLYTIC ACTIVITY AND VO2 MAX
Fibrinolytic Activity(mm2) V02 max
No. Pre A %
Controls 9 131 70 53.5 36
No CAD 14 57 20 34.9 23
CAD 20 66 15 22 18
Legend
Ex vivo fibrinolytic activity before exercise (pre), the 
incremental change ( A ), the percentage increase (%) 
after exercise, and the calculated maximal 02 consumption 
(V02 max) in healthy subjects (controls), and patients with 
and without coronary artery disease (CAD). Values are mean
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coronary artery disease could predispose to thrombotic 
events.
The production of plasmin-antiplasmin complexes, and 
an increases in degradation of the AAlpha chain of 
fibrinogen post-exercise, drew Collen et al., (1977) to 
the same conclusion as the present study, that plasmin 
formation occurred to some extent in man following
exercise. Despite the rise in BBeta 15-42 fragment with
exercise, indicating plasmin generation, the lack of 
change in alpha2-antiplasmin levels (the major plasmin 
inhibitor) suggests that extensive plasmin generation does 
not occur. No change in FDP concentrations were detected, 
but this test detects only major increases in fibrin 
(ogen) degradation.
The measurement of fibrinopeptide A concentration 
allows an accurate assessment of thrombin generation 
(Amiral et al., 1984) and significant increases in 
fibrinopeptide A concentrations after exercise were noted 
in the men without coronary artery disease. In normal 
subjects, exercise has been shown to increase 
fibrinopeptide A concentrations (Hyers et al., 1980), 
although smaller studies have failed to detect this change
(Vogt et al., 1979; Marsh and Gaffney, 1982). It may be
that this activation of coagulation could directly lead to 
the stimulation of fibrinolysis which was noted in this 
group. The lack of thrombin generation in the patients 
with coronary artery disease might, in part, explain the 
poorer fibrinolytic responses (in vivo and ex vivo) 
induced by exercise.
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Dynamic tests of fibrinolysis using venous occlusion 
and sub—maximal exercise have revealed abnormalities of 
fibrinolysis occur more commonly in men with coronary 
artery disease (Khanna et al., 1975; Walker et al., 1977; 
O'Connor et al., 1984a; Estelles et al., 1985), but we 
have been unable to show any differences in the response 
of plasma fibrinolytic activity between the men with and 
without coronary artery disease in the present study. Our 
study allows us to make comparisons only with the 2 
previous exercise studies (Khanna et al., 1975; Estelles 
et al., 1985). While all 3 studies involved similar 
numbers of patients, the use of the euglobulin clot lysis 
time, treadmill exercise, a much longer exercise time and 
greater fibrinolytic responses may in part explain the 
discrepancy in the results between the present study and 
that of Khanna et al (1975). Using the fibrin plate 
assay, Estelles et al., (1985) also failed to note any 
difference in response to bicycle exercise between
patients with a previous myocardial infarction and healthy 
controls, although the patients had lower t-PA activity 
and a reduced response of t-PA activity to exercise. 
These authors also suggested that this poor response may 
be related to increased levels of t-PA inhibitor and a
previous study has shown elevated levels of t-PA inhibitor 
in patients with coronary disease (Paramo et al., 1985). 
These studies suggest a mechanism for defective
fibrinolysis and provide some support for the association 
of defective fibrinolysis with coronary artery disease. 
The fibrin plate method therefore may not be sufficiently
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specific to detect the differential effect of exercise in 
vivo, as seen using the BBeta 15-42 assay, since not all 
activators and inhibitors active ex vivo may be active in 
vivo. Indeed the lack of correlation between the 
fibrinolytic activity and BBeta 15-42 levels indicates 
that the 2 assays measure different aspects of 
fibrinolysis.
The relationship of exercise workload to fibrinolysis 
has been assessed mainly in normal healthy volunteers. 
The plasma fibrinolytic responses to exercise has been 
noted to show positive correlations with V02 max (Davis et 
al., 1976) and to parallel changes in heart rate (Marsh 
and Gaffney, 1982). In the present study, using greater 
number of patients, we have been unable to confirm these 
associations of the plasma fibrinolytic activity, although 
the changes in fibrinolytic activity with exercise in our 
volunteers and middle-aged subjects do suggest an 
association with the V02 max (table 5.4). There is a 
diurnal variation of the fibrinolytic response to exercise 
with greater responses noted around 4pm (Rosing et al., 
1970). For practical reasons our studies in patients and 
healthy volunteers were performed at different times of 
day and therefore direct comparisons between these groups 
have not been statistically evaluated. We have shown 
however that the rise of in vivo fibrinolysis is clearly 
related to the duration and intensity of exercise. The 
patients with coronary artery disease exercised for a 
shorter period and performed slightly less work than the 
patients with no coronary disease, and it may be that the
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f noted in plasmin-mediated fibrinolysis are 
simply related to these differences in workload rather 
than the presence of coronary artery disease. The lack of 
a significant difference in V02 max and the small 
difference in exercise duration between the groups argues 
against such a possibility. This merits further study.
We have been unable to demonstrate that beta-blockers 
alter the fibrinolytic responses to exercise, confirming 
previous studies (Cohen, et al., 1968; Korsan-Bengtsen and 
Conradson, 1974; Small et al., 1984a), and that the 
resting level of fibrinolysis is affected by 
beta-blockade. We have also been unable to show that 
smoking has any effect on either resting or exercise 
stimulated fibrinolysis. The effect of smoking has been 
discussed in detail in chapter 2.4.
In summary, we have shown that alterations of 
exercise induced in vivo fibrinolysis can be demonstrated 
in men with coronary artery disease. Whether the poor 
response of BBeta 15-42 is related to coronary artery 
disease or simply the exercise workload is unclear at 
present. If the response is related to coronary diseaese 
it may then predispose to a hypercoagulable state, which 
is of importance in view of the growing evidence for a 
close association between hypercoagulability and coronary 
artery disease (Meade et al., 1980; Baker et al., 1982; 
O'Connor et al., 1984a; Wilhelmsen et al., 1984; Sugrue et 
al., 1985; Yarnell et al., 1985). Epidemiological 
prospective studies have, to date, failed to show a 
significant difference in fibrinolytic potential ex vivo
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in men who die of cardiovascular disease as compared to 
survivors (Meade et al., 1980) and in men who sustained a 
myocardial infarction compared to men who remain healthy 
(Wilhelmsen et al., 1984). The results presented in this 
paper suggest that tests of in vivo fibrinolysis 
(generation of the BBeta 15-42 fragment) may be more 
relevant to coronary artery disease.
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CHAPTER 6
BASAL FIBRINOLYSIS AND CORONARY ARTERY DISEASE
104
2-1 INTRODUCTION
The established risk factors for coronary artery 
disease, cigarette smoking, hypertension and elevated 
blood lipids accounts for only 50% of the total coronary 
risk in population studies (Zumoff, 1981). Hormonal and 
haemostatic tests have been investigated to assess their 
contribution (if any) to coronary artery disease and it 
has been shown that fibrinogen and factor VII are risk 
associations for cardiovascular death at least as strong 
as that between cholesterol and cardiovascular death 
(Meade et al., 1980). As discussed before (Chapter 2.7) 
the. association between defective plasma fibrinolytic 
activity and coronary artery disease remains unproven. 
The effect of the severity of coronary artery disease on 
plasma fibrinolytic activity and the components of 
fibrinolysis had not been investigated when this study was 
commenced. An inverse association of defective
fibrinolysis with increasing severity of coronary artery 
disease would provide further evidence to support a role 
for fibrinolysis in coronary artery disease.
Recent studies have suggested that endogenous 
hyperoestrogenaemia may be a risk factor for ischaemic 
heart disease, possibly due to enhanced atherogenesis or 
defective fibrinolysis (for references see Small et al., 
1985a). Our study allowed us to analyse these postulated
mechanisms of oestradiol action.
The aims of our study were to see whether 
associations existed between fibrinolysis, hormones, 
lipids and the severity of coronary artery disease; to
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ABSTRACT
Twenty type I I  (non- insul in  dependent) poorly con tro l led  diabet ics 
had tests of coagulation and p la te le t  funct ion performed whi le receiving 
high dose sulphonyl urea therapy and at 1 and 3 months fo l low ing  t h e i r  
conversion to in s u l in .  Although no overal l  change in glycaemic control 
(assessed by glycosylated haemoglobin) was noted, a reduct ion in 
thrombin generation was observed, as judged by a s ig n i f i c a n t  f a l l  in 
f ib r inopept ide  A concentrat ions. No changes in fac to r  V I I IC ,  fac to r  
VII IR:Ag, or anti thrombin I I I  were found. Glycosylated haemoglobin 
concentrat ions showed s ig n i f i ca n t  corre la t ions with anti thrombin I I I  and 
fac to r  V I I I :C ,  suggesting that improved glycaemic control  might lead to 
an improvement of anti thrombin I I I  funct ion and lower fac to r  V I I I :C  
concentrat ions. No changes in p la te le t  funct ion were detected. The 
in t roduct ion  of an insu l in  regimen that improves glycaemic control  might 
lead to a reversal of the "hypercoagulable state"  found in type I I  
diabetes.
INTRODUCTION
Abnormali t ies of blood coagulation and p la te le t  funct ion have been 
reported and suggest that diabetes m e l l i tus  is associated with a hyper­
coagulable state (1 -4) .  I t  has been shown that by using a 24 hour 
insu l in  in fus ion ,  via the a r t i f i c i a l  pancreas, improvements in 
erythrocyte deformab i l i ty  and p la te le t  funct ion occur and tha t  the 
changes in the red cel l  are due to a d i rec t  e f fec t  of insu l in  (5- 7) .  
Approximately 5% of type I I  d iabet ics each year, i n i t i a l l y  well 
con tro l led  on sulphonyl urea drugs, develop hyperglycaemia and require 
in s u l in  to a l l e v ia te  the symptoms of poorly contro l led diabetes (8) .  In 
c l i n i c a l  pract ice these patients are usual ly given l i f e lo n g  da i ly  
subcutaneous insu l in  in jec t ions .  We wished to see i f  favourable 
changes in haemostasis could be produced by th is  route and method of 
i n s u l in  admin is tra t ion . The aims of our study were f i r s t l y  to document 
the e f fec t  of insu l in  on some aspects of coagulation and p la te le t  
funct ion and secondly to assess the contr ibu t ion  of glycaemic control to 
these tests  in patients with secondary fa i l u re  on sulphonyl urea therapy. 
METHODS
Twenty type I I  d iabet ic  pat ients (15 female, 5 male) whose mean 
age was 62 years (range 51-72), durat ion of diabetes 7.5 years (1-26) 
and percentage of ideal body weight (Geigy s c ie n t i f i c  tables ) of 103% 
(72-125) took part in the study. Despite high dose sulphonyl urea 
admin is tra t ion (g l ib e n d  ami de 15 mg.bd), the patients had constant 
hyperglycaemia and were therefore judged to have secondary f a i l u r e  of 
sulphonyl urea therapy and to require i n s u l in .  Two pat ients were also 
taking the biguanide drug metformin. Five patients had evidence of 
microangiopathy (4 background and 1 p r o l i f e r a t i v e  ret inopathy)  without 
c l i n i c a l  features of nephropathy or neuropathy. Six pat ients were 
receiving ant i  hypertensive or ant i-angina l therapy but no other
3medication was taken during the study per iod. On the morning of t h e i r  
f i r s t  insu l in  in je c t io n  and at 1 and 3 months th e re a f te r  a fas t ing  
venous blood sample was taken fo r  glycosylated haemoglobin (Hb) and 
assessment of haemostasis.
Diabet ic Assessment
A l l  pat ients  attended the c l i n i c  on a regular basis to be given 
the education appropriate to an in s u l in - re q u i r in g  d ia b e t ic .  Each 
pat ient was placed on Lentard MC (NOVO) h igh ly  p u r i f ie d  beef/porcine 
lente insu l in  with the dosage adjusted the rea f te r  u n t i l  most ur ine tes ts  
before breakfast showed no glycosuria, a mid-morning c l i n i c  c a p i l l a r y  
glucose level of 10 mmol/I was attained or u n t i l  hypoglycaemic symptoms 
had ensued. Blood fo r  glycosylated Hb. assay was ant icoagulated with 
EDTA and the assay performed by agar gel elect rophoresis (G ly t rac ,  
Corning),  the non-diabet ic normal range being 5.5-8.5% in our 
labora tory .  Residual beta ce l l  funct ion was assessed, in the fas t ing  
s ta te ,  by measuring the C-peptide response to a 1 mg. in je c t io n  of 
glucagon given in t raveous ly . Serum C-peptide was determined by 
radioimmunoassay (RIA) using reagents suppl ied by NOVO Laboratories 
L td . ,  both before and 6 minutes fo l lowing glucagon i n je c t io n .
Coagulation and P la te le t  Function Tests
Venous blood was anticoagulated with 0.13 M tr isodium c i t r a te  
(9:1, v o l : v o l )  and plasma obtained fo r  measurement of fac to r  V I I I  
coagulant a c t i v i t y  (V II I :C)  by a one stage method (9);  fac to r  V I I I  
rela ted antigen (VII IRiAg) and anti  thrombin I I I  antigen (AT I I I  antigen) 
by the Laurel l  method (10); AT I I I  a c t i v i t y  by chromogenic substrate 
assay ("Chromozym", Boehringer); f ib r inopep t ide  A (FPA) and 
beta-thromboglobul in (B-TG) by RIA using reagents supplied by IMCO, 
Stockholm and the Radiochemical Centre,Amersham respect ive ly ;  6-oxo^PGF]^o/
4was measured by RIA on unextracted plasma with antibody k ind ly  donated 
by Dr.F.E, Preston (Sheff ie ld)  and thromboxane 82 (TXB2) by RIA with 
antibody provided by Upjohn (Kalamazoo).
S ta t i s t i c a l  analysis
S ta t i s t i c a l  comparisons were performed using the Wilcoxon matched- 
pairs signed rank te s t ,  and corre la t ion  was determined by the Spearman 
rank order corre la t ion c o e f f i c ie n t .
RESULTS
Diabet ic Control
While in s t i t u t i o n  of insu l in  therapy was associated with an 
improvement in wel l-being and reduction in glycosuria, no s ig n i f i c a n t  
improvement in glycaemic contro l ,  as judged by glycosylated Hb leve ls ,  
was noted. Prior  to insu l in  therapy glycosylated Hb concentrat ion was
13.2 ± S.D. 2.3% as compared with mean values of 13.1±2.1% and
12.3 ± 2.1% at 1 and 3 months respect ive ly .  No pat ient  had a glyco­
sylated Hb level w ithin  the normal range a f te r  3 months of insu l in  
admin is tra t ion.
Haemostatic tests
Samples fo r  FPA were obtained at 0 and 3 months only and com­
parison samples were avai lable fo r  13 pa t ien ts .  A 33% f a l l  (p<0.05)  in 
FPA concentrations was noted at 3 months (table 1, f i g .  1), but no 
s ig n i f i c a n t  change in any other haemostatic tes t  was found (table  1) .
The corre la t ions between glycosylated Hb concentrat ions, A T - I I I ,  
C-peptide. and the factor  V I I I  complex are shown in table  2. No other 
s ig n i f i c a n t  correlat ions between glycaemic control  and the haemostatic 
tes ts  were found. With the pat ients on sulphonyl urea therapy a pos it ive  
co r re la t ion  of AT I I I  antigen and glycosylated Hb was noted with a 
negative trend of AT I I I  a c t i v i t y  with glycosylated Hb. At 3 months 
a f te r  in t roduct ion of insu l in  therapy no s i g n i f i c i a n t  associations were
5noted, but reversals in the trends were found. Glycosylated Hb corre­
lated p o s i t iv e ly  both with V I I I :C  and C-peptide concentrat ions. Factor 
V I I I :C  also correlated s i g n i f i c a n t l y  with C-peptide concentrat ions 
(r=0.49, p <0.05) .  During the study a modest co r re la t ion  of AT I I I  
antigen and a c t i v i t y  was found (r=0.32, p < 0.02) with a stronger 
associat ion of V I I I :C  and V I I I  R:Ag ( r  = 0.58, p < 0.001). When 
glycosylated Hb, C-peptide and the haemostatic tests  were compared in 
pat ients  with and without microvascular disease, no s ig n i f i c a n t  
d i f ferences were detected.
DISCUSSION
FPA is a small peptide cleaved from the N terminal end of the 
chain of f ibr inogen by thrombin, and is a sens it ive  ind ica to r  of
thrombin generation (11) and therefore of act ivated coagulat ion.
Normal plasma contains less than 2-3 pmol/ml of FPA and pat ients  with 
type I diabetes have been shown to have s l i g h t l y  elevated leve ls  
compared to controls (12,13). The basel ine FPA concentrat ions in our 
type I I  d iabet ic  patients were elevated ind ica t ing  increased thrombin 
generation. More important ly ,  the in t roduct ion of insu l in  therapy was 
associated with a s ig n i f i c a n t  reduction of FPA concentrat ions. The 
diminished thrombin generation could not be explained by improved 
glycaemic control  since glycosylated Hb levels were unchanged. A d i rec t  
e f fe c t  of insu l in  on the coagulation system is possible since there is 
evidence that insu l in  has d i rec t  effects at other s i tes such as the 
endothel ia l  ce l l  (14-16) and the erythrocyte (5 ,6 ) .
AT I I I  is the major physiological i n h ib i t o r  of thrombin and a
number of act ivated coagulation enzymes and, in diabetes, levels  of th is
coagulation i n h ib i t o r  have varied (1,4,12,13,17-26).  This may be 
re lated to di f ferences in the funct ional assay methods, discrepancies 
between the funct ional and immunological assays which these studies have
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employed, and due to a fa i lu re  to d is t inguish between insul in-dependent 
(type I ) ,  insu l in - t rea ted  and non-insulin-dependent (type I I )  d iabe t ic  
pa t ien ts .  Some studies in type I I  diabetes have shown a reduct ion in 
funct ional a c t i v i t y  (4,17,26) with normal immunological levels of AT I I I  
(26).
Although the concentrations of AT I I I  a c t i v i t y  were not s i g n i f i c a n t l y  
lower than AT I I I  antigen in our study, the modest co r re la t ion  co­
e f f i c i e n t  between a c t i v i t y  and antigen (r= 0.32), during the study is 
lower than expected (24) and indicates a discrepancy between the 
funct ional and immunological concentrat ions of AT I I I .  This discrepancy 
could be explained by a s t ru c tu ra l l y  modified protein which re ta ins 
immunoreact ivi ty but is func t iona l ly  depressed (3). There is i n - v i t r o  
evidence that glycosylat ion of th is  plasma protein leads to such a 
defect (27), whi le studies on the association betwen glycaemic control  
and AT I I I  have been c o n f l i c t in g  (12,21,24,25,28-30). On the basel ine 
sample we have shown a pos it ive  co r re la t ion  of glycosylated Hb with AT 
I I I  antigen and a negative trend with AT I I I  a c t i v i t y ;  a f t e r  3 months 
of insu l in  treatment, reversal of these associations were found. These 
corre la t ions  noted provide fu r the r  evidence that glycaemic control is  a 
determinant of AT I I I  concentrat ion and funct ion, and.that insu l in  
therapy may help improve the funct ion of A T I I I .  The small ,  non­
s i g n i f i c a n t ,  reduction in glycosylated Hb concentrat ions may have lead 
to th is  a l te ra t io n .
High levels of factor  V I I I :C  may be an ind ica tor  of a hyper­
coagulable state (2) and have an associat ion, in an epidemiological 
study, with  an increased r isk  of subsequent cardiovascular death (31)< 
Poor glycaemic control  in type I diabetes, as assessed by HbA  ^ and 
ur inary sugar excret ion, has been associated with raised fac to r  V I I I :C  
and VII IRiAg concentations (32,33) and we have confirmed a pos i t ive
7association of glycaemic control  and fa c to r  V I I I :C  in the type I I  
d iabe t ic  pat ients in our study. The measurement of C-peptide allows an 
accurate assessemnt of endogenous in su l in  concentrations since C-peptide 
is  secreted from the p -ce l1 of the pancreas in equimolar amounts with 
i n s u l in .  To our knowledge-, no studies have recorded the e f fec ts  of 
i nsu l in  on the fac tor  V I I I  complex. We have shown a s ig n i f i c a n t  
co r re la t ion  of the basal, fas t ing  C-peptide with fac to r  V I I I :C  
concentrat ions which could ind icate a ro le fo r  insu l in  in the 
determination of c i r c u la t in g  fac to r  V I I I iC  concentrat ions.
A l te rn a t iv e ly ,  th is  associat ion may re f le c t  the underlying pos i t ive  
associat ion of C-peptide with glycaemic control and th is  requires 
fu r th e r  study.
Improvements of coagulation and p la te le t  funct ion have been noted 
in type I I  diabetes with improved glycaemic control  due to a high f i b re  
d ie t  (34), sulphonyl urea therapy (4,35) and insu l in  therapy in pat ients 
with mild carbohydrate intolerance without glycosuria (22). In our 
pat ients with more severe carbohydrate intolerance no s ig n i f i c a n t  change 
in glycaemic control  was noted fol lowing the in t roduct ion of a once 
da i ly  insu l in  regimen and i t  is not surpr is ing therefore that no 
a l te ra t io n s  in the concentrat ions of fac to r  V I I I ,  AT I I I  or the p la te le t  
assays were noted.
In summary, we have shown re la t ionsh ips betwen glycaemic control  
and fac to r  V l l l rC  and AT I I I ,  which suggest that improved glycaemic 
control  would lead to an improvement of AT I I I  funct ion and lower fac to r  
V I I I :C  concentrat ions. Along with the lowering of f ib r inopept ide  A 
levels  demonstrated in th is  study, these changes in the fac to r  V I I I  and 
AT I I I  complex ind icate that a reversal of the hypercoagulable state in 
type I I  diabetes could be achieved by an insu l in  regimen that improved 
glycaemic c o n t ro l .
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TABLE I
Haemostatic tests  before and a f te r  insu l in  administrat ion
0
TIME (Months) 
1 3
FPA (pmol/ml) 4.9 
± 2.5
-
+
3.3*
1.9
AT I I I  antigen (%) 96 103 95
± 14 ± 12 + 15
AT I I I  a c t i v i t y  (%) 89 91 94
± 17 ± 20 + 16
V I I I :C  ( lU /d l ) 180 197 200
± 83 ± 109 ± 98
VIIIR:Ag ( lU /d l ) 180 203 201
± 69 ± 72 + 69
P-TG (ng/ml) 41 44 50
± 14 ± 26 ± 34
TxB2 (pg/ml) 115 95 100
± 39 ± 30 + 33
PGF^o^ (pg/ml ) 17 
± 9
17 
± 9 +
19
7
Values are mean ± ISD 
* p<0.05
15
TABLE II
Corre la t ion of glycaemic control  with AT I I I ,  
fac to r  V I I I  and C-peptide
Glycosylated Hb. 
TIME (Months)
0 3 0+1+3
AT I I I  antigen 0.47* - 0.25 0.24
AT I I I  a c t i v i t y - 0.31 0.38 0.09
AT I I I  a n t ig e n /a c t iv i t y 0.63** - 0.33 0.10
V I I I :  C 0.28 0.73*** 0.46***
VIIIR:Ag - 0.04 0.41 0.15
C-peptide 0.48*
* p <10.05
**  p <0.01
***  p< 0.005
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reduction of the luminal diameter. To give a more
accurate reflection of the degree of coronary
atherosclerosis a coronary score system was devised. As 
no uniform method of 'scoring' coronary angiograms is
available, we devised a system which divided the 3 major 
vessels into 9 sections to include the left main stem, 
proximal left anterior descending (LAD), mid LAD, distal 
LAD, first diagonal, proximal circumflex, distal 
circumflex, proximal right coronary argery (RCA) and 
distal RCA. Each section was scored from 0-4 points 
depending on the degree of vessel occlusion in each
section:- no occlusion = 0; < 50% = 1; 50-74% = 2; 75-99%
= 3; 100% = 4. The patients score over the total possible 
(9 X 4 = 36) was expressed as a ratio and called the
'coronary index'. The angiograms were reviewed blindly at 
the end of the study by a single cardiologist.
6y2^2 Blood Tests
Prior to coronary angiography, and after a 12 hour 
fast, a resting venous blood sample was obtained between 
8-9am for a variety of tests as listed below. Plasma 
fibrinolytic activity, BBeta 15-42 antigen, plasminogen 
activity, FDP's, alpha2-antiplasmin antigen,
alpha2-macroglobulin antigen, fibrinogen and
fibrinopeptide A were assayed as described in chapter 3. 
The results of the inhibitors of fibrinolysis, 
alpha2-antiplasmin and alpha2-macroglobulin are expressed 
Qs -^ Le percentage of normal pool plasma. Plasma total 
cholesterol, HDL cholesterol and triglyceride were
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assess any inter-relationships between these tests and to 
analyse the effects of a number of clinical factors 
(smoking, beta-blockade, myocardial infarction, peripheral 
arterial disease, body weight) on the components of 
fibrinolysis in a large group of men with proven coronary 
artery disease.
6.2 METHODS
Patients
We studied 100 consecutive white males, admitted for 
elective coronary angiography. Patients were excluded if 
they had sustained a myocardial infarct within 3 months of 
coronary investigation , or if they had valvular heart 
disease, as the above factors are known to affect some of 
the haemostatic and lipid variables measured. None of the 
patients had diabetes mellitus or chronic liver disease 
and patients had normal secondary sex characteristics. As 
an estimate of obesity, the body mass index was used. A 
history of smoking, beta-blocker administration, 
peripheral arterial disease and previous myocardial 
infarction were recorded. Peripheral arterial disease was 
diagnosed on a history of claudication plus absent 
peripheral pulses.
_6._2.^ Study Design
Coronary angiography was performed by the Judkins 
technique (Judkins, 1967). Coronary artery disease was 
scored as the number of major vessels having at least 50-g
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measured by the Technicon SMA II and Boehringer kits 
(Carlson, 1973 ) .
Oestradiol was measured in ether extracts of serum 
using a sensitive radioimmunoassay (RIA) based on a 
Steranti rabbit antiserum raised against oestradiol- 
6 - (carboxymethyl) oxime-BSA, oestradiol-6-
(0-carboxymethyl) oximino-2- (1251) iodohistamine and a 
double antibody separation system. This method is capable 
of a sensitivity of better than 20 pmol/1 and yields a 
male reference range of 20-300 pmol/1 with mean intra and . 
inter-assay coefficients of variation of 8% and 12% 
respectively. Serum testosterone was measured in ether 
extracts of serum using a double antibody RIA based on a 
rabbit anti-testosterone-3- 0- carboxymethyl oxime- BSA 
serum and a 1251 radioligand prepared from the histamine 
derivative of testosterone - 3- 0- carboxymethyl oxime.
Oestradiol and the haemostatic samples were stored at -70^ 
C and assayed in batches.
^.^.■4 Statistics
Differences in means were analysed by Mann-Whitney U 
test and correlations were determined by the Spearman rank 
order correlation coefficient. Nominal data was analysed 
using Fisher's exact probability test.
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RESULTS
§_.3.l_ Clinical Characteristics
Table 6.1 shows some of the clinical characteristics 
of the groups (number, age, body mass index, smoking, use 
of beta-blockers, prevalence of myocardial infarction, 
hypertension and peripheral arterial disease), in relation 
to the extent of coronary artery disease. No significant
differences between the groups were found (Fishers test).
.^3_._2 Severity of Coronary Artery Disease
Tables 6.2 and 6.3 list the concentations of the 
fibrinolysis, hormone and lipid tests in relation to the 
extent of coronary artery disease. No significant
difference's in the tests were seen in patients with 1, 2,
or 3 vessel coronary artery disease although a trend for 
higher fibrinogen concentrations with increasing severity 
of coronary artery disease was noted. When the coronary
index values were correlated with these variables,
positive associations were noted between the coronary 
index and both age (r = 0.35, p < 0.001), and fibrinogen 
(r = 0.21, p < 0.05.) No correlation of age and fibrinogen 
was found (r = 0.07) and no other significant associations 
with the coronary index were noted.
^.^._3 Myocardial Infarction
Oestradiol concentrations were higher in men with a 
previous myocardial infarction in comparison to those with 
coronary artery disease but no previous myocardial
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TABLE 6.1
PATIENT GROUP CLINICAL CHARACTERISTICS
CORONARY VESSEL INVOLVEMENT
1 2 3
Number 22 25 53
Age (years) 49 
± 9
46 
± 9
51 
± 8
Body Mass 
Index
26
± 2
26 
± 4
27 
± 2
Smokers 10 9 25
Beta-blocker
treated 14 14 37
Myocardial
Infarction 11 16 29
Peripheral Arterial 
Disease 3 3 7
Legend
Clinical characteristics in relation to the severity of 
coronary artery disease. Values are mean ± SD.
TABLE 6.2
FIBRINOLYSIS AND THE SEVERITY OF CAD
CORONARY
1
VESSEL
2
INVOLVEMENT
3
Coronary Index .076 .236 .397
±  .011 ± .020 + .018
BBETA 15-42 1.17 1.33 1.22
(pmol/ml) + 0.55 ± 0.46 ±0.43 .
Fibrinolytic 79 79 78
Activity (mm2) ± 21 ± 22 + 23
Plasminogen 4.8 4.7 4.8
(cu/ml) ± 0 . 8 ± 0.7 + 0.6
o( 2-Antiplasmin 100 99 103
(%) ± 12 ± 17 ± 14
oC 2-Macroglobulin 81 89 83
(%) ± 17 ± 29 + 29
F.D.P. 's 5.4 4.4 6.5
(ug/ml) ± 4.5 ± 2.6 + 4 . 4
Fibrinogen 3.19 3.28 3.40
(g/i) ± 0.68 ± 0.69 ±0.77
Fibrinopeptide A 2.00 2.85 2.69
(pmol/ml) ± 1.07 ± 1.97 ±1.80
Legend
Components of fibrinolysis in relation to the severity 
of coronary artery disease (CAD), as indicated by the 
number of vessel involvement and the coronary index. 
Values are mean ± SD.
TABLE 6 .3
HORMONES, L IP ID S  AND THE SEVERITY OF CAD
CORONARY VESSEL INVOLVEMENT
1 2 3
Oestradiol 111 127 112
(pmol/1) + 48 + 53 + 56
Testosterone 19.7 20.0 18.3
(nmol/1) + 7.2 + 7.5 + 5.4
Cholesterol 6.3 6.5 6.7
(mmol/1) + 0.9 + 1.6 + 1.1
Triglyceride 2.00 2.94 2.54
(mmol/1) + 1.00 + 1.90 + 1.50
HDL 1.38 1.26 1.29
(mmol/1) + 0.27 + 0.28 + 0.26
Legend
Concentrations of hormones and lipids in relation to the 
severity of coronary artery disease (CAD). HDL = High 
Density Lipoprotein. Values are mean + SD.
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infarction (mean ± SD: 126 + 39 versus 101 + 62 pmol/1, p 
< 0.01) , but no other differences in testosterone, lipids 
or the fibrinolysis tests (table 6.4) were noted.
^.2-A Age
To assess whether abnormalities of fibrinolysis 
occurred in younger men, we took men under 5 0 years of age 
(n = 47), and found no differences in the tests of 
fibrinolysis in relation to the severity of coronary 
artery disease. Younger men with a previous myocardial 
infarction (n = 28) had higher plasma fibrinolytic
activity than men without a previous myocardial infarction 
(83 + 2 3  vs 69 + 20 mm2, p < 0.05), but no other
differences were noted. No correlation between age and 
plasma fibrinolytic activity (r = 0.04) or between age and 
the other fibrinolytic tests were noted.
Peripheral Arterial Disease
Peripheral arterial disease was detected in 13 
patients (previous angiography confirmed the diagnosis in 
3 patients). Significant elevations in plasma 
fibrinolytic activity, and trends to higher BBeta 15-42, 
fibrinogen and fibrinopeptide A concentrations were noted 
in this patient group compared to patients with coronary 
artery disease but without peripheral arterial disease 
(table 6.5).
6_._3 . 6 Smoking and Beta-Blockade
No differences in the fibrinolysis tests were
TABLE 6 .4
FIBRINOLYSIS AND MYOCARDIAL INFARCTION
CORONARY ARTERY DISEASE 
With MI Without MI
Number 56 44
BBETA 15-42 1.24 1.23
(pmol/ml) + 0.45 + 0.48
Fibrinolytic 80 76
Activity (mm2) + 21 ± 23
Plasminogen 4.8 4.8
(cu/ml) + 0.6 + 0.7
cX 2-Antiplasmin 99 104
(%) + 13 + 16
cX 2-Macroglobulin 86 82
(%) + 27 + 27
F.D.P. 's 4.9 5.0
(ug/ml) + 3.6 + 4.2
Fibrinogen 3.31 3.33
(9/1) + 0.78 + 0.65
Fibrinopeptide A 2.53 2.63
(pmol/ml) + 1.71 + 1.76
Legend
Components of fibrinolysis in patients with coronary 
artery disease with and without a previous myocardial 
infarction (MI). Values are mean ± SD.
TABLE 6 .5
FIBRINOLYSIS AND PERIPHERAL ARTERIAL DISEASE
PERIPHERAL
YES
ARTERIAL DISEASE
NO
Number 13 87
BBETA 15-42 1.41 1.21
(pmol/ml) + 0.54 + 0.45
Fibrinolytic 97* 75
Activity (mm2) + 30 + 19
Plasminogen 4.3 4.8
(cu/ml) + 1.4 + 0.7
oC 2-Antiplasmin 99 101
(%) + 15 + 14
cxC. 2-Macroglobulin 82 84
(%) + 30 + 21
F.D.P. 's 4.7 5.2
(ug/ml) + 4.5 + 2.9
Fibrinogen 3.68 3.25
(9/1) + 0.93 + 0.69
Fibrinopeptide A 2.90 2.44
(pmol/ml) + 2.20 + 1.20
Legend
Components of fibrinolysis in men with coronary artery 
disease with or without peripheral arterial disease. 
Values are mean ± SD.
*p  < 0 .0 1
I l l
detected in smokers compared to non-smokers (table 6.6), 
patients with and without beta-blocker 
administration (table 6.7). Trends for smokers to have 
higher fibrinogen and lower fibrinolytic activity were 
noted.
^.3_*Z Lipids
To examine the effects of hyperlipidaemia, 
comparisons were made between the concentrations of the 
fibrinolytic tests in patients with severe
hypertriglyceridaemia (plasma triglyceride > 3mmol/l) and 
hypercholesterolaemia (plasma cholesterol > 7 mmol/1) and 
patients with lower levels (tables 6.8 and 6.9). Patients 
with severe hypertriglyceridaemia had significantly higher 
concentrations of alpha2-antiplasmin but no other 
differences were noted. No associations between the 
fibrinolysis and lipid tests were found except for a 
correlation of alpha2-antiplasmin antigen (r = 0.31, p < 
0.005), and alpha2-macroglobulin antigen (r = -0.25, p < 
0.05) with the plasma triglyceride concentration.
Z ‘Z-8. Hormones
No significant associations were noted between the 
hormonal tests (oestradiol, testosterone) and the lipid 
and fibrinolysis tests
^.^.9 Correlations between the tests of fibrinolysis
Significant correlations of plasminogen (r — —0.23),
and FDP's (r =0.38) with the BBeta 15-42 fragment were
TABLE 6 .6
FIBRINOLYSIS AND SMOKING
SMOKERS NON-SMOKERS
Number 44 56
BBETA 15-42 1.25 1.23
(pmol/ml) ± 0.50 ± 0.44
Fibrinolytic 75 81
Activity (mm2) . ± 24 ± 20
Plasminogen 4.7 4.8
(cu/ml) + 0.8 + 0.6
oC 2-Antiplasmin 99 103
(%) ± 13 ± 15
o< 2-Macroglobulin 85 83
(%) + 30 ± 244
F.D.P. 's 5.7 4.5
(ug/ml) ± 5.2 ± 2 . 5
Fibrinogen 3.41 3.22
(9/1) + 0.69 ± 0.76
Fibrinopeptide A 2.78 2.43
(pmol/ml) ± 1.88 ± 1.62
Legend
Components of fibrinolysis in relation to smoking. 
Values are mean ± SD.
TABLE 6.2 
FIBRINOLYSIS AND BETA-BLOCKADE
BETA-BLOCKADE 
YES NO
Number 65 35
BBETA 15-42 1.20 1.30
(pmol/ml) + 0.46 + 0.47
Fibrinolytic 77 81
Activity (mm2) + 23 + 20
Plasminogen 4.7 4.8
(cu/ml) + 0.8 + 0.6
oC 2-Antiplasmin 97 104
(%) ± 18 ± 14
oC 2-Macroglobulin 84 82
(%) + 31 + 24
F.D.P. 's 5.0 4.7
(ug/ml) + 4.6 + 3.1
Fibrinogen 3.31 3.30
(9/1) + 0.72 + 0.78
Fibrinopeptide A 2.71 2.35
(pmol/ml) + 1.84 + 1. 50
Legend
Components of fibrinolysis in patients with and without 
beta-adrenoceptor blocker administration.
Values are mean ± SD.
TABLE 6 .8
FIBRINOLYSIS AND HYPERTRIGLYCERIDAEMIA
PLASMA TRIGLYCERIDE 
>3 mmol/1 ^3 mmol/1
Number 24 73
Triglyceride 4.5 1.8
(mmol/1) + 1.7 + 0.6
BBETA 15-42 1.27 1.22
(pmol/ml) + 0.44 + 0.47
Fibrinolytic 80 76
Activity (mm2) + 27 ± 34
Plasminogen 4.8 4.8
(cu/ml) + 0.8 ± 0.7
oc 2-Antiplasmin 107* 99
(%) + 12 ± 15
cX. 2-Macroglobulin 78 86
(%) + 24 ± 27
F.D.P. 's 4.8 5.1
(ug/ml) + 4.3 ± 3.7
Fibrinogen 3.27 3.31
(9/1) + 0.73 ± 1.00
Fibrinopeptide A 3.16 2.48
(pmol/ml) + 2.15 ± 1.56
Legend
Components of fibrinolysis in relation to plasma 
triglyceride concentrations. Values are mean + SD.
*p  < 0 .0 1
TABLE 6 .9
FIBRINOLYSIS AND HYPERCHOLESTEROLAEMIA
>
PLASMA 
7 mmol/1
CHOLESTEROL
< 7 mmol/1
Number 32 66
Cholesterol 7.9 5.9
(mmol/1) + 1.0 + 0.6
BBETA 15-42 1.21 1.24
(pmol/ml) ± 0.39 + 0.50
Fibrinolytic 82 75
Activity (imti2) + 25 ± 30
Plasminogen 4.8 4.7
(cu/ml) + 0.8 + 0.7
ex. 2-Antiplasmin 103 100
(%) ± 17 + 15
c< 2-Macroglobulin 86 84
(%) + 27 + 27
F.D.P. 's 5.7 4.6
(ug/ml) + 5.3 + 2.8
Fibrinogen 3.32 3.30
(9/1) + 0.79 + 0.90
Fibrinopeptide A 2.65 2.56
(pmol/ml) + 1.96 + 1.64
Legend
Components of fibrinolysis in relation to plasma cholesterol 
concentrations. Values are mean ± SD.
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noted (table 6.10) but no other significant correlations 
between the tests of fibrinolysis were detected.
Body Mass Index 
Correlations of triglyceride (r = 0.36, p < 0.001),
cholesterol (r = 0.28, p < 0.01), testosterone (r = -0.20, 
p < 0.05), and plasminogen (r = 0.20, p < 0.05) with body 
mass index were noted. No other correlations with the 
fibrinolytic tests were noted, although a negative trend 
with BBeta 15-42 was seen (r = -0.18).
6.A DISCUSSION
Severity of Coronary Artery Disease 
We have been unable to demonstrate any difference in 
plasma fibrinolytic activity in relation to the severity 
of coronary artery disease (Small et al., 1984b), findings 
which have subsequently been confirmed (Paramo et al., 
1985). We have, in addition, been unable to relate the 
severity of coronary artery disease to in vivo 
fibrinolysis, as indicated by the BBeta 15-42 fragment, or 
to the other major components of the fibrinolytic enzyme 
system - findings which have not previously been 
reported. Our study therefore fails to provide any 
support for the association of basal fibrinolysis with 
established coronary artery disease. We did not study 
fibrinolytic capacity which may be impaired in coronary 
artery disease (Khanna et al., 1975; Walker et al., 1977;
TABLE 6.10
CORRELATION OF BBETA 15-42 WITH THE TESTS OF FIBRINOLYSIS
BBeta 15-42 antigen (pmol/ml)
'r ' 'P'
Fibrinolytic 
Activity (mm2)
0.12 NS
Plasminogen
(cu/ml)
-0.23 0.05
c<. 2-Antiplasmin 
(%)
0.13 NS
oC 2-Macroglobulin 
(%)
0.04 NS
F.D.P. 's 
(ug/ml)
0.38 0.001
Fibrinogen
(9/1)
0.14 NS
Fibrinopeptide A 
(pmol/ml)
0.03 NS
Legend
Spearman correlation (r) values of in vivo fibrinolysis 
(BBeta 15-42) with the other components of fibrinolysis
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O'Connor et al., 1984a; Estelles et al., 1985) possibly 
due to increased levels of plasminogen activator inhibitor 
(Estelles et al., 1985; Paramo et al., 1985). In a more 
recent epidemiological study of 100 men with angina 
(detected by a health screening questionnaire) and 400 
matched controls (Lowe et al., 1985), no relationship of 
angina to BBeta 15-42, alpha2-antiplasmin or 
alpha2-macroglobulin was observed. This is consistent 
with the negative findings of these 3 variables in the 
present, angiographic study.
For many years there has been great argument on the 
relative importance of the lipid and thrombogenic 
hypothesis for atheroma and it is probable that both play 
an important role in the aetiology of atheroma (Meade, 
1981; Smith, 1981). Cholesterol is an established risk 
factor for coronary artery disease and there is also a 
strong inverse association between cardiovascular 
mortality and HDL cholesterol (Yaari et al., 1981). 
Angiographic studies have shown a relation of coronary 
artery disease with all lipid and lipoprotein 
concentrations (Jenkins, Harper and Nestel, 1978; Breier 
et al., 1985 ) or with only HDL cholesterol (Miller et al., 
1981), but we have been unable to confirm these 
associations (Small et al., 1985b). Different patient 
populations, coronary score systems, assay and statistical 
analysis methods may explain these discrepant findings. 
We have noted however a modest, but significant 
correlation of fibrinogen with the severity of coronary 
artery disease which we previously observed in a smaller
Il4
study (Lowe et al., 1980). This is consistent with the 
post mortem study showing high fibrinogen levels in 
arterial intima and mural thrombi (Smith and Staples, 
1981) and adds further support to the recent evidence 
showing the important association of fibrinogen with 
ischaemic heart disease (Meade et al., 1980; Baker et al., 
1982; Wilhelmsen et al., 1984; Sugrue et al., 1985). 
Increasing age is probably the most powerful predictor of 
the risk of ischaemic heart disease (Meade, 1981) and it 
is not surprising therefore that we have noted a 
significant correlation of age with the coronary index. 
This association supports the use of the coronary index 
that we employed. No correlation of age and fibrinogen 
was noted (r = 0.07) in our study and therefore the
association of both age and fibrinogen with the coronary 
index cannot be explained by an underlying association 
between age and fibrinogen in the present study. It 
should be noted however that fibrinogen does increase with 
increasing age in epidemiological studies over a wider age 
range (Meade et al., 1977).
.^j4 .2 Hormonal Associations
We have found no association between oestradiol or 
testosterone levels and the severity of coronary artery 
disease or the tests of fibrinolysis (Small et al., 
1985a). The postulated mechanisms whereby raised 
oestradiol levels exert their harmful effect does not 
therefore appear to be related to either accelerated 
atherogenesis (Philips, 1978), or defective fibrinolysis
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(Andersen, and Ejermami, 1983b). ime
noted elevated oestradiol levels in men with a previous 
myocardial infarction compared to men without a previouis 
myocardial infarction but with coronary artery disease. 
This is in keeping with the view that elevated oestradiol 
concentrations may be a risk factor for ischaemic heart 
disease (Philips et al., 1983).
6_-^ .3_ Myocardial
Apart from oestradiol levels no differences in any of 
the blood tests were noted for patients with or without a 
previous myocardial infarction. In previous controlled 
studies younger patients were more commonly associated 
with defective fibrinolysis (Chakrabarti et al-, 1968; 
Walker et al., 1977; O'Connor et al-, 1984a), and we
therefore analysed patients with and without a previous 
myocardial infarction under 50 years of age. These
younger patients had increased fasting plasma fibrinolytic 
activity. Patients with peripheral arterial disease also 
had higher plasma fibrinolytic activity and non—fasting
fibrinolytic activity was higher in men with a previous 
myocardial infarction in our study on exercise and 
fibrinolysis (Chapter 5.3). These findrngs remain
unexplained, but possibly a greater vascular endothelial 
damage, associated with these patients groups, could lead 
to a higher plasma fibrinolytic activity. Some caution 
must be placed on the results of the patients with 
peripheral arterial disease since a diagnosis of this 
condition made on history and examination may wrongly
Il6
classify patients in between 20-50% of cases (Marinelli, 
Beach and Glass, 1979; Janka, Standi and Mehnert, 1980).
Lipids ■
The relationship between hypertriglyceridaemia and 
depressed fibrinolytic activity has previously been
discussed (Chapter 2.5) but we have been unable to confirm
this association in the present study. We have however 
noticed significant and different associations between 
plasma triglyceride levels and the inhibitors of 
fibrinolysis, alpha2-antiplasmin antigen (positive 
association) and alpha2-macroglobulin antigen (negative 
association) . Since alpha2-antiplasmin is the major
fibrinolytic inhibitor it is likely that this protein
would have the most important in vivo effect. An increase 
in alpha2-antiplasmin could promote fibrin deposition in 
several ways. Alpha2-antiplasmin inhibits plasminogen 
activator, is the major inhibitor of plasmin, inhibits the 
absorption of plasminogen to fibrin, and cross-links to 
fibrin rendering it less susceptible to plasmin (Collen, 
1980; Aoki et al., 1981). When the patients were
subdivided into groups with and without severe 
hypertriglyceridaemia the only difference between the
groups was of elevated alpha2-antiplasmin levels in 
patients with hypertriglyceridaemia. Similar findings
have been reported in patients with type II 
hyper1ipoproteinaemia (Lowe et al., 1982), while an
association of alpha2-antiplasmin with triglyceride levels 
has been noted in a recent epidemiological study (Lowe et
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al., 1985). A previous epidemiological study failed to 
find such an association (Scarabin, Bara and Jacqueson, 
1983). Recently, increased triglyceride levels have been 
associated with increased t-PA inhibitor levels (Brommer 
et al., 1984a). Hypertriglyceridaemia therefore is 
associated with a raised level of fibrinolytic inhibitors 
acting at distinct sites against plasmin and t-PA. The 
negative association between alpha2-macroglobulin and 
triglyceride concentrations could be a homeostatic 
compensatory mechanism to partially offset the raised 
alpha2-antiplasmin concentrations, but this requires 
further study. While defective fibrinolysis may be a 
feature of hypertriglyceridaemia there appears to be 
little evidence to suggest a causal association between 
triglyceride levels and ischaemic heart disease (Hulley et 
al., 1980). The role of fibrinolysis in coronary artery 
disease is given no support from this observation.
.^4_._5 Inter-relationships of the Fibrinolysis Tests
BBeta 15-42 fragment is a new, sensitive indicator of 
in vivo plasmin-mediated fibrinolysis and its relation to 
the other components of fibrinolysis has not been 
evaluated. Since synthesis of various components of 
fibrinolysis may increase during a phase of increased 
fibrinolytic activity, the measurement of plasminogen and 
fibrinogen may, in addition, not be consistent with BBeta 
15—42 levels due to these compensatory phenomena (Walenga 
et al., 1984). We have found that BBeta 15-42 levels show 
significant correlations with plasminogen (negative) and
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FDP s (positive). This is consistent with the scheme: 
increased activation of plasminogen reduces plasminogen 
levels and increases plasmin digestion of fibrin (ogen), 
ie, BBeta 15-42 and FDP fragments. We have also found a 
correlation of BBeta 15-42 and FDP in stroke patients 
(Douglas et al., 1986). The lack of correlation between 
euglobulin fibrinolytic activity (ex vivo fibrinolysis) 
and BBeta 15-42 (in vivo fibrinolysis) indicates that 
these assays measure different aspects of fibrinolysis and 
casts doubt as to the validity of using euglobulin 
fibrinolytic activity as an overall assessment of
fibrinolysis. We have previously described a dissociation 
between the BBeta 15-42 fragment and plasma fibrinolytic 
activity in normal volunteers given stanozolol (Small et 
al., 1983a; Small et al., 1983b) and in patients following 
major surgery (Douglas et al., 1985). The lack of
correlation between euglobulin fibrinolytic activity and 
t-PA antigen in patients with coronary artery disease has 
also led others to question the value of euglobulin 
fibrinolytic activity as an in vivo assessment of
fibrinolysis (Paramo et al., 1985).
Smoking
Population studies of over 700 men (Korsan-Bengtsen 
et al., 1972) showed no difference in fibrinolytic 
activity in smokers compared to non-smokers, while a 
slight decrease in fibrinolytic activity was noted in 
smokers in a population study of over 1600 men (Meade et 
al., 1979). While a trend towards reduced fibrinolytic
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activity in smokers was seen, it is not surprising that 
smokers showed no significant difference in fibrinolytic 
activity, or the tests of fibrinolysis, in view of the 
smaller numbers in our study. Healthy males who are heavy 
smokers have defective fibrinolytic activity compared to 
healthy non-smoking males (Allen et al., 1983) and it is 
clear that to demonstrate an effect of smoking on 
fibrinolysis requires either large numbers or a highly 
selected group of subjects.
Body Weight
Epidemiological studies have shown a relationship 
between a high body mass index and coronary heart disease 
mortality (Jarrett, Shipley and Rose, 1982; Rhoads and 
Kagan, 1983). The expected correlations of body mass 
index and lipid levels were detected, but no correlations 
of obesity with fibrinolytic activity was found although a 
negative trend with in vivo fibrinolysis (BBeta 15-42) was 
seen. This association was significant in a recent 
epidemiological study (Lowe et al., 1985). The body mass 
index ranged from 20.5 to 32.4 with 90% of values between 
23-28. It is possible that the narrow range of body mass 
index values could explain the lack of correlation with 
the fibrinolytic activity.
Beta-Blockade
While the resting level of plasma fibrinolytic 
activity has been reported to be altered by beta—blockade 
(Chapter 4.4), the present study, involving a larger group
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of pauients, has shown no alteration of fibrinolytic 
activity or the components of fibrinolysis by 
beta—blockade. Beta—blockade does not therefore influence 
basal fibrinolysis.
Summary and Conclusions 
We have been unable to relate the tests of
fibrinolysis to the severity of coronary artery disease 
and can therefore offer no support for an association 
between these two variables. Fibrinogen showed a closer 
association with the severity of coronary artery disease 
and it is possible that coagulation and not fibrinolysis 
is the more important haemostatic system with respect to 
coronary artery disease. The negative findings of this
study may reflect the homogenous patient population, but 
the advantage of such a group is that the large patient 
numbers allow associations of the biochemical and
haemostatic tests with the clinical characteristics of the 
group to be studied. Thus important observations on the 
severity of coronary artery disease, fibrinolysis, 
oestradiol and lipids have been reported (Small et al.,
1985a; Small et al., 1985b) and the effect of lipid levels 
on the inhibitors of fibrinolysis have been recorded.
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CHAPTER 7
THE EFFECTS OF INTRAMUSCULAR STANOZOLOL ON FIBRINOLYSIS IN
HEALTHY MALE SUBJECTS
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Z-1 i n t r o d u c t i o n
The principle physiological stimulus to fibrinolysis, 
exercise, has already been discussed and the following 
chapters will concentrate on pharmacological potentiation of 
the fibrinolytic enzyme system by the anabolic steroid 
stanozolol.
The previous studies using stanozolol (17—beta—hydroxy— 
17-alpha-methylandrostano (3.2,-c) pyrazole) have been 
discussed more fully in Chapter 2.8. It was well recognised 
that stanozolol could enhance fibrinolysis in various forms 
of vascular disease when given orally (Davidson et al., 
1972; Cunliffe et al., 1975; Jarrett et al., 1978; Burnand 
et al., 1980) but a greater interest in this drug developed 
following the demonstration that oral administration of 
stanozolol to normal subjects could lead to a rapid
enhancement of fibrinolysis (Preston et al., 1981). It was
felt that if stanozolol could improve fibrinolysis in normal 
subjects then it would have an even greater potential to 
improve fibrinolysis in patients with vascular disease and 
defective fibrinolysis. An intramuscular depot preparation 
of stanozolol was available whose effects on fibrinolysis 
had not been studied. This form of administration could 
offer advantages in a number of clinical settings, such as 
the non-compliant and/or ill patients unable to take oral 
medication. In particular we wished to see if this
preparation could cause short-term potentiation of the 
fibrinolytic system which might then be tested as a
prophylactic agent to prevent spontaneous or post—operative 
deep vein thrombosis, as abnormal fibrinolysis has been
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reported in both these conditions (Chapter 2.2).
The aim of the present study was therefore to assess 
the onset, duration and degree of change induced in the 
fibrinolytic enzyme system by a single intramuscular 
injection of stanozolol.
1_.2 METHODS
Z*Z*Z Patients
Local Ethical Committee permission was obtained and 12 
healthy male subjects (age range 22-45, mean 30.8 years) 
with no history of jaundice or liver disease took part in 
the study.
2'Z'Z Study Design
The volunteers fasted overnight and after 15 minutes at 
rest, blood was withdrawn, without compression by a 
tourniquet, for estimation of baseline fibrinolysis tests. 
The volunteers were then given a 1 ml (50mg) intramuscular 
injection of stanozolol and repeat fasting samples taken at 
1, 2, 7, 14, 21, 28 and 56 days following the injection. 
All sampling was carried out between 9-lOam and the subjects 
were requested to abstain from alcohol during the 2 4 hours 
prior to each test day.
Z*Z*Z Blood Tests
Plasma fibrinolytic activity, plasminogen activity, 
FDP's, alpha2-antiplasmin activity, alpha2-macroglobulin 
antigen and fibrinogen were measured as previously described
(chapter 3). The results of the inhibitors of fibrinolysis 
are expressed as a percentage of normal pool plasma.
Z*Z*A Statistics
Statistical comparisons were performed using the paired 
Wilcoxon rank sum test.
7.1 RESULTS
Plasma fibrinolytic activity increased significantly (p 
< 0.05) 24 hours following the injection and remained
elevated for 7 days (figure 7.1). Plasminogen
concentrations also increased above baseline values by day 2 
and remained significantly elevated for 3 weeks following 
the injection (figure 7.2). No alteration in the other 
tests of fibrinolysis were noted (table 7.1).
7.4 DISCUSSION
The increases noted in plasma fibrinolytic activity and 
plasminogen in our normal volunteers are consistent with the 
findings of Preston and colleagues (1981) using oral 
stanozolol. Given via the intramuscular route this 
enhancement of fibrinolysis occurs earlier than any previous 
reports - the percentage increase from baseline being about 
30% for one week and 50% over the subsequent 3 weeks. We 
were unable to confirm a fall in fibrinogen or
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Figure 7.1
Illustrates the concentrations (mean ^  83) of fasting 
plasma fihrinol;>^ic activity (fi) following the 
intramuscular injection (50 mg) of stanozolol in healthy 
male subjects. Changes are compared to basal values.
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Figure 7°2
Illustrates the concentrations (mean SD) of plasminogen 
activity following the intramuscular injection ($0 mg) of 
stanozolol to healthy male subjects. Changes are compared 
to basal values.
TABLE 7 .1
I.-M . STANOZOLOL: EFFECTS ON FIBRINOLYSIS IN  NORMAL MALES
DAYS OC2-AP oC2-MG F .D.P.'s Fibrinogen
(lU/ml) (%) (ug/ml) (g/i)
BASE 1.43 85 2.7 2.24
+ 0 . 42 + 26 + 0.7 ± 0.48
1 1-19 84 2.1 2.48
+ 0.24 + 25 + 0.7 ± 0.55
2 1.62 70 2.6 2.35
+ 0.59 + 24 + 0.7 ± 0.48
7 1.95* 90 2.4 2.06
+ 0.55 + 36 + 1.0 ± 0.24
14 1.62 79 2.5 2.32
+ 0.80 + 27 + 0 ± 0.42
21 1.28 83 2.5 2.20
+ 0.59 + 34 + 0 ± 0.38
28 1.86 75 2.5 2.28
+ 0.76 28 + 0 ± 0.24
Legend
Table 7.1 lists the values (mean ± SD) of alpha2-antiplasmin 
(o<2-AP), alpha2-macroglobulin (C<2-MG), FDP's and fibrinogen 
following a single intramuscular (I.M.) injection (50 mg) of 
stanozolol.
*p < 0.05, changes relative to base.
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alpha2-macroglobulin concentrations ( P r e s t o n  e t  a l . ,  1981) 
which may due to the differences in dosage or to the lower 
baseline fibrinogen concentrations of our volunteer 
subjects. This enhancement of fibrinolysis via a single 
intramuscular injection (Small et al., 1982b) w a s  felt to be 
of sufficient magnitude to warrant using such a regimen in 
an attempt to prevent post-operative deep vein thrombosis 
(Blarney et al., 1984) and to perform a further pilot study 
in medical patients which will be discussed in the following 
chapter -
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CHAPTER 8
THE EFFECTS OF INTRAMUSCULAR STANOZOLOL ON 
FIBRINOLYSIS IN ELDERLY MEDICAL PATIENTS
127
1-i i n t r o d u c t i o n
Following the demonstration of a rapid enhancement of 
fibrinolysis by a single intramuscular injection of 
stanozolol (Small et al., 1982b) a controlled trial was 
performed in general surgical patients which showed that 
while stanozolol prevented the post-operative shutdown in 
fibrinolysis, it failed to prevent DVT (Blamey et al., 
198 3; Blamey et al., 1984).
Patients in general medical wards have a high 
incidence of venous thrombosis, due partly to age, 
immobilisation, acute myocardial infarction, cardiac 
failure, cerebrovascular disease and chest infection 
(Simmons, Sheppard and Cox, 1973; Sigel et al., 1975; 
Belch et al., 1981; Warlow 1981). It has also been 
reported that medical patients with diabetes mellitus 
(Chapter 2.9), ischaemic heart disease (Chapter 2.7) and 
cerebrovascular disease (Mettinger et al., 1979 ) may have 
reduced fibrinolytic activity. In addition, studies on 
the relationship between defective fibrinolysis and the 
development of recurrent and/or idiopathic venous 
thrombosis suggest an aetiological association (Chapter 
2.2). The effects of stanozolol on fibrinolysis in 
medical patients, who do not undergo the stress of major 
surgery, had not been studied. Prophylactic 
anti-thrombotic therapy in medical patients has received 
scant attention, despite studies showing the effectiveness 
of subcutaneous heparin in selected patients (McCarthy et 
al., 1977; Belch et al., 1981; Halkin et al., 1982). In a
pilot study of elderly medical patients at risk of venous 
thrombosis, and having conditions associated with 
defective fibrinolysis, we have examined the effects on 
fibrinolysis following stanozolol administration. If a 
single intramuscular injection were to induce favourable 
effects on fibrinolysis its practical advantage over twice 
daily, often painful, heparin injections would then merit 
a controlled study with respect to DVT.
S.2 METHODS
Patients
Local Ethical Committee permission was obtained and 
12 patients (age range 60-79, mean 70.8 years) gave 
informed consent to receive a single intramuscular 
injection of stanozolol. Overall we selected 12 elderly 
immobilised patients to take part in the study most of 
whom had established vascular disease, but who were not 
acutely unwell. Of the 7 males and 5 females, 6 patients 
(5 females: 1 male) were immobilised with old, dense
cerebrovascular accidents. Two of this group with 
cerebrovascular disease were type II diabetics, of whom 
one had sustained an acute myocardial infarction and the 
other a myocardial infarction 2 months prior to the 
study. Three men being treated with bedrest on day 4 
following an acute myocardial infarction entered the 
study, and 3 immobilised men (one with severe Parkinson s 
disease, an ischaemic diabetic foot ulcer, and chronic
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obstructive airways disease) were also included. Only 2 
of the patients were current cigarette smokers and none of 
the patients were taking drugs known to have an effect on 
the fibrinolytic system. In view of the known effects of 
anabolic steroids, patients with liver disease, cardiac 
failure or prostatic tumour were excluded from the study. 
Patients taking anticoagulant drugs or with intercurrent 
infection were also excluded as these might modify the 
measurement of fibrinolysis and complicate data analysis.
study Design
Following the baseline sample a 1 ml (50mg) 
intramuscular injection was given and blood samples taken 
1, 2 , 5  and 7 days later. All samples were taken between
8am and 9am, at rest, and following an overnight fast. 
The timing of samples was chosen to detect the major 
changes which occured in the volunteer study (Chapter 7).
^.2.3 Blood Tests
Plasma fibrinolytic activity, plasminogen activity 
and alpha2-antiplasmin activity were measured as 
previously described (Chapter 3). Protein C antigen was 
kindly assayed by Dr R M Bertina (Leiden, The Netherlands) 
by electroimmunoassay (Bertina et al., 1982). 
Alpha2-macroglobulin and FDP u were not assayed since no 
alterations in these parameters were detected in the 
volunteer study. Serum for liver function tests (albumin, 
globulin, bilirubin, alkaline phosphatse, aspartate and 
alanine transaminase) was analysed on the baseline and day
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7 sample (Technicon SMAC).
8.2.4 Statistics
Statistical comparisons were performed using the 
Wilcoxon matched pairs signed-rank test.
RESULTS
The results of the fibrinolysis tests are listed in 
table 8.1. No change in plasma fibrinolytic activity, 
plasminogen, alpha2-antiplasmin or fibrinogen occurred 
during the study and no adverse effects on liver function 
tests were detected. The concentrations of plasma 
fibrinolytic activity were consistently low and fibrinogen 
consistently high during the study. Protein C levels 
increased significantly in the 2 days following stanozolol 
injection and by day 5 the highest recorded levels (29% 
above baseline) were noted and these remained 
significantly elevated at day 7.
8.4 DISCUSSION
Both the fasting plasma fibrinolytic activity and 
plasminogen levels showed no increment following 
stanozolol administration to elderly medical ptients. The 
results on fibrinolytic activity, which show a marked
TABLE 8 .1
I 'M .  STANOZOLOL; EFFECTS ON FIBRINOLYSIS IN  MEDICAL PATIENTS
BASE 1
TIME (DAYS) 
2 5 7
Fibrinolytic 64 65 68 63 55
Activity (mm2) + 21 + 23 ± 19 + 18 + 13
Plasminogen 3.5 3.2 3.2 3.3 3.2
(cu/ml) + 0.7 + 0.3 ± 0.3 + 0.3 + 0.5
o4 2-Antiplasmin 110 113 113 118 117
(%) + 22 + 19 ± 21 + 11 + 19
Fibrinogen 5.6 5.5 5.3 5.5 4.8
(g/i) + 1.6 + 1.3 + 1.2 + 1.1 + 2.0
Protein C 120 127 135* 156* 150*
( % ) + 22 + 25 ± 23 + 25 + 27
Legend
Table 8.1 lists the changes in the fibrinolytic tests 
(mean ± SD) following a single intramuscular injection 
(50 mg) of stanozolol.
*p < 0.01, changes relative to base.
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contrast to the volunteer study involving young healthy 
male subjects (Small et al., 1982b), are illustrated in 
figure 8.1. Since the sample times and assay methods were 
identical in both these studies, the failure of stanozolol 
to effect an increase in fibrinolytic activity and 
plasminogen may be due either to the presence of medical 
illness, or to the difference in age. It is well known
that fibrinogen levels show a marked rise with increasing 
age (Hamilton et al., 1974; Meade et al., 1977) and still 
higher levels occur in vascular disease (Lowe, 1981). 
Compared to our healthy volunteers (mean age 30.8 years)
our present study group (mean age 70.8 years) had
significantly higher fibrinogen and lower basal levels of 
fibrinolytic activity. Meade and colleagues (1979) found 
a fall in fibrinolytic activity in subjects aged 60-65 
compared to young controls while Hamilton et al., (1974) 
found no difference in patients 20-40 years compared to 
subjects 66-75 years old. Medical illness, rather than 
age, may be a more important factor in relation to the 
defective fibrinolysis demonstrated in our patients (Lowe, 
1981). The difference noted between volunteers and
patients illustrates the importance of documenting drug 
effects in patient groups. Stanozolol has been shown to 
increase extrinsic plasminogen activator levels (Kluft et 
al., 1984b) and since the resting fibrin plate lysis area 
reflects total plasminogen activator, of which only a 
small part is . extrinsic plasminogen activator, it is 
possible that a rise in extrinsic plasminogen activator 
could have occurred following stanozolol administration.
FA(mm2)
A
120 
110 
100
90
80“
70-
60“
50“
40“
0
Young normals’
base
Elderly medical 
patients
* p<0.05  
**p <0 .01
-T->7
Days
Fi gure 8 .1
Illustrates the concentrations (mean +_ SEM) of fasting 
plasma fibrinolytic activity (FA) in the two groups 
following stanozolol ($0 mg I.Mo) administration. 
Changes are compared to basal values.
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This study has confirmed the pharmacological 
potentiation of protein C with stanozolol (Kluft et al., 
1964a) in medical patients at high risk of venous 
thrombosis. Moreover we have illustrated the time course 
of onset of protein C elevation following a single 
intramuscular injection. Whether such elevation of
protein C with its potent anticoagulant properties could 
prevent thrombosis is unknown. Protein C is also known to 
enhance fibrinolysis (Comp and Esmon, 1981) but the 
increased concentrations of protein C during the study 
were not associated with an improved plasma fibrinolytic 
activity.
In summary we have shown that elderly medical 
patients have elevated fibrinogen and depressed
fibrinolytic activity and that a single intramuscular 
injection of stanozolol fails to improve these
pro-thrombotic abnormalities (Small et al., 1984c).
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CHAPTER 9
THE EFFECTS OF ORAL STANOZOLOL ON PLASMA AND SALIVARY 
FIBRINOLYSIS IN HEALTHY MALE SUBJECTS
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9.1 INTRODUCTION
Previous studies of oral stanozolol have not 
investigated the immediate changes in fibrinolysis and 
most have concentrated on changes after one month on 
therapy, but Preston et al., (1981) in a study on healthy 
volunteers, demonstrated that significant changes in the 
components of fibrinolysis were detected between 7-14 days 
after commencing oral stanozolol. The recorded increases 
in fibrinolytic activity using stanozolol however may have 
been falsely high due to the effect of the lower 
fibrinogen levels (which stanozolol also induced) on the 
euglobulin clot lysis time which was used to measure 
fibrinolytic activity. Although the authors argued 
against such a possibility it has been shown that an 
increase in the fibrinogen level delays plasmin-induced 
clot lysis (Freidman and Clifton, 1958), and thus changes 
in fibrinogen levels are likely to alter the euglobulin 
clot lysis time results. While subjects are taking 
stanozolol a measurement of fibrinolytic activity which is 
independent of the fibrinogen concentration, such as the 
fibrin plate technique, may be a more appropriate assay.
At the time the study was performed there was no 
available assay of tissue plasminogen activator and since 
saliva was known to possess fibrinolytic activity 
(Southam, 1981; Moody, 1982) we were interested to see if 
stanozolol could alter tissue fibrinolytic activity. The 
effects of stanozolol on in vivo fibrinolysis had not been 
studied previously and as the BBeta 15-42 fragment became
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available at this time it was used as a reflection of 
induced fibrinolytic activity.
The aims of our study were threefold: to examine the
effects of oral stanozolol on plasma fibrinolytic activity 
using the more specific fibrin plate technique; to assess 
in vivo fibrinolysis using BBeta 15-42 measurements and to 
document the effects of stanozolol on the fibrinolytic 
activity of saliva in normal male subjects.
2-2 METHODS
Patients
Local Ethical Committee permission was obtained and 
nine healthy male subjects (age range 19-35, mean 26.8 
years) gave informed consent to take part in the study.
Study Design
Stanozolol was administered over a 14 day period 
this time interval being chosen since statistically 
significant changes in blood fibrinolysis had been 
detected during that period (Preston et al., 1981). A 
baseline blood sample was taken and repeat samples at 7 
and 14 days while on stanozolol and 14 days after the 
treatment course had stopped. All sampling was carried 
out in the fasting state, between 9-lOam, and the subjects 
were requested to abstain from alcohol the day before each
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sample.
2*2.2 Tests
Plasma fibrinolytic activity, BBeta 15-42 antigen, 
plasminogen activity, alpha2-macroglobulin antigen and 
fibrinogen were assayed as previously described (Chapter 
3). Saliva (4 mis) was collected into universal 
containers and, after spinning, 20 /il of the supernatant 
was assayed for fibrinolytic activity on fibrin plates. 
All the above samples were placed immediately on ice and 
centrifuged (at 4°c, 2000 g for 20 mins.) within 30
minutes of collection. Aliquots of plasma and saliva were 
then stored at -70^c until assayed in batches.
2*2.2 Statistics
Statistical comparisons were performed using the 
Wilcoxon matched pairs signed-rank test.
2*1 RESULTS
The results are listed in table 9.1. No change was 
seen in either plasma fibrinolytic activity or plasminogen 
levels in the 14 days on treatment. However a significant 
increase in salivary fibrinolytic activity to 142% of 
baseline was observed at 14 days returning to baseline 
levels off treatment. One subject consistently failed to
TABLE 9 .1
ORAL STANOZOLOL: EFFECTS ON FIBRINOLYSIS IN  NORMAL MALES
BASE
DAYS 
ON TREATMENT 
7 14
DAYS OFF 
TREATMENT 
14
Fibrinolytic 73 73 69 65
Activity ± 17 + 11 + 12 + 12
(Plasma: m m 2 )
Fibrinolytic 52 54 74** 58
Activity + 8 + 12 + 14 + 13
(Saliva: m m 2 )
BBeta 15-42 0.84 1.54 * * 1.18* 0.90
(pmol/ml) + 0.30 + 0.45 + 0.39 + 0.57
Plasminogen 5.2 5.3 4.5 3 . 9++
(cu/ml) + 0. 6 + 0.3 + 0.3 0.3
c<. 2-Macroglobulin 87 89 75* 91 +
(%) + 26 + 31 + 31 ± 24
Fibrinogen 2.32 1.57 ** 1.71** 2.44
(9/1) + 0.37 ± 0.30 ± 0.27 ± 0.60
Legend
Table 9.1 lists the changes in the fibrinolysis tests 
(mean ± SD) following a 14 day course of oral stanozolol, 
and also 14 days following cessation of stanozolol 
administration.
*p < 0.05,
+p < 0 .0 5 ,
**p < 0.01, changes relative to base
++P < 0.01, changes relative to day 14
on stanozolol
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show any fibrinolytic activity in saliva during the
study. BBeta concentrations also increased significantly 
on stanozolol therapy and returned to baseline values on 
stopping therapy. Fibrinogen levels fell to 67% and 74% 
of the baseline value at 7 and 14 days respectively and
there was a small increase in fibrinogen to 105% off 
treatment. At 14 days alpha2-macroglobulin had fallen to 
87% of the baseline value and there was a small increase 
to 105% after cessation of treatment.
2-4 DISCUSSION
We found that short-term oral stanozolol therapy had 
no effect on plasma fibrinolytic activity in normal males 
using the fibrin plate method. This difference in results 
from those of Preston et al., (1981), may be due to the 
lowering of fibrinogen decreasing the euglobulin clot 
lysis time. Using the fibrin plate method, fluctuations 
in plasminogen or fibrinogen in the euglobulin fraction do 
not influence the assay (Kluft et al., 1976). While more 
prolonged therapy with oral stanozolol may cause 
fibrinolytic enhancement in normal subjects this 
enhancement is not seen within 14 days. A number of 
studies with stanozolol have shown a fall in fibrinogen 
and, using euglobulin lysis times, a rise in plasma 
fibrinolytic activity (Davidson et al., 1972; Cunliffe et 
al., 1975; Walker et al., 1978; Burnand et al., 1980). 
These studies therefore may have overestimated the rise in
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plasma fibrinolytic activity. Indeed following our 
observations Kluft et al., (1984b) have compared the 
changes in fibrinolytic activity as measured by fibrin 
plate and euglobulin lysis times, following stanozolol 
administration, and showed a much smaller change in 
fibrinolytic activity using the fibrin plate assay. Their 
study in addition showed a good correlation between the 2 
assays before and after therapy (r = 0.82) but a poorer 
correlation while patients were taking stanozolol (r = 
0.54). It has more recently been shown that patients 
given a 14 day course of oral stanozolol (10 mg/day) prior 
to surgery have improved euglobulin clot lysis times with 
no significant improvement in t-PA levels (Sue-Ling et 
al., 1985). Our initial observation has therefore 
highlighted a problem in assaying overall plasma 
fibrinolytic activity using euglobulin clot lysis times 
when changes in fibrinogen also take place.
In our study we have also failed to show that 
plasminogen concentrations increase during the 14 days on 
stanozolol therapy but have confirmed the effects, in 
normal subjects on plasma fibrinogen and
alpha2-macroglobulin.
Previous studies on fibrinolytic enhancement by 
stanozolol have concentrated on the fibrinolytic activity 
of plasma and we thought it of importance to look at the 
fibrinolytic activity of saliva as a possible measure of 
tissue plasminogen activator activity. Saliva is known to 
possess fibrinolytic activity which is due to its 
epithelial cell component (Southam, 1981; Moody, 1982).
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Our results suggested that stanozolol increases tissue 
activator, without a concomitant increase in plasma 
fibrinolytic activity. Since stanozolol has been shown to 
improve venous lipodermatosclerosis (Burnand et al., 1980) 
- a condition associated with extravascular fibrin 
deposition (Burnand et al., 1982) it was felt that this 
enhancement of tissue fibrinolysis may be relevant to its 
therapeutic effects.
We have also shown, for the first time, that anabolic 
steroid therapy with stanozolol is associated with 
enhanced plasmin - mediated fibrinolysis, as indicated by 
elevated BBeta levels while patients were on active 
medication, and this has recently been confirmed (Douglas 
et al., 1985). It is clear therefore that in normal 
individuals oral stanozolol is capable of inducing rapid 
changes in fibrinolysis in vivo. The changes in BBeta 
concentrations were not mirrored by the plasma 
fibrinolytic activity which again indicates that these 2 
assays measure different aspects of fibrinolysis. This 
has also been noted in patients with coronary artery 
disease (Chapter 6).
In summary, we suggest that changes in fibrinogen 
concentration, while patients are taking stanozolol, may 
falsely exaggerate the effects on plasma fibrinolytic 
activity as assessed by euglobulin clot lysis times, and 
that stanozolol is capable of rapidly improving salivary 
fibrinolytic activity and plasmin-mediated fibrinolytic 
activity in normal subjects (Small et al., 1983a; Small et 
al., 1983b).
i4o
CHAPTER 10
CHARACTERISATION OF THE FIBRINOLYTIC ENZYME SYSTEM IN
DIABETES MELLITUS
l 4 l
10 INTRODUCTION
Although studies on the fibrinolytic enzyme system in 
diabetes mellitus have produced conflicting results 
(Chapter 2.9) the weight of evidence seems to favour an 
association of defective fibrinolysis with type II 
diabetes (Hathorn et al., 1961; Fuller et al., 1979; 
Colwell et al., 1983) which is perhaps more closely linked 
to type II diabetics treated with sulphonylurea drugs 
(Farid et al., 1974; Aimer and Nilsson, 1974; Aimer, 
1984). Previous studies on fibrinolytic activity have 
tested diabetics at different times of day, have often 
failed to differentiate between type I and type II 
diabetes, have involved small numbers of patients, and 
have utilised a variety of assays of plasma fibrinolytic 
activity. These factors therefore may help explain the 
lack of uniformity of results.
The effect of glycaemic control on fibrinolytic 
activity is also controversial (Chapter 2.9), while the 
effect of glycaemic control on the other components of 
fibrinolysis has received less attention. Hyperlipidaemia 
in non-diabetics has been associated with defective 
fibrinolysis while in diabetes there is a close 
association of poor glycaemic control with
hyperlipidaemia. Whether the hyperlipidaemia, consequent 
upon poor glycaemic control, could be the mechanism of 
defective fibrinolysis in diabetes has not been formally 
evaluated. In vivo fibrinolysis, measured by the BBeta 
15-42 antigen, has also not been evaluated in diabetes. 
We have therefore compared the basal components of
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fibrinolysis in a large, well classified group of
diabetics to a large healthy control group, and have
assessed whether a variety of clinical factors (type of
diabetes, diabetic treatment, body mass index, smoking,
sex, microvascular disease) have any influence on these 
tests of fibrinolysis.
10.2 METHODS
Patients
Informed consent was obtained and 9 0 stable, non­
ketotic diabetic out-patients were studied. Following 
Ethical Committee approval, these patients were recruited 
and subsequently took part in a number of studies of 
fibrinolysis in diabetes some of which will be presented 
in later chapters (eg. Myocardial Infarction Study - 
Chapter 11; Fibrinolytic Enhancement by Insulin and
Stanozolol - Chapters 12 and 13; DDAVP stimulation - 
ongoing study). These studies produced balanced groups of 
diabetics on insulin, oral hypoglycaemics (all of whom 
were receiving sulphonylurea therapy), and diet alone, and 
some of the group characteristics are listed in table 10.1 
and subsequent tables. All patients were clearly diabetic 
as defined by WHO criteria (WHO, 1980), and all had been 
diagnosed as diabetic for at least 6 months. Patients 
with impaired glucose tolerance were not studied.
Diabetics who could not easily be clinically stratified 
into type I or type II groups were not studied.
TABLE 1 0 .1
CONTROL AND PATIENT GROUP CHARACTERISTICS
Controls
All
Diabetics Type I Type II
Number 59 90 27 63
Age 46 56++ 47** 60++
(years) ± 6 + 10 + 11 + 8
Diabetes 8.3 13.8 6.0**
Duration - + 8.7 ± 11.7 + 6.2
(years)
Body Mass 26.1 27.1 25.2** 27.9+
Index + 3.9 ± 4.3 ± 3.0 + 4.5
Legend
The number, age, duration of diabetes and body mass index
the control and diabetic groups. Values
+P < 0.05 )
++P < 0.01 ) Controls versus Diabetics
**p < 0.01 ) Type I versus Type II
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Microvascular disease was diagnosed by the presence of 
diabetic retinopathy or nephropathy. Fundal examination 
(pupils dilated) was carried out in all patients, in a 
darkened room, by a physician with formal training in the 
assessment of diabetic eye disease (MS), and nephropathy 
was defined as persistent proteinuria in a longstanding 
diabetic, without evidence of either urinary tract 
infection or non- diabetic renal disease. No patient had 
a history suggestive of autonomic neuropathy. A smoker 
was defined as either a current cigarette, pipe or cigar 
smoker, and non-smokers included ex-smokers who had
stopped for at least 3 months prior to evaluation. The 
body mass index was used as an indicator of under or
overweight.
As a control group 5 9 healthy subjects were chosen. 
These subjects were employees of the Imperial Tobacco 
Company in Glasgow, who lived in the same area as the 
diabetic patients. These "control" subjects were on no 
drug therapy and were non-hypertensive (BP < 160/95). The 
control group had no family history of diabetes mellitus, 
and random urinalysis and fasting plasma glucose levels 
excluded undiagnosed, asymptomatic diabetes. Neither the 
diabetic nor control females were receiving the oral
contraceptive pill and all patients were white - ethnic 
differences and use of oral contraceptives are known to
influence fibrinolysis (Meade et al., 1977).
20.2*2 Study Design
A single, resting, fasting blood sample was taken
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from all patients with minimal venostasis, via an 
antecubital vein. Diabetic patients were told to withhold 
their insulin or sulphonylurea medication on the morning 
of the study. The controls were all tested at their place 
of employment (approximately 400 metres from our 
hospital).
20*2*^ Blood Tests
Plasma fibrinolytic activity, BBeta 15-42 antigen, 
alpha2-antiplasmin activity and fibrinogen were measured 
as previously described (Chapter 3). Plasminogen activity 
was measured by chromogenic substrate assay (S-2251, Kabi 
Diagnostica). Glycosylated haemoglobin was measured by 
the glycosylation of the haemoglobin Al subfraction 
(HbAl); the non-diabetic normal range being 5.5-8.5% in 
our laboratory. Blood for HbAl was anticoagulated with
EDTA (1.5 mg/ml) and the assay performed by agar gel
electrophoresis (Glytrac, Corning). Serum triglyceride
levels were measured by the Technicon SMA II. During the
course of these studies our laboratory plasminogen assay 
changed (from a caseinolytic to chromogenic assay) and 
chromogenic plasminogen levels were not available for all 
diabetic subjects. The data allowed comparison of
plasminogen in the control groups with the diabetics as a
whole, but did not allow analysis of the diabetic
sub-groups.
20.2.4 Statistics
Statistical comparisons were performed by the
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Mann-Whitney U test, correlation by the Spearman rank 
order correlation coefficient and nominal data by Fisher's 
exact probability test.
2£.2 RESULTS
Table 10.2 lists the correlation matrix of age, body 
mass index, HbAl, and triglyceride levels with the tests 
of fibrinolysis. Alpha2-antiplasmin correlated
significantly with both triglyceride levels (r = 0.40) and 
the plasma fibrinolytic activity (r = -0.51), while BBeta 
15-42 levels were correlated with HbAl (r = -0.25). The 
body mass index correlated with triglyceride (r = 0.30),
but not with any of the fibrinolysis tests. Neither the 
duration of diabetes nor fibrinogen levels showed any 
significant correlations (results not listed, all r values 
< 0.10) while fibrinopeptide A was associated with HbAl (r 
= 0.30, p < 0.05).
Table 10,3 lists the values of HbAl, triglyceride and 
the tests of haemostasis in the controls, diabetics and 
diabetic subgroups (type I and II; insulin, sulphonylurea 
and diet therapy). Three diabetics were insulin-requiring 
(type II diabetics) and were deleted from the sub-analysis 
of diabetic treatment and fibrinolysis. As a group, 
diabetics had higher triglyceride levels compared to 
controls, but type I patients had lower levels than 
controls. HbAl levels were higher in the sulphonylurea 
treated patients compared to type I (p < 0.01) and diet
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TABLE 10.3
LABORATORY TESTS IN CONTROL AND DIABETIC PATIENTS
ALL TYPE I TYPE II
CONTROLS DIABETICS INSULIN DRUGS DIET
Number 59 90 27 38 22
Hb A^ (°/o) 11.1 10.1* 12.2 10.2
+_ 2.7 ±  1.7 + 2.9 + 2.5
Triglyceride 
(mmol/l )
1.66 
1.00
2 .41* 
+_ 2.50
1.05^
0.63 +
3.04**
3.20*
3.01**
1.4 2*
Fibrinolytic^ 
Activity (ram )
82
±  25
85
+ 19
86
+ 13 +
87
22
81 
±  20
BBeta 15-42  
(pmol/ml)
1.32
0 .8 4
1.62
1.12
1.79 
_+ 1.34 +
1.53
1.11
1.74
0.94
o62-Antiplasmin
(%)
97
12
117^^^
_+ 24
104 
^  24 +
112***
22
126*** 
±  28
Plasminogen 104 95
(%) ±  19 20
Fibrinogen
(9/ 1 )
3.21 
±  0.75
3o34
±  0.90
3.25 
±  0.79 +
3.29
0.96
3.45
i  0.95
Fibrinopeptide A 
(pmol/ml)
2 .1 0  
±  1.51
■ 3.23^^ 
+_ 2 .1 2
3. 27*
+ 2.08 +
3. 82* * *
2.37
2.03
0.88
Legend
The values of the laboratory tests are analysed with respect to type of 
diabetes and diabetic treatment and comparisons made to a matched control 
group. Values are mean +. 8D
*p <  0.05) type I versus type II
■^ p <  0.05 )
"^ "^ p <  OoOl ) control versus diabetic 
+++P <. OoOOl)
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control patients (p < 0.05). Diabetics had significantly 
higher alpha2-antiplasmin levels which were due to 
significantly higher levels in type II patients compared 
to controls. A trend to higher BBeta 15-42 levels was 
noted (p < 0.06) in the diet controlled diabetics compared 
to controls. Fibrinopeptide A levels were significantly 
higher in diabetes mellitus. Fibrinopeptide A levels were 
also significantly higher (p < 0.03) in the sulphonylurea 
treated patients compared to those treated by dietary 
measures alone.
No differences in the tests of haemostasis were noted 
in diabetics with and without microvascular complications 
{table 10.4).
Table 10.5 analyses the effect of sex on the
haemostatic tests. No sex differences in either the 
control or diabetic groups were noted for body mass index, 
BBeta 15-42 antigen, or fibrinogen levels. Male diabetics 
had significantly higher plasma fibrinolytic activity than 
either the male controls or female diabetic patients. 
Alpha2-antiplasmin levels were significantly higher only 
in the female diabetic patients compared to female 
controls. We have noted that alpha2-antiplasmin levels 
are raised in type II diabetes but no significant 
difference in the proportion of male and female type II 
diabetic patients were noted (Fisher's test). No
significant differences were found when we sub-analysed 
these groups to compare the concentrations of 
alpha2-antiplasmin (mean ± SD) in type II females (118 +
21) to both type II males (111 ± 29) and type I females
TABLE 10 .4
HAEMOSTATIC TESTS AND MICROVASCULAR DISEASE
MICROVASCULAR DISEASE 
YES NO
Number 17 7 3
Fibrinolytic 90 84
Activity (mm2) + 20 + 19
BBeta 15-42 1 .69 1.62
(pmol/ml) + 0.99 + 1.14
2-Antiplasmin 113 111
(%) + 18 + 25
Fibrinogen 3.27 3.33
(g/i) + 0.78 + 0.92
Fibrinopeptide A 2.49 3.36
(pmol/ml) + 1.39 + 2.19
Legend
The effect of microvascular disease on the 
haemostatic tests are listed. Values are mean + SD
TABLE 1 0.5
EFFECT OF SEX ON HAEMOSTASIS
MALE
CONTROLS
FEMALE
DIABETICS 
MALE FEMALE
Number 37 22 53 37
Type II (%) 74 65
Body Mass 25.7 26.8 26.3 27.3
Index + 2.4 + 5.7 + 5.3 + 4.4
Fibrinolytic 79 87 90** 73
Activity (mm2) + 25 + 25 + 18 + + 19
BBeta 15-42 1.36 1.25 1.84 1.43
(pmol/ml) + 0.97 + 0.54 + 1.06 + 1.14
oC 2-Antiplasmin 96 98 106 115++
(%) + 13 + 10 + 25 + 23 .
Fibrinogen 3.23 3.22 3.31 3.36
(9/1) + 0.83 + 0.59 + 0.87 + 0.94
Fibrinopeptide A 1.93 2.38 2.76 3.89*
(pmol/ml) + 1.08 + 2.04 + 1.88 + 2.26
Legend
The sex differences in haemostatic tests and body mass index 
in the control and diabetic patient are listed. Values are 
mean ±  SD
* P < 0.05 )
* * P < 0.01 ) Males versus Females
+ P < 0.05 )
+ + P < 0.01 ) Controls versus Diabetics
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(109 ± 30). Female diabetics also had significantly
higher fibrinopeptide A levels than both their male 
counterparts and female controls.
The overall frequency of diabetic and control smokers 
was very similar, while slightly more diabetic males 
smoked (table 10.5). In the control group smokers had 
significantly higher alpha2-antiplasmin levels, although 
no differences were noted between smoking and non-smoking 
diabetics. Of the type II patients, 7 0% were non-smokers 
and this may explain the higher alpha2-antiplasmin levels 
seen in non-smoking diabetics compared to controls. 
Higher fibrinogen levels were found both in the diabetic 
(p < 0.05) and the non-diabetic smokers (NS) compared to
their respective controls. Smoking had no effect on 
plasma fibrinolytic activity or BBeta 15-42 levels.
10.-i DISCUSSION
2^._4. 1^ Effect of Type, and Treatment of Diabetes
In the epidemiological study of Fuller and co-workers 
(1979), using the fasting dilute blood clot lysis time, 
diabetics, especially type II diabetics, had defective 
fibrinolysis. Badawi and colleagues (1970) also noted 
defective fibrinolytic activity, assessed by the dilute 
blood clot lysis time, in diabetics compared to controls, 
but not in the same patients using the euglobulin clot 
lysis time. They postulated that the defective 
fibrinolytic activity in diabetes mellitus depended on an
TABLE 1 0 .6
EFFECT OF SMOKING ON HAEMOSTASIS
'CONTROL
YES
SMOKER
NO
DIABETIC
YES
SMOKER
NO
Number (%) 44 56 38 62
Males (%) 50 73 62 55
Fibrinolytic 88 77 90 83
Activity (mm2) + 28 + 22 + 17 + 20
BBeta 15-42 1.22 1.40 1.78 1.57
(pmol/ml) + 0.55 + 0.99 + 1 .30 + 0.96
2-Antiplasmin 100* 93 111 112++
(%) + 11 + 11 ± 22 + 24
Fibrinogen 3.37 3.10 3.65 3.12*
(9/1) + 0.79 + 0.67 ± 0.79 + 1.00
Fibrinopeptide A 1.79 2.36 3.25 3.23
(pmol/ml) + 1.14 1.74 + 2.25 + 2.03
Legend
The effect of smoking on the haemostatic tests in the control 
and diabetic patients are listed. Values are mean ± SD.
*p < 0.05, smoker versus non-smoker
+ + P  < 0.01, control versus diabetic
increased anti-fibrinolytic activity detected by the whole 
blood clot lysis method. In the present large, 
cross-sectional study, we have found significantly 
elevated alpha2-antiplasmin levels in type II diabetes and 
this could explain the poor fibrinolytic activity measured 
on whole blood clot lysis times, since raised antiplasmin 
levels have been shown to influence even the euglobulin 
clot lysis time in a clinical study (Stegnar, Accetto and 
Keber, 1981 ) .
Reports on the levels of alpha2-antiplasmin in 
diabetes mellitus have produced conflicting results. 
While some controlled studies have found no significant 
difference in alpha2-antiplasmin levels in type I diabetes 
(Coccheri et al., 1983; Dornan et al., 1983), type II 
diabetes (Grignani et al., 1981; Hughes et al., 198 3) or 
in diabetes in general (Christe et al., 1984), other 
reports have found raised alpha2-antiplasmin levels 
associated with type I diabetes (Ambrus et al., 1979) and 
microvascular disease (Christe et al., 1984). The weight 
of evidence suggests that type I diabetics have normal 
alpha2-antiplasmin levels, while the large numbers in the 
present study would suppport the view that
alpha2-antiplasmin levels are raised in type II diabetic 
patients.
We have previously noted a positive correlation of 
triglyceride levels and alpha2-antiplasmin in patients 
with coronary artery disease (Chapter 6.3),
hyperlipidaemia and healthy subjects (Chapter 2.5), and 
this has been confirmed in the present study. We have
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found that our type II diabetics have significantly higher 
triglyceride levels than type I diabetics and this may, in 
part, contribute to the increased alpha2-antiplasmin 
levels found in type II diabetics.
There has been some debate as to whether 
fibrinopeptide A levels are elevated in type I diabetes 
(Borsey et al., 1984; Rosove, Frank and Harwig, 1984) but 
we have confirmed the recent findings of Jones (1985) 
indicating that both type I and type II diabetes are
associated with augmented thrombin activity. The slightly 
raised levels of BBeta 15-42 may, in part, be secondary to 
this activation of coagulation.
1_0.£.^ Effect of Glycaemic Control
In 1980 an inverse correlation of fibrinolytic 
activity with HbAl levels was first noted (Gunnarsson et 
al., 1980) since when others have failed to confirm this 
finding (Grignani et al., 1980; Dornan et al., 1983; 
Christe et al., 1984; Haitas et al., 1984). While the
present study has failed to show a significant
relationship between HbAl and plasma fibrinolytic 
activity, we have found that both plasmin and thrombin 
generation (assessed by BBeta 15-42 and fibrinopeptide A) 
are influenced to a small, but significant extent by 
glycaemic control, such that good control is associated 
with improved fibrinolysis and . diminished thrombin
generation. These findings are in keeping with the in 
vitro studies showing that glycosylation of haemostatic 
factors occurs, and that such a process may alter the
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function or concentration of these factors (Chapter 2.9).
Although type I diabetics (all receiving insulin) had 
lower HbAl and triglyceride concentrations than type II 
patients, no significant differences in the components of 
fibrinolysis were noted between the groups, except for 
raised alpha2-antiplasmin levels as previously noted.
When the type II patients were subdivided into those 
receiving sulphonylurea therapy and those patients treated 
with diet alone, the sulphonylurea patients had worse 
glycaemic control, slightly lower BBeta 15-42 levels and 
significantly higher thrombin generation. While this 
fails to support the other cross-sectional studies showing 
that fibrinolytic activity is lower and fibrinogen levels 
higher in patients treated with sulphonylurea drugs (Farid 
et al., 1974; Aimer and Nilsson, 1974; De Silva et al., 
1979) it does suggest that such patients have an increased 
pro-thrombotic tendency. It has been stated that 
hypertriglyceridaemia in diabetes is associated with 
reduced plasma fibrinolytic activity (Aimer 1975a; Aimer 
et al., 1975b) but we have been unable to confirm this and 
in addition, have failed to relate triglyceride levels to 
any of the other components of fibrinolysis. The slightly 
high triglyceride levels in our normal control group is in 
keeping with triglyceride levels found in an 
epidemiological study of healthy males in the West of 
Scotland (Lorimer et al., 1974).
%0y4y2 Effect of Microvascular Disease
We have found that microvascular disease did not
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effect the unstimulated tests of fibrinolysis, and this is 
in agreement with other studies (Aimer et al., 1975b; 
Fuller et al., 1979; Haitas et al., 1984; Christe et al., 
1984; Lowe et al., 1986). Three studies used venous 
occlusion as a dynamic stimuli, and a defective response 
of plasma fibrinolytic activity was noted in patients with 
microvascular disease in 2 of these studies (Aimer et al., 
1975b; Haitas et al., 1984; Christe et al., 1984). No 
firm statement on the effect of microvascular disease on 
fibrinolysis can at present be given.
L0._4.j4 Effect of Sex
In the control group plasma fibrinolytic activity 
was, as expected, slightly lower in males when compared to 
female patients (Chakrabarti et al., 1978; Meade et al., 
1979) but in diabetic patients the reverse was true. In 
fact, diabetic male patients had significantly higher 
plasma fibrinolytic activity (and slightly higher BBeta 
15-42 levels) than control male subjects or diabetic 
females. We have found a negative correlation of 
alpha2-antiplasmin and plasma fibrinolytic activity which 
suggests that alpha2-antiplasmin is either associated with 
the levels of those plasminogen activators or other 
inhibitors which are precipitated in the euglobulin 
fraction, or else is measured in the fibrin plate assay. 
Which of these mechanisms is correct is unclear, since 
euglobulin preparation is thought to eliminate 
fibrinolytic inhibitors, and alpha2-antiplasmin shows no 
correlation with in vivo fibrinolysis, measured by BBeta
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15-42 antigen. The raised alpha2-antiplasmin may explain 
the slightly lower levels of plasma fibrinolytic activity 
in our female patients. A previous study has shown 
significantly higher alpha2-antiplasmin levels in female 
subjects (Teger-Nilsson, 1979) and our female diabetics 
had significantly higher alpha2-antiplasmin levels than 
their female non-diabetic counterparts. The higher 
alpha2-antiplasmin . levels in the female diabetics cannot 
be explained by a greater percentage of type II diabetics 
being female, since in fact the reverse is true. The sex
difference in fibrinolytic activity in diabetes is in
keeping with the epidemiological study of Fuller and
co-wcrkers (1979) who noted type I males had normal 
fibrinolytic activity while a slight reduction of
fibrinolytic activity was noted in type I females. 
Diabetic females, in addition to their poorer 
fibrinolysis, have more active coagulation with enhanced 
thrombin generation, as evidenced by elevated 
fibrinopeptide A levels.
In non-diabetics the general epidemiology of 
fibrinolytic activity and fibrinogen suggests that these 
may well be implicated in the pathogenesis of ischaemic 
heart disease (Meade et al., 1979). In diabetics however, 
the protective effect of female sex on the development of 
cardiovascular disease is lost (Kannel and McGee. 1979; 
Jarrett et al., 1982; Rytter, Troelsen and Beck-Nielson, 
1985; Uusitupa et al., 1985). Whether such adverse 
haemostatic changes of defective fibrinolysis and active 
coagulation in female diabetic patients could be related
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to their increased risk of cardiovascular disease remains 
speculative.
Effect of Weight 
Two large studies in diabetic patients have found a 
negative association between body weight, plasma 
fibrinolytic activity and plasminogen activator content of 
the vessel wall (Aimer, 1975a; Fuller,' 1981). We have 
been unable to confirm this association, and it may be 
that larger numbers are required to demonstrate such an 
association.
Effect of Smoking 
As found in the coronary artery disease study 
(Chapter 6), we have been unable to show an effect of 
chronic smoking on plasma fibrinolytic activity and this 
has been confirmed in another large diabetic group (Aimer, 
1975a). Smoking did not affect the BBeta 15-42 or 
alpha2-antiplasmin levels in the diabetics or controls, 
while fibrinogen levels were greater in smokers, as has 
been well documented in the past (Meade et al., 1979).
1^.4.7_ Summary
Alpha2-antiplasmin levels are elevated in type II 
patients and in diabetic females and are also influenced 
by triglyceride levels. In addition, female diabetic 
patients have reduced fibrinolytic activity and enhanced 
coagulation which may be relevant to the increased risk of
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cardiovascular disease in female subjects. Our results 
also suggest that sulphonylurea treatment is associated 
with a change in the haemostatic balance favouring a 
thrombotic tendency.
We have shown that glycaemic control influences both 
in vivo fibrinolysis and coagulation to some extent, but 
that overall, diabetics have no significant differences in 
fibrinolysis compared to a well matched control group 
(except for raised alpha2-antiplasmin levels). We have 
shown however that both sex status and type of diabetes 
affects fibrinolysis and by 'lumping' all the diabetics 
together we have cancelled out these differences. The 
aetiology and clinical manifestations of diabetes reveals 
that it is a heterogeneous condition, and it is not 
unreasonable therefore to divide patients into their 
appropriate categories. Future studies in diabetes must 
allow for these factors which influence fibrinolysis.
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CHAPTER 11
FIBRINOLYSIS IN DIABETIC PATIENTS WITH AND 
WITHOUT MYOCARDIAL INFARCTION
IJ^ . 1_ INTRODUCTION 
Atherosclerotic occlusive vascular disease is the 
most common complication of diabetes mellitus and accounts 
for approximately 75% of all deaths, mainly manifesting as 
cardiovascular disease (Ganda., 1980; Steiner., 1981;
Aro., 1984). Coronary artery disease is common in
diabetes (Shapiro, 1984; Uusitupa et al., 1985) with an
increased incidence of myocardial infarction (Garcia et 
al., 1974) and recent studies have revealed a 2-3 fold 
increase in mortality following myocardial infarction 
(Jaffe et al., 1984; Smith et al., 1984; Gwilt et al., 
1985; Rytter et al., 1985). It is generally believed that 
the increased risk of macrovascular disease arises from a 
greater frequency and/or severity of 'risk factors' 
(hypertension and hyperlipidaemia) in the diabetic 
patients, although prospective studies which have examined 
the predictive effect of the major risk factors have 
failed to establish them as the explanation for the extra 
risk in diabetes (Jarrett, 1984). It has been suggested
that other factors, such as abnormal haemostasis could 
explain the excess risk (Jarrett, 1984), and to assess
whether alterations in the fibrinolytic enzyme system are 
associated with large vessel disease in diabetes we have 
examined a number of tests of fibrinolysis in diabetic men 
with and without a previous myocardial infarction and a 
matched control group.
11.2 METHODS
Patients
Fifteen established diabetic men who had sustained a 
well documented myocardial infarction were studied (Group 
A). They were compared to 15 male diabetics, matched for 
age, smoking history, weight, type and duration of 
diabetes (Group B), and to 15 healthy non-diabetic men 
(controls). Group B and the controls had neither clinical 
nor EGG evidence of occlusive vascular disease and were 
not hypertensive (BP < 160/95). Group C had no family 
history of diabetes, no glycosuria and normal fasting 
glucose concentrations.
1J^ ._2.2 Study Design
A single, fasting blood sample was taken, without a 
tourniquet, from all subjects after informed consent was 
obtained. Patients with myocardial infarction were 
studied at least 3 months after the acute event in view of 
the known alterations in lipids and fibrinolysis which 
occur after an acute myocardial infarction.
3 Blood Tests
Plasma fibrinolytic activity, BBeta 15-42 antigen, 
fibrinogen and fibrinopeptide A were measured as 
previously described (Chapter 3). Total serum
cholesterol, HDL cholesterol and triglyceride
concentrations were measured by the Technicon SMA II and 
Boehringer kits (Carlson., 1973). Glycosylated 
haemoglobin (HbAl-Glytrac, Corning) and fasting plasma
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glucose (Beckman II autoanalyser) were assayed as an 
indicator of glycaemic control. HbAl was not measured in 
the control group as it is known that HbAl is not a useful 
screening test for diabetes mellitus.
Statistics
Statistical comparisons were performed using the 
unpaired Wilcoxon rank sum test, correlations by the 
Spearman rank order correlation coefficient and nominal 
data by Fishers exact probability test.
IJ^.2 RESULTS
The clinical characteristics of the groups are listed 
in Table 11.1. The diabetic groups A and B were well 
matched in all respects and no significant differences 
between the groups were noted (Fishers test). The control 
group was significantly younger than the diabetic groups 
(p < 0.01) but was well matched as regards smoking history 
and body mass index. No significant differences in lipid 
levels were noted between the 3 groups, and no differences 
in glycaemic control were found between groups A and B 
(Table 11.2) Overall the diabetic patients had 
significantly elevated plasma fibrinolytic activity and 
BBeta 15-42 levels compared to controls and no differences 
between groups A and B were detected (Table 11.3). 
Neither fibrinogen nor fibrinopeptide A levels differed 
significantly between groups A, B or controls (table
TABLE 11.1
CONTROL AND DIABETIC GROUP CHARACTERISTICS
CONTROLS
, DIABETICS 
Group A Group B
Number 15 15 15
Age (years) 51 59* 59*
± 3 ± 8 ± 7
Smokers 6 4 7
Body Mass 26.2 27.8 24.9
Index + 2.3 ± 6.8 ± 2.7
Diabetes 7.2 6.3
Duration - ± 7.9 ± 5.1
(years)
Therapy
- insulin - 4 3
- sulphonylurea - 7 8
- diet — 4 •4
Complications
- Retinopathy - 3 3
- Hypertension 8 0
Legend
Clinical characteristics of the control and diabetic patients 
with (Group A) and without (Group B) a previous myocardial 
infarction. Three patients on insulin in each group were 
type I diabetics. Values are mean ± SD.
< 0.01, controls versus diabetics
TABLE 11 .2
LIPID LEVELS AND GLYCAEMIC CONTROL
CONTROLS
DIABETICS 
Group A Group B
Triglyceride 1.7 2.7 1.9
(mmol/1) + 0.4 + 2.6 + 0.9
Cholesterol 5.9 6.2 5.8
(mmol/1) ± 1.0 t 1.1 ± 0.9
HDL Cholesterol 1.1 1.1 1.2 .
(mmol/1) ± 0.3 ± 0.4 + 0.3
HbAl 10.1 10.6
(%) — + 3.2 + 2.9
Fasting
Glucose 4.8 9.5 9.4
(mmol/I) + 0.3 + 5.1 + 2.6
Legend
Lipid levels and glycaemic control in the control and 
diabetic patients with (Group A) and without (Group B) 
a previous myocardial infarction. Values are mean + SD
TABLE 11 .3
HAEMOSTATIC TESTS IN CONTROL AND DIABETIC PATIENTS
CONTROLS D
Total
I A B E T 
Group A
I C S
Group B
Fibrinolytic 71 9 3++ 89 9 6++
Activity (mm2) ± 28 ± 21 + 21 + 21
BBeta 15-42 1.17 2.14+++ 2.35++ 1.97 +
(pmol/ml) ± 0 . 3 0 ± 1.00 ± 0.96 + 1.04
Fibrinogen 3.31 3.47 3.40 3.53
(9/1) ± 0.52 + 0.91 ±  0.89 + 0.95
Fibrinopeptide A 2.11 2.56 1.96 3.15
(pmol/ml) ± 1.22 ± 0.36 ± 0.51 + 2.0
Legend
Haemostatic tests in control and diabetic patients with
diabetics subdivided into those with (Group A) and without 
(Group B) a previous myocardial infarction.
Values are mean ± SD.
+ p < 0.05 )
++ p < 0.01 )
+++ p < 0.001 )
Controls versus diabetics.
11.3). No significant correlations between age and both 
plasma fibrinolytic activity (r = -0.28) and BBeta 15-42 
(r = -0.37) were noted in the diabetic patients, and no
correlation of plasma fibrinolytic activity and BBeta 
15-42 was found (r = -0.05).
11. j4 DISCUSSION
We have previously demonstrated that basal 
fibrinolysis is not influenced by microvascular disease 
(Chapter 10) and the aim of the present study was to 
assess if macrovascular disease affected fibrinolysis, 
which may be relevant to the increased prevalence and 
mortality associated with large vessel disease in 
diabetes. Compared to our control group, diabetics had 
significantly better ex vivo and in vivo fibrinolysis 
which could not be explained on the basis of differences 
in weight, smoking and lipid levels. The diabetics were 
slightly (but significantly) older than the control group, 
but since no correlations were found between age and 
either in vivo or ex vivo fibrinolysis, we feel this 
cannot explain the increased fibrinolysis in diabetes. 
The diabetic patients with and without a prior myocardial 
infarction were, in addition, closely matched for duration 
of diabetes, typé of treatment and glycaemic control, and 
no significant differences in the fibrinolysis tests were 
noted between the groups. This implies that diabetes per 
se and not myocardial infarction is associated with an
l60
enhanced fibrinolysis. This is in keeping with our 
previous findings that diabetic males have increased 
plasma fibrinolytic activity and slightly higher BBeta 
15-42 levels than in male controls (Chapter 10). The 
interpretation of our results require caution with regard 
to the selection of our 2 diabetic groups. Asymptomatic 
coronary artery disease is common in diabetes (Shapiro,
1984) and some of our apparently healthy diabetic controls 
may have had coronary artery disease. Our diabetic 
controls however had no clinical or resting EGG evidence 
of coronary artery disease although coronary angiography 
was not performed. The patients with myocardial 
infarction are a highly selected group since they are 
survivors of an acute myocardial infarction - a condition 
associated with a high mortality rate. Our patients were 
studied at a minimum interval of 3 months following their 
myocardial infarction and it is known that in the first 
month following an acute myocardial infarction diabetics 
have approximately a two-fold increase in mortality of 
about 40% compared to non-diabetics (Rytter et al.,
1985). These survivors therefore could have had better 
(or different) fibrinolysis compared to those who died, 
although the lack of difference between the survivors and 
healthy diabetic controls would suggest that this is 
unlikely.
In summary we have found that male diabetics have 
enhanced fibrinolysis which is not related to occlusive 
vascular disease. Our results suggest that fibrinolysis 
plays no role in the prevalance and mortality associated
l6l
with macrovascular disease. This is an agreement with the 
epidemiological studies showing that fibrinolysis in 
non-diabetics is not a risk factor for cardiovascular 
disease (Meade et al., 1980; Wilhelmson et al., 1984).
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CHAPTER 12
ENHANCEMENT OF FIBRINOLYSIS FOLLOWING INSULIN ADMINISTRATION
IN TYPE II DIABETES MELLITUS
12^.1 INTRODUCTION
Cross-sectional studies on diabetic patients have 
suggested an association of defective fibrinolysis with 
the use of sulphonylurea drugs (Aimer and Nilsson, 1974; 
Farid et al., 1974; Aimer, 1984), but a prospective study 
on the effects on fibrinolysis of changing patients from 
sulphonylurea therapy to insulin has not been reported.
Approximately 5% of diabetics each year initially 
well controlled on sulphonylurea drugs develop 
hyperglycaemia and, despite maximum dose of sulphonylurea 
therapy, require insulin to alleviate the symptoms of 
poorly controlled diabetes (Anonymous, 1981). These 
patients, with secondary failure of sulphonylurea therapy, 
are usually given life-long daily subcutaneous injections 
of insulin. We have therefore measured a variety of tests 
of fibrinolysis, in a homogeneous group of connecting (C-) 
peptide positive, type II diabetics with secondary failure 
on sulphonylurea drugs, and assessed the effects of 
substitution of insulin.
12^.2 METHODS
1^.2" 1.' Patients
Local Ethical Committee approval was obtained and 2 0 
(15 women, 5 men) type II diabetic patients gave informed 
consent and were recruited to the study. Mean age of the
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patients was 62 years (range 51-72), duration of diabetes 
7.5 years (1-26) and mean body mass index of 26.1 (range 
17.8-31.4). All patients had been receiving sulphonylurea 
therapy for at least one year with adequate glycaemic 
control initially. Despite maximum dose sulphonylurea
administration (glibenclamide 15 mg/bd), however the 
patients had developed constant glycosuria, with random 
clinic capillary glucose values between 15-25 mmol/1, and 
some had symptoms related to hyperglycaemia. They were 
therefore judged to have failed on sulphonylurea therapy 
and to require insulin. Five patients had clinical 
evidence of microangiopathy (4 background and 1 
proliferative retinopathy) and 6 had evidence of 
macroangiopathy (4 patients with ischaemic heart disease 
and 2 with peripheral arterial disease). Six patients 
were receiving anti-hypertensive or anti- anginal therapy 
but no other medication was taken during the study 
period. All patients had normal blood urea and 
electrolyte concentrations and none had persistent 
proteinuria.
22 • 2.-2 Study Design
On the morning of their first insulin injection and 
at 1 and 3 months thereafter a fasting blood sample was 
taken for HbAl and assessment of fibrinolysis. The final 
dose of glibenclamide had been taken at 5pm on the day 
before starting insulin therapy.
All patients attended the clinic daily for one week,
then weekly for one month to be given the education 
appropriate to an insulin-requiring diabetic. Each 
patient was placed on Lentard MC (Novo), highly purified 
beef/porcine lente insulin starting at 28 units each day. 
Insulin dosage was adjusted thereafter until most urine 
tests before breakfast showed no glycosuria, a mid-morning 
clinic capillary glucose level of < 10 mmol/1 was attained 
or until hypoglycaemic symptoms had ensued.
C-peptide is secreted in equimolar quantities to 
insulin and its measurement therefore gives an indication 
of endogenous insulin secretion. Residual beta-cell 
function was evaluated, in the fasting state by measuring 
C-peptide before and 6 minutes after a Img, intravenous 
injection of glucagon (Faber and Binder, 1977).
22*2*2 Blood Tests
Plasma fibrinolytic activity, BBeta 15-42 antigen, 
plasminogen activity, alpha 2-antiplasmin, alpha 
2-macroglobulin, fibrinogen, and fibrinopeptide A were 
measured as previously described (Chapter 3). HbAl was 
performed by agar gel electrophoresis (Glytrac, Corning), 
the non-diabetic normal range being 5.5-8.5% in our 
laboratory. Serum C-peptide was determined by
radioimmunoassay (Novo Laboratories Ltd).
12.2.4 Statistics
Statistical comparisons were performed using the 
Wilcoxon matched- pairs signed-rank test, and correlation 
was determined by the Spearman rank order correlation 
coefficient.
12.3 RESULTS
Table 12.1 lists the haemostatic tests over the study 
period. Both the plasma fibrinolytic activity and BBeta 
15-42 increased significantly following the introduction 
of insulin therapy (figures 12.1 and 12.2). No difference 
in the baseline, peak or increment (peak-basal) in plasma 
fibrinolytic activity or BBeta 15-42 were noted for 
patients without vascular disease when compared to those 
with either micro or macrovascular disease. No 
significant changes in the other components of the 
fibrinolytic system were noted except for a 12% rise in 
the minor inhibitor of fibrinolysis, alpha 2-macroglobulin 
(p < 0.05), after 3 months of insulin therapy. Samples
for fibrinopeptide A were obtained at 0 and 3 months only 
and comparison samples were available for 13 patients. A 
33% fall (p < 0.05) in fibrinopeptide A concentrations 
were noted at 3 months.
No major hypoglycaemic episodes occurred, but 
occasional symptoms of nocturnal hypoglycaemia were 
reported by some patients. Due to symptomatic 
hyperglycaemia two patients were transfered to twice-daily
TABLE 12 .1
EFFECT OF INSULIN ON HAEMOSTASIS
0
TIME (MONTHS) 
1 3
Fibrinolytic 79 91* 93**
Activity (mm2) + 20 ± 23 + 22
BBeta 15-42 0.96 1.31 1.44**
(pmol/ml) + 0.58 + 0 . 67 + 0.66
Plasminogen 2.8 3.1 3.0
(cu/ml) + 0.5 ± 0.5 + 0.5
oc 2-Antiplasmin 114 112 107
(%) + 29 ± 37 + 22
c< 2-Macroglobulin 111 112 123*
(%) + 37 ± 29 + 36
Fibrinogen 2.99 3.16 3.22
(9/1) + 0.77 ± 1.11 + 0.64
Fibrinopeptide A 4.9 - 3.3*
(pmol/ml) + 2.5 + 1.9
Legend
Table 12.1 lists the concentrations of the haemostatic 
tests (mean ± SD) at baseline (0 months) and after 
1 and 3 months on insulin therapy.
*p < 0.05 )
**p < 0.01 ), changes relative to base
FA ( m m 2)
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Figure 12ol
.Illustrates the individual values of fasting plasma fibrinolytic 
activity (FA) while patients were receiving sulphonylurea drugs, 
and 1 and 3 months following the introduction of insulin.
The horizontal bar indicates the mean value.
^ 0.05, <  OoOl, changes are relative to time 0.
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Figure 12 .2
Illustrates the individual values of BBeta 15-42  
antigen while patients were receiving sulphonylurea 
drugs, and 1 and 3 months following the introduction 
of insulin. The horizontal tar indicates the mean value, 
**p -4. 0 .0 1 , changes relative to time O.
insulin injections (Mixtard, Nordisk) by 3 months, while 
the others were still receiving Lentard MC. Mean daily 
insulin dosage was 42 units (range: 28-68), and mean
patient weight gain at 3 months was 5.7 lbs (range: -1-21 
lbs). Institution of insulin therapy was associated with 
an improvement in well-being, abolition of symptoms o:^  
thirst and polyuria, and reduction of diurnal glycosuria, 
however no significant improvement in glycaemic control, 
as judged by HbAl levels, was observed. Prior to insulin 
therapy the mean HbAl concentration was 13.2 + 2.3% as 
compared with mean values of 13.1 + 2.1% and 12.3 + 2.1%
at 1 and 3 months respectively. No patient had a HbAl 
level within the normal range after 3 months of insulin 
administration. No correlations between HbAl and plasma 
fibrinolytic activity or any other fibrinolytic tests were 
noted. Normal or elevated fasting C-peptide levels were 
detected in all patients confirming that these patients 
were not insulin-dependent. No correlations were noted 
between the basal, peak or incremental change in C-peptide 
(following glucagon) and the tests of fibrinolysis 
measured on the baseline sample.
12.± DISCUSSION
We have shown that on stopping sulphonylurea drugs 
and substituting insulin therapy, improvement of plasma 
fibrinolytic activity and increased plasmin-induced 
fibrinolysis occurs. This fibrinolytic enhancement could 
not be explained by the patient's weight change following
insulin therapy, an alteration of glycaemic control, and 
was not influenced by the presence of pre-existing macro 
or microvascular disease.
It is possible that sulphonylurea therapy has a 
deleterious effect on fibrinolysis, with a rebound 
improvement in fibrinolytic activity upon cessation of 
such therapy. Prospective assessment of fibrinolysis in a 
small group of newly diagnosed type II patients, placed on 
sulphonylurea therapy for one year, has not shown any 
impairment of fibrinolysis (Bogie et al., 1976) but this 
does not exclude a possible effect on fibrinolysis with 
high dosage and prolonged treatment, as found in the 
present study group. If longterm sulphonylurea treatment
does indeed lead to impaired fibrinolysis, then it is 
interesting to speculate whether the high frequency of 
cardiovascular deaths in sulphonylurea treated diabetic 
patients, observed in the University Group Diabetes 
Programme Study (1970), could be linked to a depression of 
fibrinolysis.
Alternatively, insulin treatment may stimulate
fibrinolysis and there is evidence that endothelial cells 
bind and internalise insulin (Kaiser et al., 1982) and 
that insulin has a direct effect on the endothelial cell 
(Osterby, Gundersen and Christensen, 1978; Fortes, Garcia 
Leme and Scivoletto, 1984) which is the site of storage of 
vascular plasminogen activator. Other studies have noted 
that type I diabetics have an increased plasma 
fibrinolytic activity when compared to controls (Cash and
McGill, 1969; Bern et al, 1981; Elder et al., 1981;
Sharma, 1981) although in the study by Sharma (1981) 
however it is not clear whether patients were receiving 
insulin at the time of estimation of their fibrinolysis. 
Further support for the role of insulin on fibrinolysis is 
given by the findings of Sandberg and colleagues (1963) 
who noted that diabetic plasma took a shorter time to lyse 
a standard fibrin clot, and noted an inverse correlation 
between total daily insulin requirements and clot lysis 
time - ie, the higher insulin dose the shorter the lysis 
time. In our study however we did not note any 
association between fasting insulin levels, insulin 
secretion (measured by glucagon stimulated C-peptide 
release), and either plasma fibrinolytic activity or BBeta 
15-42 levels. The effect of endogenous beta-cell function 
on fibrinolysis in type II diabetes has not previously 
been evaluated. Why type I diabetics should have elevated 
plasminogen activator level (measured as euglobulin lysis 
times) is unknown, although it has been postulated that 
this is a physiological response to relative 
hypercoagulability (Cash and McGill, 1969). It should be 
noted however that other studies involving type I 
diabetics have not confirmed these results (Fuller et al., 
1979; Juhan-Vague et al., 1984).
We have also found that the introduction of insulin 
therapy was associated with a significant reduction of 
fibrinopeptide A concentrations and therefore diminished 
thrombin generation. Improvements in coagulation and 
platelet function have been noted in type II diabetes with 
improved glycaemic control due to high fibre diet (Simpson
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et al., 1982), sulphonylurea therapy (Paton et al., 1981; 
Hughes et al., 1983), and insulin therapy in patients with 
mild carbohydrate intolerance without glycosuria (Evans et 
al., 1982). In our patients, with more' severe glucose 
intolerance, better glycaemic control could not explain 
the changes noted in fibrinopeptide A (or fibrinolysis) 
since overall glycaemic control was unaltered.
Our results of insulin treatment in poorly 
controlled, type II diabetic patients are in accordance 
with a similar study (Peacock and Tattersall, 1984), where 
a once daily insulin regimen failed to improve glycaemic 
control in most subjects after 6 months. It is quite 
clear therefore that in younger patients with secondary 
sulphonylurea failure a once daily lente preparation is 
inadequate to offer good glycaemic control. In older 
patients requiring insulin our aim is not to achieve 
normoglycaemia, but to keep patients asymptomatic and in 
this context a once daily lente insulin is satisfactory. 
The best treatment for type II diabetic patients in whom 
dietary measurements have failed, is currently the subject 
of a multicentre study in the UK (Multi-Centre Study,
1983). A fair criticism of the present study is that it 
is not controlled and therefore the alterations in 
haemostasis may have occurred with the passage of time and 
possibly unrelated to sulphonylurea or insulin therapy. 
The only relevant control group would have been similar 
patients with symptomatic hyperglycaemia who were failing 
on sulphonylurea therapy. We felt that it would be 
unethical to deny these patients insulin and therefore
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accept that some caution must be placed on our results due 
to lack of a suitable control group.
In summary, we have shown that improved fibrinolysis 
(Small et al., 1986a) and diminished thrombin generation 
(Small et al., 1986c) occurs when, in our routine clinical 
practice, we transfer patients from high dose 
sulphonylurea therapy to insulin. Whether the correction 
of these pro-thrombotic abnormalities are due to 
withdrawal of sulphonylurea therapy or a direct effect of 
insulin requires further study. Nonetheless our 
observations indicate the potential advantage of insulin 
therapy in such diabetic patients.
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CHAPTER 13
THE EFFECTS OF ORAL STANOZOLOL ON FIBRINOLYSIS AND 
GLYCAEMIC CONTROL IN TYPE II DIABETES MELLITUS
13.1 INTRODUCTION
The weight of current evidence suggests that type II 
diabetes is associated with defective fibrinolysis 
(Chapter 2.9). The high prevalence of vascular disease, 
which is more marked in type II diabetes, and the need for 
anti-thrombotic drugs provides a rationale for the 
evaluation of stanozolol in diabetes mellitus. While the 
combination of phenformin and the anabolic steroid, 
ethylestrenol, have been shown to enhance fibrinolysis in 
newly diagnosed type II diabetic patients (Chakrabarti and 
Fearnley, 1974), the effects of anabolic steroid therapy 
alone on fibrinolysis in diabetes have not been studied.
Steroid drugs have marked effects on carbohydrate 
tolerance such that corticosteroids cause severe 
impairment of carbohydrate tolerance and may even 
precipitate diabetes. Different categories of anabolic 
steroids have differing actions on carbohydrate metabolism 
although stanozolol has been reported to improve fasting 
blood glucose concentrations in diabetes (Tainter et al., 
1964). More accurate assessment of glycaemic control is 
now available with measurement of glycosylated proteins 
which are of use in the appraisal of drugs as oral 
hypoglycaemic agents.
Since we have previously documented a failure of 
stanozolol to enhance the depressed fibrinolysis in 
elderly medical patients (Small et al., 1984c) and since 
the effects of stanozolol on fibrinolysis in diabetes have 
not been reported we decided to perform a
placebo-controlled pilot study on the effects of 
stanozolol on fibrinolysis and glycaemic control in type 
II diabetes mellitus.
13.2 METHODS
1_3._2.]^  Patients
Local Ethical Committee permission was obtained and 
12 type II diabetic patients gave informed consent to take 
part in the study. Mean age of the patients was 5 8 years 
(range 36-70) , duration of diabetes of 3.8 years (range 
0.5-10) and body mass index of 29.8 (range 24.4-35.4). 
Four patients had ischaemic heart disease, 4 had 
peripheral arterial disease, 4 were hypertensive, 1 had 
background retinopathy and 1 patient had gout. Four 
patients were taking sulphonylurea drugs, 4 were taking 
beta-adrenoceptor blocking drugs and 1 patient was taking 
allopurinol.
Study Design
The patients attended the diabetic ward at 9.0 0am 
after an overnight fast on either 6 or 7 occasions. 
Patients took a matched placebo between -2 and 0 weeks 
after which they were started on 10 mg of stanozolol/day 
for either 4 weeks (n = 5) or 8 weeks (n = 7). Patients 
had further samples taken at 2, 4 and 8 weeks while taking
stanozolol and 4 weeks after after cessation of stanozolol 
administration.
1^.2'2 Blood Tests
At each visit plasma fibrinolytic activity, BBeta 
15-42 antigen, plasminogen activity (caseinolytic 
activity) alpha2-antiplasmin activity, alpha-2
macroglobulin antigen and fibrinogen were measured as 
previously described (Chapter 3). Glycaemic control was 
assessed by fasting plasma glucose and glycosylation of 
haemoglobin (G.Hb), plasma proteins (G.P.P.), and albumin 
(G.Alb). Plasma glucose was measured by a Beckman II 
glucose analyser and blood for G.-Hb was anticoagulated 
with EDTA and the assay performed by agar gel 
electrophoresis (Glytrac, Corning). Our laboratory's 
non-diabetic range is 5.5-8.5%. G.P.P. and G.Alb were 
measured using a microcolumn technique (Leiper et al., 
1985), the non-diabetic normal ranges being 2.6-3.9% and 
1.3-2.0% respectively.
A Statistics
Statistical comparisons were performed using the 
paired Wilcoxon rank sum test.
1 3 . 3  RESULTS
Fibrinolysis
Table 13.1 lists the concentrations of the tests of 
fibrinolysis during the study period. There were no 
significant changes in the tests over the 2 week interval 
(week -2 to week 0) while patients were taking placebo. 
The concentrations of the various tests while patients 
were receiving stanozolol were therefore compared to week 
0. No significant alterations in plasma fibrinolytic 
activity, BBeta 15-42, alpha2-antiplasmin or
alpha2-macroglobulin were noted throughout the study. 
Significant increases in plasminogen and ' decreases in
fibrinogen were noted while patients were taking 
stanozolol, although significant changes were not detected 
at all time points while patients were receiving active 
medication (figure 13.1). Four weeks after stopping 
stanozolol, significant falls in plasminogen and increases 
in fibrinogen concentrations were detected.
%2._3 Glycaemic Control
Fasting plasma glucose concentrations (mmol/1, mean ± 
S D ) were as follows; 10.9 + 2.9 at -2 weeks, 10.9 + 2.4 at 
week 0, 10.0 + 2.8 at week 2 (p < 0.05), 9.0 + 2.7 at week
4 (p < 0.05) and 8.1 + 3.2 at week 8. After 4 weeks off
active medication glucose concentrations had risen to 11.1 
± 3.4 mmol/1 (p < 0.05, compared to final glucose levels
while taking stanozolol therapy). The alterations in 
G.Hb, G.P.P. and G.Alb are illustrated in figure 13.2. A 
significant fall in G.Hb was found after 8 weeks on
TABLE 13.1
ORAL STANOZOLOL: EFFECTS ON FIBRINOLYSIS
IN TYPE II DIABETES MELLITUS
F.A.
(mm2 )
BBeta 
15-42 
(pmol/ml)
0(2-AP 
(%)
cX2
(
-MG
%)
Weeks
-2 76 1.00 121 100
± 20 ± 0 . 5 3 ± 25 ± 32
0 83 1.12 126 99
± 20 ± 0.49 ± 20 ± 28
+2 79 1.23 122 71
± 18 ± 0 . 9 3 ± 24 ± 47
+ 4 82 1.24 126 92
± 21 ± 0.84 ± 20 ± 30
+ 8 81 1.09 119 93
± 30 ± 0.64 ± 25 ± 39
12 80 1.26 106 108
± 13 ± 0.61 + 30 ± 29
Legend
Table 13.1 lists the changes in the tests of fibrinolysis 
(mean ± S D), while on placebo (-2 to 0 weeks), on stanozolol 
(0 to 4 or 8 weeks), and 4 weeks after cessation of stanozolol 
(week 12). Plasma fibrinolytic activity (F.A.), 
alpha2-antiplasmin (c<2-AP), alpha2-macroglobulin (oC2-MG) .
F i b r i n o g e n  C g / 1 ) 
P l a s m i n o g e n  C C . U . / m l  ]
F i b r i n o g e n
P l a s m i n o g e n
P l a c e b o S t a n o z o l o l
-2 0 2 4 8
T i m e  C w e e k s  3
12
Figure I3.I
Illustrates the concentrations (mean +_ ISD) of fibrinogen and 
plasminogen on placebo ( - 2  to 0 weeks), stanozolol (O to 4 or 
8 weeks) and 4 weeks after stopping stanozolol (week 1 2) in 
type II diabetic patients.
*p 0.05, **p ^  0.01, changes relative to week 0
^p /C 0.05, ^^p 0.01, changes relative to week 4 or
% Glycosylation 
À
15
13
11
G.Hb
G.P.P.
t t f  G.AIb
Placebo Stanozolol
-2 0 2 4 8
— 1—  
12
Time (weeks)
Figure 1 3 .2
Illustrates the concentrations (mean +_ SD) of glycosylated 
haemoglobin (G.Hb), plasma proteins (GoP.P.) and albumin 
(G.Alb) during the study.
<  0 .0 5 ,
++
•< OoOl, changes relative to week 0
^  OoOl, changes relative to week 4 or
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stanozolol. Significant decreases in G.P.P. (10%), and 
G.Alb (9%) were noted after the 2 week placebo run-in 
period and therefore changes in G.P.P. and G.Alb while on 
stanozolol were compared to week 0. A significant and 
progressive fall in glycosylated proteins occurred while 
on active medication with significant regression towards 
pre-treatment levels on cessation of drug administration. 
Eleven of the twelve patients demonstrated improvements in 
the above measures of glycaemic control while the control 
of one subject (also receiving glibenclamide) deteriorated 
on stanozolol. The other three patients on sulphonylurea 
therapy demonstrated similar falls in the above variables 
as those patients with diabetes controlled on diet alone.
il-i DISCUSSION
Oral administration of stanozolol has been shown to 
enhance plasma fibrinolytic activity in ischaemic heart 
disease, Raynaud's disease, DVT, 1ipodermatosclerosis 
cutaneous vasculitis, superficial thrombophlebitis, 
protein C and antithrombin III deficiency, haemophilia A 
and B, and normal subjects (Chapter 2.8). In our poorly 
controlled diabetic patients, as indicated by the high 
fasting plasma glucose and elevated glycosylated 
haemoglobin, albumin and plasma protein concentrations, 
stanozolol failed to exert its characteristic effects on 
plasma fibrinolytic activity (Kluft et al., 1984b), BBeta 
15-42 concentrations (Small et al., 1983b; Douglas et al..
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1985) and alpha2-macroglobulin concentrations (Walker et 
al., 1975; Preston et al, 1981; Kluft et al., 1984b). 
Stanozolol did induce a reduction in fibrinogen and 
elevation of plasminogen concentrations although
significant alterations in these plasma proteins were not 
seen at all time intervals while patients were taking 
stanozolol. Stanozolol does not therefore display the 
same pronounced effects on fibrinogen and plasminogen as 
seen in other patient groups. The lack of changes noted 
in ex vivo .and in vivo fibrinolytic activity despite 
improved glycaemic control fails to support the view that 
glycamic control is a major determinant of fibrinolysis.
Recent studies have carefully evaluated the mode of 
action of stanozolol on fibrinolysis and it is clear that 
the rise in plasma fibrinolytic activity is due to a fall 
in t-PA inhibitor (Verheijen et al., 1984). The lack of
change in fibrinolytic activity in our study suggests that 
changes in t-PA inhibitor may not have occurred in our
diabetic patients.
We have shown that stanozolol administration to type 
II diabetic patients is associated with a significant 
improvement of glycaemic control without the occurrence of 
hypoglycaemic attacks. The similar falls in blood sugar 
levels in patients controlled by dietary measures alone 
compared to those on diet plus oral hypoglycaemic drugs 
suggests no major interaction of stanozolol with the 
sulphonylurea agents occurred. The improvements in 
fasting blood glucose and G.Hb concentrations are of a 
similar magnitude to those reported in obese type II
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diabetics given metformin (Lord et al., 1983). The mode 
of action of stanozolol on carbohydrate metabolism is 
unknown but since the anabolic steroid methandienone has 
been shown to augment insulin responses (Landon, Wynn and 
Samols, 1963), it may be that stanozolol also possesses 
such a 'sulphonylurea like' hypoglycaemic action.
Due to the long life span of the red cell (120 days), 
G.Hb concentrations remain elevated for several weeks 
after the attainment of improved glycaemic control, while 
plasma proteins like albumin (t-1/2 of 20 days) detect 
glycaemic changes earlier (Jones et al., 1983). Improved 
control over a 2 week period, measured by glycosylated 
serum proteins, has been demonstrated in diabetic children 
without any significant change in fasting glucose 
concentrations (Strickland et al., 1984). In our study we 
noted an improvement in glycosylated protein 
concentrations (without alteration of fasting glucose 
concentrations) while the patients were on the 2 week 
placebo run-in period. This illustrates the well 
recognised phenomenon that closer medical supervision of 
patients by itself can lead to improved glycaemic 
control. It seems likely that the improved glycaemia was 
related not only to intensive patient surveillance but to 
some intrinsic effect of stanozolol, since control 
deteriorated sharply when patients, still under close 
supervision, stopped taking the drug.
The present study population was comprised of 
patients with hypertension, obesity, poorly controlled 
diabetes and, in some cases, overt occlusive vascular
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disease. An anti-thrombotic drug may have therapeutic 
potential in such a group of patients. While stanozolol 
has shown favourable effects on carbohydrate metabolism 
the failure of stanozolol to stimulate fibrinolysis in 
type II diabetes suggests that anabolic steroid therapy 
may not modify the pro-thrombotic state associated with 
diabetes mellitus.
l8l
CHAPTER 14
METABOLIC EFFECTS OF STANOZOLOL
l±.l INTRODUCTION
Although stanozolol has been used since the early 
1960 's in numerous different clinical settings, its 
effects on other metabolic systems have received scant 
attention. While the effects of stanozolol on 
fibrinolysis have been considered elsewhere (Chapters 6, 
7, 8, 13), these studies also allowed us to evaluate other 
possible sites of action of this anabolic agent. We felt 
it important to document its actions on hepatic function, 
sex-hormone status, lipid concentrations and rheology 
since adverse effects on these systems would be important 
with regard to prescribing stanozolol to different patient 
groups. The favourable effects on glycaemic control in 
type II diabetes have been discussed in chapter 13, and 
the following remarks summarise very briefly the metabolic 
effects of stanozolol we have evaluated.
Hepatic Actions
Since danazol, a closely related steroid, was shown 
to induce marked changes in a number of hepatic proteins 
(Laurell and Rannevik, 1979) it was postulated that 
stanozolol may alter hepatic enzyme systems (Preston et 
al., 1981) and we presented some evidence to support such 
a hypothesis (Small et al., 1982b; Small et al., 1983c). 
To evaluate whether stanozolol could effect such changes 
by inducing hepatic enzymes, we measured antipyrine 
kinetics and urinary 6 beta-hydroxycortisol excretion 
(indicators of hepatic monooxygenase activity) in normal
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males given oral stanozolol. We found no change in these 
markers of enzyme induction and concluded that the effects 
of stanozolol on plasma proteins were not due to any 
action on the cytochrome P450 system (Thompson et al., 
1984). In this study we have also shown that stanozolol 
was porphyrinogenic, which may be relevant to the 
successful treatment of aplastic anaemia with anabolic 
steroids (Wilson and Griffin, 1980). As far as routine 
liver function tests are concerned, we have noted no 
adverse effects in normal subjects or patients given 
intramuscular stanozolol, or a short course of oral 
stanozolol (Small et al., 1982b; Small et al., 1984c). In 
the study involving diabetic patients 2 of the 12 patients 
had disturbances in liver function tests - both were 
asymptomatic. A fourfold rise in alanine transaminase was 
found in one female after 2 weeks on stanozolol, which had 
improved after a further 2 weeks while the patient was 
still taking stanozolol and returned to normal levels on 
cessation of stanozolol administration. The other patient 
had an elevation of alanine transaminase just outwith the 
normal range which settled while the patient was still 
taking stanozolol. Our limited experience of short-term 
administration of stanozolol has not therefore led to any 
problems with liver dysfunction.
1_4 . 3_ Endocrine Effects 
From early work on animal studies it was reported 
that stanozolol had the highest anabolic to androgenic 
ratio of the anabolic steroids, and therefore it was less
likely to cause androgenic side-effects (Arnold, Potts and 
Beyler, 1963; Gribbin and Flavell Matts, 1976). No 
previous studies have assessed the hormonal effects of 
stanozolol in men, and we have found that stanozolol, 
given orally or intramuscularly to normal male subjects, 
has prolonged and pronounced effects on the pituitary- 
testicular and pituitary-thyroidal axis (Small et al., 
1983c; Small et al., 1984d). Stanozolol reduced 
luteinising hormone, follicle stimulating hormone, 
testosterone, thyroxine (T4) and triiodothyronine (T3) 
concentrations. The effects on T4 and T3 were due to a 
reduction in thyroxine binding globulin concentrations 
(synthesised in the liver) while free T4 concentrations 
were unchanged. The reduction in total and free
testosterone levels makes it likely that stanozolol has a 
suppressive effect on luteinising hormone secretion by the
pituitary gland. All the aforementioned changes were
reversible on stopping stanozolol administration but the 
long-term effects of anabolic steroid therapy on 
gonadotrophin suppression and spermatogenesis in the male 
are not known. Other anabolic steroids have been
evaluated as a male oral contraceptive (Schurmeyer et al.,
1984). Androgenic side effects are common in female 
patients given stanozolol (Jarrett, Morland and Browse, 
1979), and in our study involving diabetic patients we 
have had to stop stanozolol administration because of the 
development of marked hirsutism and acne in one patient. 
Our studies therefore indicate that stanozolol is a potent 
androgenic agent despite previous in vitro animal studies
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(Arnold et al., 1963).
]^.j4 Lipid Effects 
Anabolic steroids have been reported to be effective 
in hyperlipidaemia (Ciswicka-Sznajderman, Berent and 
Rymaszewski, 1974; Ciswicka-Sznajderman, Berent and
Rymaszewski, 1981; Wilson and Griffin, 1980) but in normal 
males we have noted an increase in total cholesterol, LDL 
cholesterol and a fall in HDL cholesterol (Small et al., 
1982b) and in diabetics, an increase in LDL and fall in 
HDL cholesterol (Small et al., 1986b). Hyperlipidaemia is 
common in type II diabetes, the characteristic 
abnormalities being a high LDL and low HDL cholesterol 
(Goldberg, 1981). The changes in LDL and HDL would tend 
to aggrivate the abnormalities in lipoprotein levels 
observed in such patients, and since a high LDL and low 
HDL cholesterol are strong, predictive risk factors for 
coronary heart disease (Lewis, 1983), the lipoprotein 
changes could be harmful.
1^.^ Rheoloqical Effects 
It was postulated that stanozolol may reduce plasma 
viscosity due to its actions in lowering fibrinogen and 
alpha2-macroglobulin concentrations (Preston et al., 
1981). We have shown that stanozolol does indeed lead to 
a very small reduction in plasma viscosity (Small et al., 
1983a) but it has been found to exert no effect on whole 
blood viscosity (Ayres, Jarrett and Browse, 1981). It is 
dubious whether such a small reduction in plasma viscosity
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by stanozolol would have any therapeutic value.
Ü.* 8. Summary
In our experience, stanozolol appears to have adverse 
effects on lipid and sex-hormone status, and although we 
have not noted clinically apparent liver dysfunction it is 
well recognised that disturbances in liver function tests 
are common during stanozolol administration (Jarrett et 
al., 1979). It appears unlikely that the favourable 
effects on carbohydrate metabolism in type II diabetes 
outweigh these side-effects. Whether the improved 
fibrinolysis and anti-coagulant effects of stanozolol are 
clinically more relevant alterations would have to be 
evaluated for each individual patient. If patients are 
placed on long-term stanozolol administration close 
monitoring of the aforementioned aspects of metabolism are 
clearly indicated.
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